Molecular Mechanisms of Resistance and Structure-Based Drug Design in Homodimeric Viral Proteases by Lockbaum, Gordon J.
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2020-04-17 
Molecular Mechanisms of Resistance and Structure-Based Drug 
Design in Homodimeric Viral Proteases 
Gordon J. Lockbaum 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Biochemistry Commons, and the Structural Biology Commons 
Repository Citation 
Lockbaum GJ. (2020). Molecular Mechanisms of Resistance and Structure-Based Drug Design in 
Homodimeric Viral Proteases. GSBS Dissertations and Theses. https://doi.org/10.13028/368b-kn69. 
Retrieved from https://escholarship.umassmed.edu/gsbs_diss/1072 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations 
and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
i 
Molecular Mechanisms of Resistance and Structure-Based Drug Design in 
Homodimeric Viral Proteases 
A Dissertation Presented 
By 
GORDON J. LOCKBAUM 
Submitted to the Faculty of the 
University of Massachusetts Graduate School of Biomedical Sciences, Worcester 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
April 17th, 2020 
BIOCHEMISTRY & MOLECULAR PHARMACOLOGY 
 
ii 
Molecular Mechanisms of Resistance and Structure-Based Drug Design in 
Homodimeric Viral Proteases 
A Dissertation Presented By 
GORDON J. LOCKBAUM 
This work was undertaken in the Graduate School of Biomedical Sciences 
BIOCHEMISTRY & MOLECULAR PHARMACOLOGY PROGRAM 
The signatures of the Dissertation Defense Committee signify completion and 
approval as to style and content of the Dissertation 
_________________________________________ 
Celia A. Schiffer, Ph.D., Thesis Advisor 
_________________________________________ 
Daniel N. A. Bolon, Ph.D., Member of Committee 
_________________________________________ 
William Royer, Ph.D., Member of Committee 
_________________________________________ 
William Kobertz, Ph.D., Member of Committee 
_________________________________________ 
Lizbeth Hedstrom, Ph.D., External Member of Committee 
The signature of the Chair of the Committee signifies that the written dissertation 
meets the requirements of the Dissertation Committee 
_________________________________________ 
Sean Ryder, Ph.D., Chair of Committee 
The signature of the Dean of the Graduate School of Biomedical Sciences 
signifies that the student has met all graduation requirements of the School. 
_________________________________________ 
Mary Ellen Lane, Ph.D. 
Dean of the Graduate School of Biomedical Sciences 




First and foremost, thank you to my advisor, Dr. Celia Schiffer. I will always 
be grateful for your mentorship, for allowing me to join your lab, and for making me 
a better scientist and person. My sincerest thanks to Dr. Akbar Ali for always being 
there for me and for being an outstanding collaborator. I also thank Dr. Nese Kurt 
Yilmaz for your excellent feedback on my numerous writing projects. To Ellen 
Nalivaika, thank you for showing me the ropes and for being a rock in the lab. 
Special thanks to Dr. William Royer for sharing your structural biology expertise 
with me and for taking the time to answer all my questions.  
Thank you to my Thesis Research Advisory Committee (TRAC) and 
Dissertation Exam Committee (DEC) members: Daniel N. A. Bolon, Bill Kobertz, 
Sean Ryder, Bill Royer, Brian Kelch, and Liz Hedstrom for giving me a generous 
amount of time and feedback and for pushing me to be a better scientist.  
I thank the Schiffer Lab members, past and present. Florian Leidner, 
Shurong Hou, Jacqueto Zephyr, Anne Jecrois, Heather Loring, Adam Hedger, 
Mina Henes, Klajdi Kosovrasti, Dr. Ashley Matthew, Dr. Linah Rusere, Dr. Nagesh 
Desaboini, Dr. Jeong Min Lee, Dr. Jennifer Timm, Dr. Tania Silvas, Dr. Brendan 
Hilbert, and Dr. Djade Soumana. Thank you to those who directly helped me 
complete my projects and to all who made the lab a great environment for science. 
I would like to take a moment to acknowledge and thank my friends and 
family. Thank you to my college roommates who stay in touch and always have 
my back: Eric Bunker, Jon Grenier, Ian Mahoney, Trevor Rappa, Matt Rawson, 
Read Servis, Sam Sperling, and Alex Stone. Thank you to my wonderful parents, 
Gordon C. Lockbaum and Linda Denise Lockbaum, for your unwavering support. 
Thank you to my sister, Olivia, and my brother, Luke, for being cool. Lastly, thank 
you to Gwen Walsh for making life fun during a brutal five years of graduate school. 





Drug resistance is a global health threat costing society billions of dollars 
and impacting millions of lives each year. Current drug design strategies are 
inadequate because they focus on disrupting target activity and not restricting the 
evolutionary pathways to resistance. Improved strategies would exploit the 
structural and dynamic changes in the enzyme–inhibitor system integrating data 
from many inhibitors and variants.  
Using HIV-1 protease as a model system, I aimed to elucidate the 
underlying resistance mechanisms, characterize conserved protease-inhibitor 
interactions, and generate more robust inhibitors by applying these insights. For 
primary mechanisms of resistance, comparing interactions at the protease–
inhibitor interface showed how specific modifications affected potency. For 
mutations distal to the active site, molecular dynamics simulations were necessary 
to elucidate how changes propagated to reduce inhibitor binding. These insights 
informed inhibitor design to improve potency against highly resistant variants by 
optimizing hydrogen bonding. A series of hybrid inhibitors was also designed that 
showed excellent potency by combining key moieties of multiple FDA-approved 
inhibitors.  I characterized the structural basis for alterations in binding affinity in 
HIV-1 protease both from mutations and inhibitors. 
I applied these strategies to HTLV-1 protease, a potential drug target. I 
identified the HIV-1 inhibitor darunavir as a viable scaffold and evaluated 
analogues, leading to a low-nanomolar compound with potential for optimization. 
Hopefully, insights from this thesis will lead to the development of potent HTLV-1 
protease inhibitors. More broadly, these inhibitor design strategies are applicable 
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1.1 Drug Resistance is a Major Biomedical Problem 
Antimicrobial resistance is a global threat to public health that requires 
immediate action and a concerted effort.1-2 Antimicrobials include antibiotics, 
antivirals, antifungals, and antiprotozoals. More broadly, drug resistance also 
includes resistance to pesticides, herbicides, and cancer therapeutics. Drug 
resistance costs our society billions of dollars annually and causes at least 700,000 
deaths globally per year, which could increase to over 10 million by 2050 if no 
action is taken.3-4 
Over-prescription and poor adherence contribute to resistance, but 
resistance ultimately occurs any time evolution exists under the selective pressure 
of a drug that restricts growth of the wild-type yet does not entirely inhibit the growth 
of other evolutionarily accessible variants. Under sub-optimal drug concentrations, 
these heterogeneous populations eventually render effective drugs obsolete. 
Resistance is partially an inadvertent consequence of drug design where avoiding 
the probability of resistance is not included as part of the design strategy.  
Therapeutics take many forms, but most drugs are small molecules that bind 
to proteins or enzymes and alter their function in a way that cures or alleviates the 
disease. Most drug precursors are discovered by screening hundreds or 
thousands of compounds in a high-throughput inhibition assay against a particular 
macromolecular therapeutic target. After a lead compound is discovered, the 
inhibitor goes through iterative rounds of optimization to improve potency and 
binding affinity. When no structure is available, structure activity relationship (SAR) 
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studies are used to determine how changes to the inhibitor affect potency. When 
a protein-ligand structure is available, structure-based drug design (SBDD) is 
employed, where the inhibitor is designed in three-dimensional space to optimally 
interact with the target.  
These techniques, however, do not focus on the biologically relevant 
interactions of the target, but rather focus solely on disrupting the target’s activity. 
Disrupting the therapeutic target’s activity is necessary but not sufficient for 
developing a robust drug with a lower probability of resistance. The high rates of 
target-site drug resistance suggest that our current drug design paradigm is 
insufficient. Restricting the evolutionary pathways to resistance requires further 
understanding the underlying molecular mechanisms: the structural and dynamic 
changes in the enzyme–inhibitor system. Improved drug design strategies would 
integrate data across many inhibitors and variants to optimize conserved enzyme-
inhibitor interactions thereby making inhibitors more robust and reduce rates of 
resistance.  
1.2 HIV is a Good Model of Evolution    
In biological research, model systems are used to probe different questions 
by monitoring genotypic and phenotypic changes in response to different variables. 
Bacteria, yeast, flies, worms, fish, mice, and viruses can function as a model 
system. Human Immunodeficiency Virus (HIV) is a great model system to test 
evolution and adaptation. HIV is known for its large amount of heterogeneity, even 
within a single human. In 1996, it was discovered that one person living with HIV 
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for six years had the same viral diversity as influenza across the entire planet.5 
HIV’s genetic diversity comes from a high rate of replication,6-8 error prone reverse 
transcriptase,9-10 propensity for homologous recombination,11 and interactions with 
host mRNA editing enzymes like APOBECs.12 
HIV’s diversity has been illuminated by the decreasing cost of genetic 
sequencing and the standard practice of viral sequencing in clinics.13-14 One 
repository for these sequences is the Stanford University HIV Drug Resistance 
Database, which has over one hundred thousand clinical isolates obtained from 
persons infected with HIV-1.15-16 This database highlights HIV’s ability to tolerate 
many mutations throughout its genome while retaining viral fitness. Databases like 
these help scientists to determine which treatments cause mutations in the viral 
genome. Specific drugs can induce trademark mutations in different viral enzymes 
and monitoring these mutations allow doctors to better prescribe more effective 
treatments.17   
Viral sequences derived from patient isolates are incredibly valuable for 
research, but they represent a snapshot in time, often with limited context like 
patient history, including adherence and drug regimens. Generating resistant 
variants in a laboratory is commonly used to determine relative rates of resistance. 
Challenging a heterogenous pool of virus with a sub-optimal dose of inhibitor 
selects for resistant variants fit enough to pass their genes on to the next 
generation. Slowly increasing the inhibitor concentration with each viral passage 
generates extremely resistant proteins over time. This longitudinal experiment with 
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dosage and temporal control allows determination of the order of mutations against 
specific drugs at specific inhibitor concentrations.  
1.3 HIV Protease  
1.3.1 HIV Protease: The Enzyme 
HIV protease is a necessary enzyme in the viral life cycle, responsible for 
maturation of the virion into an infectious particle.18 HIV-1 protease consists of two 
99 amino acid monomers held together by a dimerization domain to form a 
functional dimer [Figure 1.1A].18-19 The protease has two flaps which are required 
to open to allow binding and close around amino acid substrates [Figure 1.1B].18-
21 In the closed conformation, the active site resembles a tunnel which orients 







Figure 1.1 HIV-1 protease structure and dynamics. (A) HIV-1 protease dimer 
shown as cartoon with inhibitor bound and catalytic aspartates shown as yellow 
sticks. HIV-1 protease dimer shown in surface representation.21 (B) Frames taken 
from a molecular dynamics simulation showing HIV-1 protease in various 
conformations, including closed, partially opened, and fully open.21 (C) The 
reaction mechanism for HIV-1 protease catalyzed proteolysis .22 (D) Michaelis-
Menten one-substrate reaction.  
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The reaction mechanism for peptide bond cleavage is shown in Figure 
1.1C,22 where the catalytic aspartates perform a coordinated, water-mediated 
backside attack of the carbonyl carbon which creates an unstable geminal diol 
tetrahedral intermediate. The intermediate can either collapse in a way that 
completes hydrolysis or that re-forms the substrate. By monitoring isotope 
exchange, the reformation of the substrate was found to occur at a rate of 0.01-
0.1 times that of the forward reaction.23 Because a majority of the enzyme-
substrate transition state is suscessfully cleaved into product, the reaction can be 
modeled with a Michaelis-Menten one-substrate mechanism [Figure 1.1D]. This 
comes with a few assumptions such as the steady state approximation, free ligand 
approximation, and the rapid equilibrium approximation. In vitro studies measuring 
product formation using very low concentrations of protease and increasing 
concentrations of hydrolysable substrate allow the determination of the initial 
velocities. The initial velocities as a function of substrate concentration are used to 
determine Vmax, kcat, and Km, where Km is approximately the ratio of kon and koff. 
The experiments show the proteolysis reaction can be explained by the Michaelis-
Menten equation and fits the assumption that the kcat is the rate limiting step in the 
reaction. Therefore, in HIV-1 protease, despite the large dynamic movements of 
the flaps, the rate determining step is the hydrolysis and product release, rather 




1.3.2 HIV Protease is a Good Drug Target 
HIV-1 protease inhibitors (PIs) are considered one of the greatest 
achievements in SBDD. The first structure of HIV-1 protease was determined in 
1989 and by 1996 three drugs were approved by the Food and Drug Administration 
(FDA) and immediately improved the life expectancies of those treated.25-26 In total, 
there have been 9 FDA-approved PIs: Saquinavir (SQV), Indinavir (IDV), Ritonavir 
(RTV), Nelfinavir (NFV), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), 
Tipranavir (TPV), and Darunavir (DRV) [Figure 1.2].27 Besides TPV, all inhibitors 
are linear peptidomimetics. Currently, only LPV, ATV, and DRV are used in clinic 
and all are taken with low-dose RTV to improve pharmacokinetics.28-29 These 
inhibitors have very high potency, with affinity to wild type (WT) protease in the 







Figure 1.2 Chemical structures of FDA-approved HIV-1 PIs, including their three-
letter abbreviation, the drug manufacturer and the year the drug was approved by 





All nine PIs have similar characteristics that contribute to their high affinity for 
HIV-1 protease. Each inhibitor has a central hydroxyl moiety which functions as a 
non-hydrolysable transition state mimetic [Figure 1.3] and creates strong 
hydrogen bond interactions with both catalytic aspartates. All inhibitors, besides 
TPV, also coordinate a “flap water” between the inhibitor and the flaps which helps 
to keep the flaps in the closed conformation [Figure 1.4]. In addition, each inhibitor 
makes a number of other direct and water-mediated hydrogen bonds as well as 





Figure 1.3 Simplified diagram of an amino acid polymer bound to HIV-1 protease 







Figure 1.4 Clinically relevant protease inhibitors. (A) DRV, (B) LPV, and (C) ATV 
bound to HIV-1 protease. All are shown with their respective chemical structures 




1.3.3 HIV Protease is an Ideal Drug Resistance Model System 
HIV’s propensity for genetic heterogeneity makes any of its enzymes a good 
model system to study drug resistance. HIV-1 protease is best suited to elucidate 
complex mechanisms of resistance and identify enzyme-inhibitor characteristics to 
optimize, due to 1) thousands of viable protease variants, 2) thousands of 
published inhibitors with inhibition data, 3) hundreds of high-resolution protein-
ligand complexes, and 4) thousands of molecular dynamics simulations.  
1.3.4 HIV Protease Mutations  
Despite needing to maintain substrate specificity, HIV-1 protease is 
exceptionally mutable. About two-thirds of its 99 amino acid sequence can tolerate 
a single site mutation and retain functionality, while about half of its sequence has 
been directly implicated in drug resistance.17, 30 Under selective pressure, when 
challenged by an inhibitor, some patient isolates have replicating viruses with 
functional proteases that contain over 25 mutations.31-36  
Resistance mutations can be found throughout the protease and are 
sometimes classified as either “primary” or “secondary,” as depicted in Figure 
1.5.30 Primary mutations usually occur first and function to reduce inhibitor binding 
affinity. Primary mutations are often located in or around the active site, which are 
referred to as “proximal” mutations. Secondary mutations generally appear later, 
away from the active site, or “distal”, and are thought to be mostly compensatory 




Figure 1.5 Primary (red) and secondary (blue) mutations mapped onto the 
structure of HIV-1 protease.30  
 
 
Primary mutations tend to directly perturb protease-inhibitor interactions, but 
if the protease variant has reduced inhibitor binding affinity, then it likely has 
reduced affinity for natural substrates as well. If the protease’s affinity of natural 
substrates is too low, then the virus will not be viable. Therefore, secondary 
mutations are necessary to restore affinity for natural substrates or to alter the 
protease dynamics to improve catalytic efficiency.  
Primary/proximal mutations have been extensively investigated in HIV-1 
protease.27, 37-39 Some primary mutations are pan-resistant against all protease 
inhibitors, but most FDA-approved PIs have signature mutations, especially drugs 
that are no longer used in clinic [Figure 1.6].17 In general, competitive inhibitors 
are most affected by proximal mutations that significantly perturb protease-inhibitor 
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contacts. This highlights the importance of proactively identifying which active site 
residues are variable and to minimize inhibitor interaction with those residues. 30 
years of HIV protease research indicates the impact of proximal mutations on 
inhibitor binding affinity can be readily understood, while the impact of distal 





Figure 1.6 Mutations in HIV-1 protease associated with resistance to each 





By definition, distal mutations cannot directly contact the inhibitor. Distal 
mutations are generally considered either a naturally-occuring polymorphisms or 
a compensatory mutation. Compensatory mutations have received a fair amount 
of research and are known to restore functionality by altering protease dynamics, 
like in the flaps. A most prevalent example is the I50V/A71V mutation 
combination.40 The I50V active site mutation at the tip of the flaps reduces affinity 
for inhibitors, but also significantly reduces rates of substrate cleavage. The A71V 
mutation, over 13 Å away from the active site, restores substrate cleavage rates 
to near WT levels, while maintaining resistance against the inhibitor. There has 
been very little research regarding if distal mutations contribute to reductions in 
inhibitor binding.  
1.3.5 HIV Protease Inhibitors  
HIV-1 protease cleaves the viral polyproteins at 11 different sites.10 
Maintaining relative binding affinity and cleavage rates between the substrates is 
critical for proper viral maturation.41-42 Although the substrate sequences are highly 
diverse, the sequences have a conserved volume when aligned which our lab has 
termed the “substrate envelope”.43 Inhibitors that protrude outside of the substrate 
envelope are more susceptible to resistance mutations that perturb inhibitor 
binding without affecting substrate binding.21  
Darunavir (DRV) is a special inhibitor because it is relatively small, extremely 
potent, and has a good resistance profile as it fits well within the substrate 
envelope.44 Despite being the most potent FDA-approved PI with low resistance 
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rates when properly administered, DRV greatly loses binding affinity against 
mutated protease variants.31, 38 Our lab found that small modifications to DRV’s P1′ 
and P2′ moieties improved inhibitor potency against a panel of resistant 
proteases.45 Over the years, each of DRV’s peptidomimetic positions, P2 to P2′, 
has undergone extensive SAR studies, resulting in hundreds of DRV analogues 
with different combinations of modifications. Changing inhibitors in a systematic 
way and testing them against a panel of resistant protease variants helps elucidate 
and optimize for the most important protease-inhibitor interactions. 
1.3.6 HIV Protease Structures  
Since the structure of HIV-1 protease was determined in 1989, it has become 
one of the most published structures, with over 700 high-resolution (< 2.5 Å) 
protease-inhibitor complexes deposited into the Protein Data Bank (PDB).46 
Despite being a success story of SBDD, the first published HIV-1 protease 
structure was infamously incorrect, with residues missing from the C terminus, a 
lack of a central alpha helix, and a poorly modeled dimerization domain.20 Luckily, 
several other labs had crystalized the protease and it was corrected shortly after.19  
X-ray crystallography relies on the repetitive and symmetrical nature of 
crystals, but internal symmetry, like the pseudo-C2-symmetric nature of the two 
monomers of HIV-1 protease, can complicate structural determination. In the apo 
form, the two monomers are highly symmetric, but binding an inhibitor or substrate 
induces asymmetry in the protease, especially in the flaps.47-48 Certain space 
groups, like P212121, are ideal because they have two unique monomers in the 
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asymmetric unit and the electron density of the inhibitor is found in one 
conformation. Other space groups, such as P61, retain high levels of symmetry 
between the monomers, so the data appears merohedrally twined and the inhibitor 
density is such that the inhibitor is best modeled in two conformations.49-50 This 
twinning can average out subtle asymmetric differences between the monomers 
and inhibitor and lead to a sub-optimal model. Even slight imperfections in the 
model can mislead SBDD efforts, therefore highly accurate cocrystal structures 
are critical.  
1.3.7 HIV Protease Dynamics 
Although so much data can be derived from cocrystal structures alone, 
proteins exist in a dynamic equilibrium in solution and the conformational dynamics 
of the enzyme–inhibitor complex should not be overlooked. The dynamic analyses 
are a necessary component to elucidate mechanisms of resistance and to properly 
analyze protease-inhibitor interactions, critical for designing robust drugs to inhibit 
a dynamic target.  
Protein structures determined by X-ray crystallography are inherently 
“packed” together, where each macromolecule interacts with neighboring proteins 
at several crystal contacts. Although a protein’s size and shape might not change 
much, dynamic regions can be highlighted through other structural techniques like 
protein nuclear magnetic resonance (NMR). Protein NMR determines the structure 
of a protein in solution by detecting the local molecular environment of each atom. 
A single protein NMR dataset can be used to determine dozens of structures and 
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indicate which regions are more flexible than others. Using protein NMR, our 
collaborators have shown how protein dynamics change with the addition of drug 
resistance mutations and how those mutations reduce inhibitor potency.51  
Our lab has specialized in utilizing molecular dynamics (MD) simulations to 
evaluate protease-inhibitor dynamics in silico. MD simulations take a structure, put 
it in a box, solvate that box, and apply force fields around each atom and let each 
atom bounce around and interact for a period of time. 3D information about every 
atom’s position over time is recorded for further analysis. The quality of a 
simulation is corelated with the accuracy of the starting model, further highlighting 
the importance of accurate structures.  
Like protein NMR, MD simulations can be used to elucidate mechanisms of 
resistance, especially distal mutations reduce inhibitor affinity. To affect inhibitor 
binding from a distance, distal mutations must propagate changes through the 
protease in a dynamic way. Using MD simulations, we have shown how some 
mutations alter protease dynamics through changes in hydrophobic packing within 
the core of the protease.52-53 We have also shown how certain mutations alter the 
hydrogen bond network throughout the protease resulting in drug resistance.54  
MD simulations can also explain how inhibitor modifications improve potency. 
Our lab has showed that just monitoring inhibitor fluctuations over the course of a 
simulation was not well correlated with inhibitor potency, but maintaining correlated 
motion with the protease was a better indicator of binding affinity.55 
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1.4 The Rise of HTLV-1 and HTLV-1 Protease as a Drug Target  
The most logical place to transfer over 20 years of knowledge inhibiting HIV 
was to try to inhibit a related virus, Human T-cell lymphotropic virus (HTLV). HTLV 
was actually the first human retroviruses described nearly 40 years ago.56-57 For 
decades HTLV-1 has been known to be highly carcinogenic and to cause severe 
paralytic neurologic disease as well as immune disorders that can increase 
susceptibility to bacterial infections. HIV was thought to be related to HTLV when 
it was first classified. HTLV-1 is transmitted via the same routes as HIV-1 (sexually, 
via blood or mother-to-child) with significant HIV/HTLV co-infections reported in 
Europe, America, and Africa.58 About 20 million people worldwide are infected with 
HTLV-1.59 Unfortunately, there are no effective vaccines or direct acting antivirals 
(DAAs) against HTLV-1.  
Treatment options for HTLV-1 infected patients are scarce. For the estimated 
3–5% of the HTLV-1 infected patients who develop adult T-cell 
leukemia/lymphoma (ATL), chemotherapy is ineffective with very poor survival 
rates and relapse leading to death.60-61 In the clinic, a combination of Zidovudine, 
an HIV-1 reverse transcriptase inhibitor, and IFN-ɑ significantly improved 
prognosis, indicating active HTLV-1 replication in ATL patients that can be targeted 
by antiretrovirals. As with HIV-1 infections, development of specific DAAs has a 
great potential to improve patient/treatment outcomes. 
HTLV-1 has a similar viral live cycle as HIV-1 and utilizes similar viral 
machinery such as reverse transcriptase, integrase, and protease. Success 
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against HIV-1 protease suggests similar potency can be achieved against HTLV-
1 protease. HTLV-1 protease is a 28 kDa homodimeric aspartyl protease that is 
28% identical to HIV-1 protease with 45% identity between active site residues,62-
63  yet HTLV-1 protease has considerably distinct substrate specificity [Figure 
1.7].63-67 The differences in substrate specificity suggest why the FDA-approved 
HIV-1 protease drugs bind HTLV-1 protease with less affinity, with the best 
candidates reaching low nanomolar potency.68 A number of novel HTLV-1 
protease inhibitors have been published, yet none have reached sub-nanomolar 
potency.  
The structure of HTLV-1 protease was determined in 2005,65 but only 10 WT 
structures have been deposited into the Protein Data Bank (PDB).69-70 Some in 
silico drug design has been reported, but no studies have utilized MD simulations 
on this complex. Also, although there is no data on drug resistant mutations in 
HTLV, our HIV protease methodology can be used to first determine a scaffold that 
will ultimately result in a clinically relevant HTLV-1 protease inhibitor. The substrate 
envelope model can be used to develop robust inhibitors likely to be less 





Figure 1.7 Comparison of HIV and HTLV-1 protease. HIV-1 protease dimer shown 
with cartoon and surface representations (PDB: 1T3R) and HTLV-1 protease dimer 




1.5 Scope of Thesis 
This thesis attempts to: 1) understand molecular mechanisms of drug 
resistance against HIV-1 PIs, arising from both proximal and distal mutations, 2) 
evaluate HIV-1 PI design strategies to improve potency and resistance profiles, 
and 3) establish a viable/novel inhibitor scaffold against HTLV-1 protease.  
Chapter 2 and Chapter 3 explore molecular mechanisms of drug resistance. 
In Chapter 2, while investigating primary resistance mechanisms, comparing 
changes at the protease-inhibitor interface showed why certain P1’ modifications 
were more potent against one common primary resistance mutation but more 
susceptible to another. In Chapter 3, for mutations distal to the active site, 
molecular dynamics simulations were necessary to elucidate that dynamic 
changes were propagated throughout the protease resulting in dramatically 
reduced DRV binding through weakened protease-inhibitor interactions. This 
research also established a new viable protease variant with 11 mutations that has 
the highest reported resistance to DRV (760 nM), binding DRV with over 150,000x 
lower affinity than WT protease. 
Chapter 4 and Chapter 5 involve evaluating HIV-1 PI design strategies and 
modifications. In Chapter 4, we show how modifications to the P2’ moiety improved 
potency against highly resistant variants by optimizing hydrogen bonds with the 
protease backbone. In Chapter 5, we characterized a series of novel hybrid 
inhibitors that showed excellent potency, but without a sulfonamide group as a 
potential allergen.  
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In Chapter 6, I applied HIV-1 strategies to HTLV-1 protease, a potential drug 
target. I identified DRV as a viable scaffold and evaluated a small panel of DRV 
analogues, leading to a lead compound with low-nanomolar potency and potential 
for further optimization.  
Lastly, in Chapter 7, I go into detail about a crystallographic method where I 
discovered an alternative method to refine hexagonal HIV-1 protease cocrystals 
resulting in better statistics.  
Together these studies highlight the complexity of drug resistance and drug 
design, but examples such as HTLV-1 protease show that we can quickly apply 
these methodologies toward the development of novel therapeutics against other 







 CHAPTER 2: 
Structural Adaptation of Darunavir Analogs Against Primary Mutations 





HIV-1 protease is one of the prime targets of agents used in antiretroviral therapy 
against HIV. However, under selective pressure of protease inhibitors, primary 
mutations at the active site weaken inhibitor binding to confer resistance. Darunavir 
(DRV) is the most potent HIV-1 protease inhibitor in clinic; resistance is limited, as 
DRV fits well within the substrate envelope. Nevertheless, resistance is observed due 
to hydrophobic changes at residues including I50, V82 and I84 that line the S1/S1′ 
pocket within the active site. Through enzyme inhibition assays and a series of 12 
crystal structures, we interrogated susceptibility of DRV and two potent analogs to 
primary S1′ mutations. The analogs had modifications at the hydrophobic P1′ moiety 
compared to DRV to better occupy the unexploited space in the S1′ pocket where the 
primary mutations were located. Considerable losses of potency were observed 
against protease variants with I84V and I50V mutations for all three inhibitors. The 
crystal structures revealed an unexpected conformational change in the flap region of 
I50V protease bound to the analog with the largest P1′ moiety, indicating 
interdependency between the S1′ subsite and the flap region. Collective analysis of 
protease-inhibitor interactions in the crystal structures using principal component 
analysis was able to distinguish inhibitor identity and relative potency solely based on 
vdW contacts. Our results reveal the complexity of the interplay between inhibitor P1′ 
moiety and S1′ mutations, and validate principal component analyses as a useful tool 




Human Immunodeficiency Virus (HIV) infects roughly 37 million people 
globally, with over 2 million new infections and over 1 million AIDS-related deaths 
occurring each year71. After 30 years of research, advances in antiretroviral 
therapies (ARTs), combinations of small molecule inhibitors, greatly extended life 
expectancy for those who receive treatment25-26. ARTs inhibit critical proteins 
necessary for viral replication and maturation, most commonly targeting HIV-1 
reverse transcriptase and protease. Although ARTs are highly effective in most 
patients, the current therapies are still an imperfect solution to a complex problem, 
as HIV-1 can evolve to confer drug resistance through accumulation of mutations9. 
Primary resistance mutations, typically occurring proximal to the active site where 
the inhibitor binds, are selected early under selective pressure of inhibition and 
directly affect inhibitor binding and allow the accumulation of additional mutations. 
Secondary mutations can occur distal to the active site but still indirectly affect 
substrate processing or inhibitor binding30, 72. No HIV-1 inhibitor is resistance-proof, 
and modifying an inhibitor to better tolerate primary resistance mutations may help 
to prevent the accumulation of additional mutations73. 
HIV-1 protease, a 99-amino acid, homodimeric, aspartyl protease18, 20 
[Figure 2.1a], is essential for viral replication and maturation, making this enzyme 
an ideal drug target41-42. The protease processes twelve unique cleavage sites on 
viral Gag and Gag-Pol polyproteins to release individual viral proteins required for 
viral replication and maturation. While the cleavage sites share low amino acid 
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sequence identity, when bound to HIV-1 protease they occupy a consensus 
volume termed the substrate envelope43. We have previously shown that inhibitors 
that fit within this volume are less prone to resistance as the protease cannot 




Figure 2.1 a) Co-crystal structure of DRV (green sticks) bound to WT HIV-1 
protease. Chain A (cyan) and chain B (magenta) are shown as a cartoon with a 
transparent surface. D25/D25’ catalytic aspartates (red) are displayed as sticks. a-
insert) Residues that contribute to primary drug resistance, shown as sticks. b) 
Spherical representation of residues that make up the S1′ subsite / P1′ pocket. 
Variable residues are shown in orange. c) Hydrogen bonds (black dashes) 
between DRV and WT HIV-1 protease. Coordinated waters are shown as red 
spheres.  
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The most potent FDA approved protease inhibitor, darunavir (DRV) [Figure 
2.2a], fits well inside the substrate envelope, yet resistance still occurs due to 
accumulation of mutations in HIV-1 protease in patient isolates31, 38. DRV is a 
peptidomimetic inhibitor with four major chemical moieties, denoted as P2, P1, P1′ 
and P2′ [Figure 2.2]. Highly mutated clinical isolates with 18 or more mutations in 
the protease have been identified, and DRV binding to these resistant proteases 
studied enzymatically and structurally31-36. Most of the patient-derived sequences 
bear a constellation of secondary mutations as well as primary mutations at the 
active site that confer DRV resistance, notably including I50V and I84V15-16, 74-75. 
Mutations at I50 are often selected together with A71V mutation, which is distal 
from the active site but compensates for the loss of enzymatic fitness76. 
Thermodynamics and structural studies of DRV binding to I50V/L and A71V 
mutations have revealed significant loss of van der Waals (vdW) contacts between 
the inhibitor and protease underlying loss of binding affinity77.  
30 
Figure 2.2 a) 2D chemical structure of DRV (with peptidomimetic moieties labeled) 
and the two DRV analogs (UMass1 and UMass6) with modifications at the P1′ 
moiety. b) WT protease (magenta) inhibited by DRV (green), UMass1 (pink), and 
UMass6 (purple) c) DRV (green) bound to WT (magenta), I84V (cyan), V82I 
(orange), and I50V (gold) protease variants.  
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DRV and analogs have been and continue to be the subject of chemical, 
viral, structural and dynamics studies78. Modifications to the bis-THF P2 moiety of 
DRV, including fluorine decorations, expansion to tris-THF and fusion into a tri-
cyclic group33, 79-80 and additional modifications of the P1 and P2’ moiety have been 
shown to improve potency and resistance profiles81-83. Our computational studies 
suggested that P1′ and P2′ moieties of DRV could be further optimized84 while still 
staying within the substrate envelope. Accordingly, we previously designed, 
synthesized and evaluated a panel of 10 DRV analogs with varying P1′ and P2′ 
moieties, and demonstrated that substrate envelope-guided design can achieve 
improved inhibition and potency against resistant variants45. These inhibitors, 
named UMass1–10, have subsequently served us as tools to probe subsite 
interdependency55, water structure85, and structural changes in solution by NMR86.  
Among these analogs, UMass1 and UMass6 share the same P2’ moiety with DRV 
but have larger hydrophobic groups at the P1′ position [Figure 2.2a] leveraging 
the unexploited space in the S1′ pocket of the substrate envelope. Thus this set of 
3 inhibitors, varying only by the size of the hydrophobic P1’ moiety, is ideal to probe 
the interplay between inhibitor modifications and protease mutations in the S1′ 
subsite. The underlying mechanism of how P1′ modifications may affect inhibitor 
response to resistance mutations surrounding the moiety had not been 
investigated. 
In this work, we investigate the interdependency of potency loss for HIV-1 
protease inhibitors that differ at the P1′ moiety (DRV, UMass1, and UMass6) 
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[Figure 2.2a], with WT and 3 variants of HIV-1 protease bearing mutations at 
residues in the S1/S1′ pocket. The hydrophobic residues I84, V82 and I50 that 
form the S1′ pocket where the P1′ moiety binds [Figure 2.1] (as well as the S1 
pocket, as the protease is a homodimer) are all highly variable, and mutations are 
implicated in many instances of drug resistance, commonly mutating to I84V, V82I, 
and I50V38, 87-88 in multi-mutant protease variants. Enzyme inhibition assays were 
performed and a complete set of 12 crystal structures were determined for the 
inhibitor–protease combinations. Principal component analysis (PCA) was applied 
for a collective analysis of the determined structures, which was able to distinguish 
inhibitor potency and identity based solely on the intermolecular van der Waals 
contacts. Based on our results, we expect similar applications of PCA can be 
extended to deconvolute the major determinants underlying resistance/potency in 
other systems, and to develop predictive models to assess inhibitor potency in drug 
design.   
2.3 Results  
To elucidate the mechanisms of resistance and impact on potency of primary 
S1′ mutations, enzymatic assays and crystal structural analysis were performed 
with WT HIV-1 protease and 3 variants. The WT protease had the near-consensus 
clade B sequence of the NL4-3 strain. All three protease variants had a single 
mutation that altered the shape of the hydrophobic S1/S1′ pocket of HIV-1 protease: 
I50V, V82I and I84V. Three inhibitors, DRV with an isobutyl P1′ moiety and 2 
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analogs in which the P1′ moiety was extended to better fill the substrate envelope, 
UMass1 with a methylbutyl and UMass6 with an ethlybutyl moiety,45 were analyzed. 
2.3.1 Enzymatic Activity of Protease Variants 
The enzymatic activity of WT HIV-1 protease and chosen variants (I84V, V82I 
and I50V) were tested using a natural substrate sequence (MA/CA)89 [Table 2.1]. 
WT NL4-3 HIV-1 protease had a Michaelis-Menten constant, Km, of 71 ± 7 µM for 
cleaving this substrate, which was similar to that of I84V and V82I variants (66 ± 4 
and 62 ± 4 µM, respectively). The primary resistance mutation I50V is known to 
reduce catalytic activity,77 and while I50V is still catalytically active, the Km value is 
beyond the limit of detection for this assay. A71V, a compensatory mutation that 
is far from the active site and almost always observed with I50V, restores the 
functionality to WT level (Km = 73 ± 9 µM), as previously reported.77 A time-course 
gel shift assay confirmed the catalytic activity of I50V single mutant, and the 
rescued activity of I50V/A71V variant in cleaving purified Gag polyprotein [Figure 
2.3]. The sustained catalytic activity of proteases across all variants indicates 
these primary mutations can indeed appear early in drug resistance pathways 
without compromising substrate cleavage.  
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Table 2.1 Km of HIV-1 protease variants measured using a natural substrate 
sequence.  
WT I84V V82I I50V I50V/A71V 
Km (µM) 71.4 ± 6.8 66.4 ± 4.3 61.7 ± 4.4 Undefined 73.2 ± 9.1 
Figure 2.3 Time course assay of I50V and I50V/A71V cleaving HIV-1 Gag 
polyprotein.  
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2.3.2 Effect of P1′ Modifications on Inhibition of Variants with Active Site 
Mutations 
The enzyme inhibition constant (Ki) was measured to determine the potency 
of inhibitors against each HIV-1 protease variant [Table 2.2] using an optimized 
assay90. The optimized assay enabled Ki determination with smaller errors and 
lower enzyme concentrations, and gave results that were overall comparable to 
previously published values45. Although the assay is optimized, the lower limit of 
detection is about 5 pM and all 3 inhibitors were too potent to obtain a reliable 
value against WT protease. The V82I mutation did not confer any measurable 
resistance for the inhibitors, with the Ki staying below 5 pM. The I84V mutation 
caused a reduction in potency, with the Ki increasing to around 25 pM for DRV and 
UMass1, and approximately half of that for UMass6. Thus, the inhibitor with the 
largest P1′ moiety performed 2-fold better than the other inhibitors against I84V 
variant. The I50V mutation was more deleterious with Ki values increasing by two 
orders of magnitude relative to WT protease. Interestingly, UMass6 performed 
slightly worse than DRV and UMass1 (Ki = 146 ±11 versus 117 ± 6 and 131 ± 8 
pM, respectively). Although both I84V and I50V mutations cause the same 
reduction in side chain size, these two mutations had the opposite effect on the 
change in potency of UMass6 compared to DRV and UMass1. 
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Table 2.2 Enzyme inhibition constant, Ki (pM), of inhibitors against WT protease 
and variants with primary mutations, measured using an optimized enzymatic 
assay.  
Inhibitor WT I84V V82I I50V I50V/A71V 
DRV < 5 25.6 ± 5.6 < 5 117.2 ± 5.8 74.5 ± 5.6 
UMass1 < 5 26.1 ± 3.7 < 5 131.3 ± 8.2 110.3 ± 8.8 
UMass6 < 5 12.8 ± 3.1 < 5 146.2 ± 10.7 100.0 ± 9.9 
2.3.3 Structural Rearrangements Underlying DRV Susceptibility to Primary 
Resistance Mutations 
To determine the structural basis of observed potency changes due to 
primary resistance mutations around the P1′ moiety, each protease variant was 
co-crystalized with each inhibitor resulting in a set of 12 crystal structures [Table 
2.3]. All structures were solved in the same space group with a resolution of 2 Å 
or better and in the same NL4-3 background, affording detailed investigation of 
atomic interactions (our previous structures of these inhibitors45 were determined 
with SF-2 protease). We determined the crystal structures of DRV, UMass1 and 
UMass6 bound to WT HIV-1 protease of NL4-3 strain, which was also used in the 
enzymatic assays above.  
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Table 2.3 X-Ray Crystallography Statistics 
Protein NL4-3 NL4-3 NL4-3 NL4-3 NL4-3 NL4-3 NL4-3 NL4-3 NL4-3 NL4-3 NL4-3 NL4-3 
Mutation WT WT WT I84V I84V I84V V82I V82I V82I I50V I50V I50V 
Inhibitor DRV UMass1 UMass6 DRV UMass1 UMass6 DRV UMass1 UMass6 DRV UMass1 UMass6 
PDB ID 6DGX 6DGY 6DGZ 6DH0 6DH1 6DH2 6DH3 6DH4 6DH5 6DH6 6DH7 6DH8 
Resolution (A) 2.00 1.95 2.00 1.90 1.97 1.98 1.91 1.94 2.00 1.97 2.00 1.95 
Space Group P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 
a (A) 51.0 51.2 51.2 51.1 51.3 51.3 51.3 51.3 51.4 51.1 51.1 51.8 
b (A) 58.3 58.0 58.2 58.1 57.9 57.8 58.0 57.8 57.9 58.0 57.8 56.7 
c (A) 61.9 62.2 62.0 61.8 62.1 62.1 62.2 62.2 62.3 62.1 62.2 61.5 
Completeness 98.1 98.0 94.1 99.9 94.6 95.0 96.9 95.6 96.8 98.5 98.5 99.4 
Tot. Reflections 84332 89641 55311 181306 73682 92688 68517 69346 88129 141343 58534 95807 
Uniq. Reflect. 12758 13687 12406 15103 12875 12775 14540 13520 12472 13416 12857 13663 
Avg I/Sig 17.5 12.6 16.0 12.4 8.9 12.6 13.6 14.1 16.9 11.3 19.8 14.8 
Redundancy 6.6 6.5 4.5 12.0 5.7 7.3 4.7 5.1 7.1 10.5 4.6 7.0 
R-Merge (Lin) 0.057 0.095 0.059 0.057 0.071 0.067 0.063 0.065 0.093 0.068 0.076 0.095 
RMSD Bonds* 0.003 0.003 0.005 0.003 0.003 0.004 0.003 0.002 0.002 0.003 0.008 0.004 



























*Based on Phenix Program
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When DRV and other peptidomimetic inhibitors bind to HIV-1 protease, the 
hydroxyl moiety is centered between the catalytic aspartates (D25/D25′) and the 
inhibitor makes a number of additional hydrogen bonding interactions with the 
backbone nitrogen and oxygen atoms of residues that line the active site [Figure 
2.1c]. DRV also makes a key water-mediated interaction with the backbone 
nitrogen of residue 50, located at the tip of each flap. DRV’s P1 and P1′ moieties 
are hydrophobic and interact with hydrophobic residues/pockets in the hinge of the 
flaps. Inhibitor potency diminishes if any of these polar or non-polar interactions 
are perturbed.  
DRV-bound crystal structures were compared to reveal any structural 
rearrangements in response to single mutations at the active site. Overall, the 
structures were highly similar [Figure 2.2]. In agreement with the maintained 
potency against V82I variant, the hydrogen bonding and packing of DRV at the 
active site was conserved in the V82I crystal structure [Figure 2.2b and Table 
2.4]. The additional steric bulk of the isoleucine side chain is not directed towards 
the inhibitor but instead is solvent exposed, and does not perturb inhibitor binding. 
As in the V82I variant, the binding mode and hydrogen bonds of DRV were not 
altered in I84V and I50V structures [Figure 2.2b]. However, van der Waals (vdW) 
interactions with residues 84 and 84’ decreased due to I84V mutation, which was 
in part compensated by increased packing against I47 and V82′ [Table 2.4]. In the 
I84V variant, residues V32′ and L23′ in chain B underwent a side chain conformer 
change relative to WT protease [Figure 2.4]. In addition, residue I47 was found in 
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an alternative rotamer in chain A, causing increased inhibitor interactions with that 
residue. This asymmetric compensation indicates subtle alterations in the overall 
packing of the inhibitor at the active site, which reduced the effect of I84V mutation 
on potency.  
A similar repacking was also observed in the I50V–DRV structure, where 
increased packing against I47 in both chains compensated lost vdW interactions 
at residue 50. Our previous computational analysis had indicated I47 as a major 
modulator of DRV-protease interactions54. Thus, the structures explain why the 
V82I single mutation did not confer resistance to DRV, and in agreement with 
previous studies reveal the rearrangements in vdW packing around DRV 
underlying susceptibility to I50V77, 91. Importantly, intermolecular interactions are 
not solely altered at the site of mutation but throughout the active site, urging a 
more detailed structural analysis. 
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Table 2.4 Change in intermolecular van der Waals (vdW) interactions between inhibitor and protease active site 
residues relative to WT complex. Only residues with changes greater than 0.40 kcal/mol are listed. Primed residue 
numbers correspond to chain B. Decrease and increase in per residue contacts with respect to WT protease are 
colored blue to red, respectively. 

















30 0.28 -0.14 -0.83 0.46 0.05 -0.44 0.00 -0.01 -0.48
47 1.22 1.07 1.12 -0.02 -0.04 1.12 1.19 -0.08 -0.18
48 0.49 0.10 0.22 0.14 0.13 0.26 0.34 0.05 -0.18
49 0.33 -0.02 0.08 0.06 0.10 0.25 0.19 0.27 -0.44
50 -0.50 -0.60 -0.53 -0.11 -0.04 0.13 -1.70 -1.32 -1.94
84 -1.17 -1.10 -1.17 -0.12 0.15 -0.01 -0.05 0.27 -0.31
23' -0.60 -0.33 -0.25 -0.06 -0.17 -0.11 0.10 -0.09 -0.07
25' -0.41 -0.31 -0.37 0.10 0.01 -0.11 -0.08 0.04 -0.30
28' -0.55 -0.34 -0.28 0.06 0.29 0.24 0.02 0.40 -0.47
47' -0.36 -0.47 -0.42 0.20 0.04 -0.02 0.49 0.09 0.41
48' -0.16 -0.03 0.03 -0.01 0.16 0.19 0.15 0.15 0.44
49' -0.09 -0.07 0.07 -0.03 0.09 0.19 0.18 0.16 0.61
50' -0.08 0.16 -0.03 -0.09 0.11 0.03 -0.84 -0.44 0.17
82' 1.17 1.03 0.83 0.23 0.41 0.27 0.10 0.15 0.21
84' -1.82 -1.61 -1.54 -0.03 -0.03 -0.02 0.03 -0.23 -0.21
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Figure 2.4 Side chains at the protease active site surrounding the bound inhibitor 
(not shown) in the crystal structures.  Alignment of protease active site residues 
when (Top) DRV, (Middle) UMass1, and (Bottom) UMass6 is bound to WT 
(magenta), I84V (cyan), V82I (orange), and I50V (gold) protease variants. 
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2.3.4 Structural Response to Modifying P1′ Moiety Against Primary 
Mutations  
The larger P1′ moieties of UMass1 and UMass6 were designed to improve 
hydrophobic packing and increase vdW contacts with the protease while still 
staying within the substrate envelope45. Accordingly, the total vdW energy of 
intermolecular interactions between the inhibitor and protease increased by 1.6 
and 4.7 kcal/mol, respectively for UMass1 and UMass6, as the P1′ moiety 
increased in size [Table 2.5]. However, the simple measure of total vdW 
interaction energy is not sufficient to explain the overall Ki value trends, suggesting 
a more comprehensive residue-based analysis may be needed to capture inhibitor 
potency. In the V82I structure, while DRV did not gain significant interactions 
compared to WT complex, UMass1 and UMass6 gained approximately 2 kcal/mol 
in vdW energy as their P1′ moieties directly interact, but not clash, with the 
sterically larger side chain. Thus, although the Ki values are below the limit of 
detection, structural analysis suggests that V82I mutation might confer hyper-
susceptibility to UMass1 and UMass6 inhibitors; thus unlike with DRV, the V82I 




Table 2.5 Total van der Waals interactions (kcal/mol) between inhibitor and 
protease in crystal structures. 
Inhibitor \ Protease WT I84V V82I I50V 
DRV -83.1 -80.6 -83.5 -82.9 
UMass1 -84.7 -82.5 -86.6 -85.7 





The co-crystal structures of UMass1 bound to WT protease and variants were 
very similar to those of DRV [Figure 2.2c], albeit with subtle alterations. Against 
I84V and I50V mutations, which are located directly at the pocket where P1′ moiety 
binds, UMass1 experienced a similar reduction in potency as DRV [Table 2.2]. 
The UMass1–I84V structure displayed the same phenomenon of asymmetric 
inhibitor repacking as with DRV [Table 2.4]. The additional methyl group in 
UMass1 is oriented away from the steric space provided by the I84V mutation but 
still makes additional contacts with P81 and V82. When UMass1 bound I50V, there 
was a reduction in vdW interactions at residue 50 and 50′ as seen for DRV, but no 
compensation at residue 47. Instead, repacking of UMass1 increased against G49 
and I84 in chain A, and residues 28–30 in chain B. However, this alternate 
compensation was more distributed and subtle, which may underlie the slightly 
worse Ki of UMass1 compared to DRV against I50V protease. Thus, the crystal 
structures indicate that although the potency loss against I50V is similar for DRV 
and UMass1, the underlying structural changes and repacking at the active site 
are distinct. 
2.3.5 I50V Mutation Induces Conformational Changes in Both UMass6 and 
Protease Flaps  
UMass6 has an even bulkier P1′ moiety than UMass1 and binds WT protease 
similar to DRV and UMass1 [Figure 2.2c] but with enhanced overall vdW 
interactions (-87.8 kcal/mol compared to -83.1 and -84.7, respectively; Table 2.5). 
Against I84V mutation, enhanced packing at the P1′ moiety of UMass6 resulted in 
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overall better interactions and potency. In UMass6, the methyl groups on both 
branches of the P1′ moiety help UMass6 to better accommodate the steric space 
provided by the I84V mutation, leading to a 2-fold improvement in Ki compared to 
the other two inhibitors.  
Contrary to the case of I84V mutation, UMass6 bound to the I50V variant 
with the lowest potency. Unexpectedly, the P1′ moiety of UMass6 in I50V protease 
structure adopted a completely different conformation compared to the other 11 
structures [Figure 2.5]. In addition to this inhibitor’s unique binding conformation, 
the flaps in I50V protease underwent rather large-scale changes: In chain A, I47 
assumed a rare rotamer to maintain interaction with the sterically smaller I50V 
[Figure 2.4]. In chain B, T80 underwent a conformational change which may affect 
flap-tip curling and flexibility92,93. This conformational change caused the flaps to 
bow outward [Figure 2.5c] away from UMass6, further reducing vdW contacts. 
Interestingly, the resulting vdW losses of UMass6 with residue 50 due to the I50V 
mutation were completely asymmetric, with a loss similar to DRV and UMass1 in 
chain A but almost no loss in chain B [Table 2.4]. However, there was no 
compensation at residue 47 interactions in either chain, due to the different 
conformer of I47, which resulted in a greater overall loss in vdW interactions, in 





Figure 2.5 The P1′ moiety of UMass6 bound to the I50V variant and the protease 
flaps exist in an alternate conformation. a) Superposition of WT-UMass6 (magenta) 
and I50V-UMass6 (gold) structures, displaying the inhibitor and the flap region. 
Residues 47-53 in both monomers are shown as sticks. b) The same superposition 
with 90° rotation to show the top view of the flap region.  
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Although the position of most of the flap residues were altered in the 
UMass6–I50V structure relative to WT complex, the typical hydrogen bond 
distances were not significantly perturbed [Figure 2.6, Table 2.6]. However, the 
flipping of the flaps caused a noticeable shift in the location of the so-called flap 
water [Figure 2.6], which is crucial for flap stabilization94, and which in turn caused 
the sulfonyl group to shift toward the flaps to maintain H-bond distances. The shift 
of the sulfonyl group fused to the aniline P2′ moiety weakened the bond formed by 
the conjugated water interacting with the side chain of D30 by making the overall 
distance longer. Weakening of inhibitor hydrogen bonding with D29-D30 has been 






Figure 2.6 a) Hydrogen bonding between inhibitor and protease active site in the 11 of 12 co-crystal structures. 
Coordinated waters are shown as green spheres. Hydrogen bonds are indicated with black dashes. (b) Hydrogen 
bonding in I50V-UMass6 crystal structure. Coordinated waters are shown as red spheres. (c) Alignment of WT-



































WT-DRV 2.9 3.2 2.8 3.0 3.2 2.5 2.9 2.5 3.0 2.8 3.1 2.9 3.1 2.9 2.9 
I84V-DRV 2.9 3.1 2.8 3.1 3.3 2.5 3.0 2.6 2.8 2.7 3.0 2.9 3.1 2.8 3.1 
V82I-DRV 2.9 3.1 2.8 3.1 3.3 2.5 2.9 2.5 2.8 2.8 3.0 3.0 3.1 2.8 2.9 
I50V-DRV 2.9 3.0 2.8 3.1 3.2 2.5 2.9 2.5 2.8 2.7 3.0 3.0 3.0 2.8 3.1 
WT-UMass1 3.0 3.1 2.8 3.1 3.2 2.6 2.9 2.5 2.8 2.7 3.0 3.0 3.1 2.8 2.7 
I84V-UMass1 3.1 3.2 2.8 3.1 3.3 2.5 2.9 2.4 2.7 2.7 2.9 3.1 3.0 2.8 3.1 
V82I-UMass1 3.1 3.2 2.8 3.1 3.2 2.5 2.8 2.5 2.8 2.8 3.0 3.1 2.9 2.8 2.9 
I50V-UMass1 3.0 3.1 2.8 3.0 3.3 2.5 2.9 2.5 2.6 2.8 2.9 3.1 2.9 2.8 3.1 
WT-UMass6 3.0 3.1 2.8 3.1 3.3 2.6 3.0 2.5 2.8 2.8 3.0 3.0 3.1 2.6 3.0 
I84V-UMass6 3.1 3.2 2.8 2.9 3.3 2.5 3.0 2.5 2.8 2.7 2.9 3.1 3.1 2.7 3.2 
V82I-UMass6 3.1 3.3 2.7 3.0 3.1 2.5 2.8 2.6 2.9 2.6 2.9 3.1 3.0 2.8 3.2 
I50V-UMass6 3.1 3.2 2.8 2.9 3.2 2.6 2.9 2.5 2.8 2.9 3.0 2.9 3.0 2.7 3.4 
 
Table 2.6 Hydrogen bonding distances (in Å) for intermolecular protease-inhibitor hydrogen bonds in the crystal 
structures. The hydrogen bonds are displayed above as black dashed lines on the WT–DRV crystal structure for 
reference, where DRV is in green sticks and water molecules are displayed as red spheres.  
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The structural rearrangements of the protease in the I50V–UMass6 
structure were quantified and visualized by distance-difference matrices [Figure 
2.7]. Distance-difference matrices measure the internal distances between alpha 
carbon atoms of every residue pair in a structure, then compare each distance to 
that in a reference structure, which in our case is the inhibitor bound to WT 
protease. This method detects conformational changes due to a mutation without 
any structural superposition bias. Comparison of the variant structures to their 
corresponding WT structures shows the discrepancy between the I50V–UMass6 
and all the other 11 structures [Figure 2.7]. Mapping the distance-differences onto 
the 3D structure revealed that the structural changes due to I50V in the UMass6-




Figure 2.7 Distance-difference matrices comparing HIV-1 protease variant-





Figure 2.8 Cartoon-putty diagrams depicting the mean changes in Cɑ distance 
differences relative to WT protease crystal structure. Tube thickness and warm 





2.3.6 Principal Component Analysis (PCA) of Residue-Specific Interactions 
The set of 12 inhibitor–protease crystal structures and the corresponding Ki 
values enabled a collective analysis of the interplay between inhibitor modifications 
and protease mutations in the S1/S1′ subsite. First, the intermolecular vdW 
interaction energy with the inhibitor for each residue in a given structure was 
calculated for each of the 12 structures to yield a 198x12 matrix. Although this 
matrix contains rich information on the molecular basis of inhibitor potency, the 
multidimensionality and complexity of the data precludes deducing what specific 
properties are responsible for the observed variation. Thus, the matrix of residue-
wise vdW contacts was subjected to principal component analysis (PCA) to extract 
principal components (PC) that best account for the variance in data. The first three 
principal components (PCs) accounted for 83% of the observed variance, with the 
first PC (PC1) accounting for approximately half (43%) of the variance [Figure 2.9]. 
In addition to reducing the dimensionality of the dataset and, the PCs reveal what 





Figure 2.9 Principal component analysis (PCA) of per residue vdW 
interactions in the 12 crystal structures. (a) Explained variance of the first 12 
principal components. (b) Loading of the first 3 principal components, showing the 
contribution of residues to the PCs.  
 
 
The PC1 separated the structures mainly according to the protease variant, 
rather than inhibitor identity [Figure 2.10]. Significantly, structures containing the 
I84V primary resistance mutation of all 3 inhibitors clustered away from the 
remaining structures. Inspection of the loading indicated PC1 was largely 
determined by changes in vdW interactions between the inhibitor and residue 84 
[Figure 2.9]. This is in agreement with our previous work that showed that 
mutations at residue 84 significantly alter the pattern of vdW contacts in a panel of 
drug resistant variants.96 Additionally, contacts between I47 and the inhibitor 
contributed significantly to the spread along PC1, which can assume a different 
side chain conformer and compensate for loss of interactions at residue 84 as 





Figure 2.10 Principal component analysis of vdW interactions in the 12 protease-inhibitor 
complexes. (left) The protease–inhibitor pairs plotted according to first and second 
principal components, PC1 versus PC2 (upper panel) and PC2 versus PC3 (lower panels).  
In the plots, circles (DRV), plus signs (UMass1), and squares (UMass 6) indicate different 
inhibitors and colors (magenta: WT, yellow: I50V, orange: V82I, cyan: I84V) indicate 
protease variant.  The blue oval and straight lines are shown to guide the eye and highlight 
clusters. (right) The contribution of individual residues to the PCs according to the loading 
vector are depicted on protease backbone structure using cartoon-putty diagrams, where 
tube thickness indicates higher weights and warm colors are positive loading and cold 
colors are negative loading. Residues with the highest weights are labeled on the cartoon-
putty for PC1.  
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The second and third principal components (PC2 and PC3) together 
accounted for 40% of the observed variance in inhibitor–protease vdW interactions. 
PC2 separated structures mostly according to inhibitor identity, rather than 
protease variant [Figure 2.10]. Inspection of the loading of PCs showed that 
variance at residues 84 and 50′ contributed significantly to the ordering of 
structures along PC2, indicating modification of inhibitor P1′ moiety caused 
alteration in packing against these residues [Figure 2.9b]. The contribution of 
residue 50 in chain A had the same direction for both PC2 and PC3 whereas the 
contributions of 84 and 50′ had the opposite direction. Contacts between the 
inhibitor and residues 84 and 50′ changed significantly in the presence of a small 
P1’ moiety but were less effected when the P1′ moiety was larger. Overall, the PCA 
captured the asymmetric compensation of vdW interactions observed in the crystal 
structures, and quantified the contribution of residue-specific interactions to the 
overall variance in the dataset.  
Strikingly, plotting PC2 and PC3 against each other enabled separating the 
12 crystal structures both according to inhibitor identity and potency [Figure 2.10]. 
All 6 inhibitor-protease pairs with <5 pM affinity clustered on a line defined by a 
linear combination of PC2 and PC3. Intriguingly, the I84V and I50V complexes fell 
on separate but parallel lines, together defining a set of 3 roughly parallel lines on 
the PC2-PC3 plane. These 3 lines were ordered according to experimentally 
measured potency, with the I84V complexes nearer to the high affinity line, 
followed by the I50V complexes. Additionally, 3 other roughly perpendicular lines 
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separated the inhibitor-protease pairs according to inhibitor identity. The inhibitors 
were also ordered, according to the chemical similarity of their P1′ moieties as 
DRV-UMass1-UMass6. Thus, the collective analysis of the set of 12 crystal 
structures using PCA enabled clustering inhibitor identity and potency based solely 
on per residue vdW contacts, indicating this information is sufficient to discern 
inhibitors. 
2.4 Discussion  
In this study the interplay between modifications of an inhibitor’s functional 
group and modifications known to confer drug resistance that surround that 
functional group.  Specifically, we have investigated HIV-1 protease inhibitor DRV 
and two analogs and assessed modifications at P1′ and how these analogs 
interactions by three single site drug resistant variants. A set of 12 high-resolution 
crystal structures comprising three analogous inhibitors bound to WT protease and 
three variants allowed a collective analysis of inhibitor-protease interactions in 
modulating potency and resistance. The overall intermolecular vdW energy or 
hydrogen bonding was not sufficient to explain the observed inhibitor potency; thus 
we employed a more comprehensive and residue-based analysis. The residue-
based vdW contact energies in all 12 structures was subjected to PCA, which not 
only identified the key residues that determined the variance in inhibitor packing 
but also captured the asymmetry in this variance. Rather than visual inspection or 
manual comparison, PCA enabled an unbiased quantitative assessment of 
intermolecular interactions collectively in all the 12 structures. 
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More significantly, clustering of the structures along major PCs was able to 
categorize the inhibitor-protease pairs according to inhibitor type and potency. This 
suggests residue-specific vdW interactions may serve as “fingerprints” to 
categorize and classify inhibitors bound to protease, particularly for inhibitors 
similar to those used here. PCA has recently been applied to overall structures of 
HIV-1 protease deposited in the PDB to cluster and categorize protease 
conformations97-98. As with any mathematical model, the training set (or the input 
data) needs to be appropriate for the purpose and expanded when possible to 
improve the model and enable assessing more diverse inhibitors. In addition, 
analyzing mutations that involve polar or charged residues will likely require 
analyzing intermolecular electrostatic interactions in addition to vdW contacts. 
Nevertheless, we found here that certain simple and linear combinations of PCs, 
derived from complex and multidimensional structural data, might be indicators or 
even predictors of inhibitor potency. 
DRV and the analogs used differ only at the P1’ moiety. The larger, flexible 
P1′ groups of UMass1 and UMass6 were previously shown to increase potency 
compared to DRV in cellular assays, specifically against a panel of WT clades and 
drug resistant variants with many mutations45. Our results validated that larger P1′ 
moieties were effective against I84V and V82I mutations, but an unexpected 
alternative mechanism of resistance was uncovered against the I50V mutation. 
The I50V mutation is commonly observed in variants that are resistant to DRV, and 
has previously been investigated34, 75. Unlike DRV and UMass1, the P1’ group of 
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UMass6 is large enough to be able to contribute a methyl group to interact with the 
destabilized hydrophobic interactions involving the flap tips. However, this 
interaction affects the orientation of V50, which to avoid an unfavorable side chain 
rotamer, induces flipping of the flaps and a rather unforeseen conformational 
rearrangement. A similar but distinct flap rearrangement was previously observed 
in response to a coevolution mutation in Gag substrate in the I50V/A71V variant, 
which enhances vdW interactions with the substrate40. Hence the relative flexibility 
of flaps in this variant might be able to enhance interactions with substrates while 
weakening inhibitor binding, thus contributing to conferring resistance. 
Unlike the other two mutations, V82I did not confer measurable resistance 
against the inhibitors tested. However, crystal structures suggested that the 
intermolecular interactions are improved for UMass1 and UMass6 relative to WT 
protease, unlike for DRV. Thus, the bulkier P1′ groups in UMass inhibitors might 
cause hyper-susceptibility to V82I and prevent selection of this mutation on 
resistance pathways. However, groups larger than that in UMass1 may act as a 
selective pressure forcing I50V to become a dominant variant. Thus, despite high 
similarity, inhibitors with P1′ modifications may select distinct mutational patterns 
of resistance. 
The analysis on three inhibitor analogs here revealed that the basic idea that 
a larger P1′ moiety would help the inhibitor to retain better interactions upon 
shortening of a side chain is not necessarily correct. Rather than a simple alteration 
in interactions at this subsite, there was an overall and asymmetric rearrangement 
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of the vdW interactions throughout the active site pocket due to either I84V or I50V 
mutation. As intended, the bulkier P1′ moiety of UMass6 helped to retain better 
potency against I84V, but the reverse was the case for I50V mutation. Thus, 
although both I84V and I50V are primary resistance mutations with the same side 
chain change in the S1′ pocket, the interplay between P1′ moiety and 
rearrangements of inhibitor interactions were distinct, and moreover contrasting for 
these two mutations. These unexpected and distributed alterations in 
intermolecular interactions prompted the application of PCA for a collective and 
comprehensive analysis of the crystal structures. The analysis revealed the 
interplay between inhibitor modifications and structural response of the target with 
primary mutations underlying resistance, indicating PCA may be a useful tool to 
extract determinants or even predictors of inhibitor potency from complex structural 
information. 
2.5 Materials and Methods 
2.5.1 Protease gene construction  
Protease gene construction was carried out as previously described40, 99. The 
NL4-3 strain has four naturally occurring polymorphisms in the protease relative to 
the SF2 strain78, 100.  In short, the protease variant genes (I50V, V82I, I84V) were 
constructed using QuikChange site-directed mutagenesis (Genewiz) onto NL4-3 
WT protease on a pET11a plasmid with codon optimization for protein expression 
in Escherichia coli. A Q7K mutation was included to prevent autoproteolysis101.  
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2.5.2 Protein expression and purification  
The expression, isolation, and purification of WT and mutant HIV-1 proteases 
used for the kinetic assays and crystallization were carried out as previously 
described40, 99. Briefly, the gene encoding the HIV protease was subcloned into the 
heat-inducible pXC35 expression vector (ATCC) and transformed into E. coli TAP-
106 cells. Cells grown in 6L of Terrific Broth were lysed with a cell disruptor and 
the protein was purified from inclusion bodies102. The inclusion body centrifugation 
pellet was dissolved in 50% acetic acid followed by another round of centrifugation 
to remove impurities. Size exclusion chromatography was used to separate high 
molecular weight proteins from the desired protease. This was carried out on a 
2.1-L Sephadex G-75 superfine (Sigma Chemical) column equilibrated with 50% 
acetic acid. The cleanest fractions of HIV protease were refolded into a 10-fold 
dilution of 0.05 M sodium acetate at pH 5.5, 5% ethylene glycol, 10% glycerol, and 
5 mM DTT. Folded protein was concentrated down to 0.5-3mg/mL and stored. This 
stored protease was used in Km and Ki assays. For crystallography, a final 
purification was performed with a Pharmacia Superdex 75 FPLC column 
equilibrated with 0.05 M sodium acetate at pH 5.5, 5% ethylene glycol, 10% 
glycerol, and 5 mM DTT. Protease fractions purified from the size exclusion column 




2.5.3 Enzymatic Assays to Determine Km and Ki 
The Km and Ki Assays were carried out as previously described89-90. In the 
Km assay, a 10-amino acid substrate containing the natural MA/CA cut site with an 
EDANS/DABCYL FRET pair was dissolved in 8% DMSO at 40nM and 6% DMSO 
at 30 nM. The 30 nM of substrate was 4/5th serially diluted from 30 nM to 6 nM, 
including a 0 nM control. HIV protease was diluted to 120 nM and, using a 
PerkinElmer Envision plate reader, 5 µL was added to the 96-well plate to obtain 
a final concentration of 10 nM. Km assays were conducted in triplicate. The 
fluorescence was observed with an excitation at 340 nm and emission at 492 nm 
and monitored for 200 counts, for approximately 23 minutes. FRET inner filter 
effect correction was applied as previously described103. Data corrected for the 
inner filter effect was analyzed with Prism7. Fluorescence intensity as a function 
of time was used to calculate initial velocities by fitting the curves as a single 
exponential increase. Initial velocities were then fit by non-linear regression to the 
Michaelis-Menten equation to determine Km and the standard error of the mean 
(SEM) was calculated.   
To determine the Ki, in a 96-well plate, each inhibitor was 2/3 serially diluted 
from 3000 pM to 52 pM, including a 0 pM control, and incubated with 0.35 nM 
protein for 1 hour. A 10-amino acid substrate containing an optimized protease cut 
site with an EDANS/DABCYL FRET pair was dissolved in 4% DMSO at 120 µM. 
Using the Envision plate reader, 5 µL of the 120 µM substrate was added to the 
96-well plate to a final concentration of 10 µM. Ki assays were conducted in 
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triplicate. The fluorescence was observed with an excitation at 340 nm and 
emission at 492 nm and monitored for 200 counts, for approximately 60 minutes. 
Data was analyzed with Prism7. Fluorescence intensity as a function of time was 
used to calculate initial velocities by non-linear regression using the one-phase 
association equation (single exponential increase). The initial velocities as a 
function of inhibitor concentration were fit by non-linear regression to the Morrison 
Equation to obtain Ki values and the standard error of the mean (SEM) was 
calucated from the global fit of all data points for triplicates.  
2.5.4 Gag Polyprotein Cleavage Assay 
 The pET28a plasmid containing full length Pr55Gag-TEV-His construct was 
a kind gift from Maria Bewley and John Flanagan. Protein expression and 
purification was done as described by Bewley et al. (Protein Expr Purif, 2017; 
130:137-145) and consists of the removal of DNA and ammonium sulfate 
precipitation. On the day of the assay, ammonium sulfate pellets were dissolved in 
resuspension buffer (10 mM HEPES pH 7.5, 500 mM NaCl, 0.1 mM TCEP and 0.1 
mM EDTA) and diluted 1:5 with the same buffer without NaCl. The final solution 
was centrifuged at 20k x g for 20 min. Cleavage of Pr55Gag polyprotein by HIV-1 
protease was monitored by SDS-PAGE of cleavage products visualized by 
Coomassie staining. Samples were taken from the reaction mixture at designated 
time points, and the cleavage reaction was quenched by adding gel running buffer 
containing SDS and boiling for 2 min. Samples without any added protease (P55) 
and the protease itself (Enz) were also visualized on the gels. Amprenavir (APV), 
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a potent HIV-1 protease inhibitor, was used in the negative controls for non-
cleavage. Gag cleavage by I50V protease was detectable even at early time points, 
indicated by disappearing of the high-molecular weight band corresponding to full-
length Gag, and appearance of lower molecular weight cleavage products. 
2.5.5 Protein Crystallization 
Discovery of the condition producing reproducible co-crystals of DRV with 
NL4-3 WT protease was achieved using the JCSG+ screen (Molecular 
Dimensions), in well G11, consisting of 2 M Ammonium Sulfate with 0.1 M Bis-
Tris-Methane Buffer at pH 5.5 with a protease concentration of 1.9 mg/mL with 3-
fold molar excess of DRV and mixed with the precipitant solution at a 1:2 ratio. 
After optimization, all subsequent combinations of co-crystals were grown at room 
temperature by hanging drop vapor diffusion method in a 24-well VDX hanging-
drop trays (Hampton Research) with protease concentrations between 1.0 to 2.4 
mg/mL with 3-fold molar excess of inhibitors set the crystallization drops with the 
reservoir solution consisting of 23-24% (w/v) Ammonium sulfate with 0.1 M bis-
Tris-methane buffer at pH 5.5 set with 2 µL of well solution and 1 µL protein and 
microseeded with a cat whisker. Diffraction quality crystals were obtained within 1 
week. As data was collected at 100 K, cryogenic conditions contained the 
precipitant solution supplemented with 25% glycerol.  
2.5.6 Data Collection and Structure Solution 
Diffraction data were collected and solved as previously described40, 104. 
Diffraction quality crystals were flash frozen under a cryostream when mounting 
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the crystal at our in-house Rigaku_Saturn944 X-ray system. The co-crystal 
diffraction intensities were indexed, integrated, and scaled using HKL3000105. 
Structures were solved using molecular replacement with PHASER106. Model 
building and refinement were performed using Coot107 and Phenix108. Ligands 
were designed in Maestro and the output sdf file was used in the Phenix program 
eLBOW109 to generate the cif file containing atomic positions and  constraints 
necessary for ligand refinement. Iterative rounds of crystallographic refinement 
were carried out until convergence was achieved. To limit bias throughout the 
refinement process, five percent of the data were reserved for the free R-value 
calculation110. MolProbity111 was applied to evaluate the final structures before 
deposition in the PDB. Structure analysis, superposition and figure generation was 
done using PyMOL112. X-ray data collection and crystallographic refinement 
statistics are presented in the Supporting Information [Table S2].  
2.5.7 Structural Analysis and PCA 
Distance-difference matrices were generated for each inhibitor-mutant 
protease pair to reveal structural changes relative to that inhibitor bound to wild-
type protease, as previously described113. Briefly, distances between all Cα pairs 
in the mutant structure were calculated as an NxN matrix (N = 198 residues for 
HIV-1 protease), and then those corresponding distances in the wild-type structure 
were subtracted to construct the distance difference matrix. The mean deviation 
from the WT structure for each residue was then calculated by taking the average 
of the absolute value of all the N distance differences involving that residue, and 
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the backbone structure was represented as a cartoon-putty with increasing 
thickness and warmer color for increasing deviation. 
To calculate the intermolecular van der Waals (vdW) interaction energies the 
crystal structures were prepared using the Schrodinger protein preparation 
wizard114. Hydrogen atoms were added, protonation states determined and the 
structures were minimized. The protease active site was monoprotonated at D25. 
Subsequently forcefield parameters were assigned using the OPLS2005 
forcefield115. Interaction energies between the inhibitor and protease were 
estimated using a simplified Lennard-Jones potential, as previously described116. 
For each protease residue, the change in vdW interactions relative to WT complex 
was also calculated for the mutant structures. PCA of the data matrix was 
performed as described earlier43. For the calculation of the principal components, 
the implementation of PCA in scikit-learn was used117. Briefly, the intermolecular 
vdW interaction energy with the inhibitor for each residue in a given structure was 
calculated for each of the 12 structures to yield a 198x12 matrix. The 
dimensionality of the data set was then reduced using PCA to identify orthogonal 
linear combinations of variables, or principal components (PCs), that best account 
for the variance in the data. The PCs are ordered starting from first PC according 
to the greatest variance represented in the data, and contribution of the original 
variables to a given PC is represented by the loading vector.  
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 CHAPTER 3: 
pM to µM–Elucidating the Role of Distal Mutations in HIV-1 Protease in 




Drug resistance continues to be a growing, global problem. The efficacy of small 
molecule inhibitors is threatened by pools of genetic diversity in all systems, including 
antibacterials, antifungals, cancer therapeutics, and antivirals. Resistant variants often 
include combinations of active site mutations, and distal “secondary” mutations which are 
thought to compensate for losses in enzymatic activity. HIV-1 protease is the ideal model 
system to investigate these combinations and underlying molecular mechanisms of 
resistance. Darunavir (DRV) binds WT HIV-1 protease with a potency of < 5 pM, but we 
have identified a protease variant that loses potency to DRV 150,000-fold, with 11 
mutations in and outside the active site. To elucidate the roles of these mutations in DRV 
resistance, we used a multidisciplinary approach, combining enzymatic assays, 
crystallography, and molecular dynamics simulations. Analysis of protease variants with 
1, 2, 4, 8, 9, 10 and 11 mutations showed that the primary active site mutations caused 
~50-fold loss in potency (2 mutations), while distal mutations outside the active site further 
decreased DRV potency from 13 nM (8 mutations) to 0.76 µM (11 mutations). Crystal 
structures and simulations revealed that distal mutations induce subtle changes which 
are dynamically propagated through the protease. Our results reveal that changes remote 
from the active site directly and dramatically impact the potency of the inhibitor. Moreover, 
we find interdependent effects of mutations in conferring high levels of resistance. These 
mechanisms of resistance are likely applicable to many other quickly evolving drug 




3.2 Introduction  
Drug resistance is a growing global problem2-3. The efficacy of current drugs is 
threatened by pools of genetic diversity in many therapeutic targets, including 
antibacterials, antifungals, cancer therapeutics, and antivirals1. Specifically, rapid 
evolution in viruses can cause emergence of variants that are not effectively inhibited by 
small molecule inhibitors. Human immunodeficiency virus (HIV) is capable of 
accumulating a large number of mutations in response to antiretroviral therapy118-119.  
The viral enzymes coded by the HIV genome, including HIV-1 protease, have been 
targets of extensive drug development efforts. HIV-1 entry, nucleoside reverse 
transcriptase, non-nucleoside reverse transcriptase, integrase, and protease inhibitors 
are used in combination to curb the emergence of drug resistance. Resistance can 
develop quickly against a single agent, with mutations resulting from the high infidelity of 
the reverse transcriptase9, 120-121 and the high recombination rate of HIV11, 122. Mutations 
may also arise from patient non-compliance due to a number of factors, such as adverse 
side effects and high pill burden123. HIV-1 protease can tolerate a large number of 
mutations, with 45 out of 99 amino acid positions able to mutate while retaining adequate 
enzymatic activity to allow replication124. Viral variants from patients who failed therapy 
and in vitro selection experiments often contain complex combinations of multiple 
mutations. Especially with potent inhibitors, a single mutation is not sufficient and many 
mutations need to accumulate to confer appreciable levels of resistance. Under drug 
pressure, resistance and compensatory mutations accumulate in the gag and gag-pol 
viral polyproteins, resulting in often unpredictable and complex mechanisms of 
resistance125-126. Given the prevalence and complexity of these mutations and underlying 
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mechanisms, HIV-1 has served as a model system to identify, analyze, and characterize 
drug resistance. 
Darunavir (DRV) is the latest and most potent FDA-approved HIV-1 protease 
inhibitor78. The potency of DRV is due to several factors, including a number of crucial 
hydrogen bonds with the protease backbone, conservation of the water-mediated 
hydrogen bonding network with the flaps, and extensive van der Waals (vdW) contacts 
with active site residues84, 127. Moreover, DRV fits well within the substrate envelope (the 
consensus volume occupied by the natural substrates43), which explains its low 
susceptibility to resistance27, 45, 128. DRV can effectively inhibit variants with common 
single primary resistance mutations such as I84V and I50V/A71V37. However, high levels 
of resistance are reached as mutations accumulate, both within and outside the active 
site of HIV-1 protease.  
The combinations of mutations in HIV-1 protease can utilize complex mechanisms 
of resistance to reach significant levels of resistance. The primary mutations proximal to 
the active site are thought to directly confer drug resistance while distal mutations are 
considered compensatory and restore catalytic function30. However distal mutations can 
also weaken inhibitor binding, as has been reported not only for HIV-1 protease but other 
drug targets as well129-132. Molecular mechanisms such as reducing the coupled motions 
of the protease and inhibitor55 and altering protein intra-molecular hydrogen bonds54 have 
all been suggested in resistance mechanisms involving mutations distal to the inhibitor 
binding site. We have previously shown that cross-correlations between protein and 
inhibitor fluctuations distinguish tight binders from weak binders in both HIV and HCV 
protease54, 104, 133. In addition to weakening inhibitor binding, mutations can alter the 
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dynamic ensemble of the protease–inhibitor complex and the balance between inhibition 
and catalytic activity. However, changes to the structure and dynamic ensemble along a 
resistance pathway, molecular mechanisms of resistance due to combinations of 
mutations, and the role of distal mutations in conferring resistance versus restoring 
catalytic activity are not well understood.  
Here we investigate highly mutated and highly DRV resistant variants of HIV-1 
protease to understand the role of distal mutations and uncover underlying mechanisms 
of resistance. While DRV inhibits wild type HIV-1 protease with picomolar inhibition 
constant, a combination of 11 mutations (3 active site and 8 distal) confers near µM 
resistance to DRV. All of these mutations have been observed in patient isolates, 
although not in this specific combination15-16. Our inhibition assays show that the active 
site mutations alone do not account for this severe loss in affinity to DRV. We generated 
protease variants with subsets of these 11 mutations (1, 2, 4, 8, and 10-mutant variants) 
and found increased resistance with accumulation of mutations. We also tease out the 
effect of two individual distal mutations on the viral evolution pathway from 8 to 10-mutant 
variants, through double-mutant cycle analysis of the two possible intermediate 9-mutant 
variants. Using high-resolution crystal structures, enzymatic and inhibition assays, and 
molecular dynamics simulations, our findings support the role of distal mutations in 
conferring drug resistance. In addition to restoring catalytic activity, distal mutations 
contribute to drug resistance through interdependent, dynamic processes propagated 





3.3 Results  
3.3.1 Viral passaging under drug pressure selected for highly mutated variants 
Viral passaging experiments were performed to elucidate drug resistance in HIV-1 
protease under increasing DRV selective pressure, and identified 2 highly abundant 
variants with 8 and 10 mutations96. At the highest drug concentration, an additional 
mutation was selected, leading to a variant with 11 total mutations (11Mut) [Figure 
3.1A,B]. Sequencing from early time points indicated that I84V (1Mut) was the first fixed 
mutation. A variant with both V82F and I84V (2Mut) was generated to investigate primary 
active site mutations. A midpoint variant between 2Mut and 8Mut was chosen to include 
2 active site and 2 flap mutations (I84V, V82F, K45I, and M46I; 4Mut variant). Addition of 
4 more mutations (I13V, G16E, V32I, and I33F) to 4Mut yielded the 8Mut variant that was 
highly abundant in the viral passaging at higher DRV concentrations. With increased DRV 
pressure, the next highly abundant variant included additional A71V and L76V mutations 
(10Mut). The possible 9-mutant intermediate variants en route to 10Mut from 8Mut were 
not observed in viral passaging. To understand the role of the additional A71V and L76V 
mutations individually, 9Mut-A71V and 9Mut-L76V variants were generated. Lastly, the 
addition of I54L mutation onto 10Mut created the 11Mut variant. For all these 8 variants 
[Figure 3.1A] and wild type protease, the catalytic activity, DRV inhibition constant, and 
high-resolution crystal structure were determined and MD simulations performed to 




Figure 3.1 A-B) Location of resistance mutations in the variants displayed on HIV-1 
protease structure, with side chain of residues mutated shown as ball and stick and 
colored to match the variant added to in panel B. DRV depicted as yellow sticks. Mutations 
V32I, V82F, and I84V are classified as proximal while all other mutations are distal. C) 
Inhibition constant, Ki, of each variant against DRV. Resistance increases as mutations 
accumulate. D) Double mutant cycle of distal mutations A71V and L76V going from 8Mut 
to 10Mut variant with 12-fold higher resistance. The additional I54L mutation (11Mut) 
further increases resistance 5-fold. E) Mutations are interdependent (ΔΔG9Mut-A71V + 




3.3.2 Resistance mutations are selected to maintain catalytic activity  
 To determine the effects of mutation accumulation on protease catalytic activity, 
an established enzyme assay for cleaving the natural MA/CA site was used to measure 
the Michaelis-Menten constant (KM) and turnover rate (kcat) [Table 3.1]. The ratio of the 
two measured values was used to calculate the catalytic efficiency (kcat/KM) for all 
protease variants. Wild type protease had a KM of 71.4 µM and kcat of 1282.7 s-1, yielding 
a catalytic efficiency of 17.1 µM-1s-1. 1Mut, 2Mut, and 4Mut variants had WT-like KM values. 
However, kcat of these variants were 2–7 fold lower than WT protease, resulting in 
decreased catalytic efficiency. 2Mut variant had a 5-fold decrease in kcat/KM compared to 
WT (kcat/KM = 3.4 ± 0.2 µM-1s-1).  
 Relative to WT protease, KM values of the highly mutated 8Mut, 9Mut-A71V, 9Mut-
L76V, and 10Mut variants increased 1.4 to 2.4-fold. The kcat value of the 8Mut and 10Mut 
decreased 2–3 fold, and the kcat/KM 3–5-fold relative to WT. The most striking loss was in 
the turnover rates of the 9Mut variants, with 2 orders of magnitude slowing in the cleavage 
rate (kcat = 16.9 ± 0.3 and 17.7 ± 0.3, respectively for 9Mut-A71V and 9Mut-L76V). 
Combined with the increase in KM, these variants were extremely inefficient with kcat/KM 
values 171-fold lower relative to WT, representing a severe enzymatic penalty for these 
intermediate variants that were undetectable in viral passaging. Strikingly, co-occurrence 
of the A71V and L76V mutations in the 10Mut variant restored catalytic efficiency (kcat/KM 
= 5.3 ± 0.1 µM-1s-1). The 11Mut exhibited restored, WT-like KM, but was 13-fold less 




Table 3.1 Enzyme kinetics of HIV-1 protease variants measured using a natural substrate 
sequence: Michaelis-Menten constant (KM), enzyme turnover number (kcat), and catalytic 
efficiency (kcat/KM). 
 KM (µM) kcat (s-1) kcat / KM (µM-1s-1) 
WT 71.4 ± 6.8 1282.7 ± 0.1 17.1 ± 0.1 
I84V 66.4 ± 4.3 782.3 ± 0.1 11.8 ± 0.1 
2Mut 55.1 ± 12.4 11.8 ± 0.1 3.4 ± 0.2 
4Mut 71.0 ± 4.6 690 ± 0.1 9.7 ± 0.1 
8Mut 123.8 ± 30.1 430.7 ± 0.2 3.5 ± 0.2 
9Mut-A71V 139.2 ± 35.3 16.9 ± 0.3 0.1 ± 0.2 
9Mut-L76V 174.1 ± 44.8 17.7 ± 0.3 0.1 ± 0.3 
10Mut 101.4 ± 14.8 532.8 ± 0.1 5.3 ± 0.1 






This enzymatic assay uses a single cleavage site for a relatively short amount of 
time. To examine how the highly mutated variants process multiple cleavage sites in full 
length Gag polyprotein (p55) over a longer time scale, a gel cleavage assay was 
utilized134-135 [Figure 3.2]. Wild-type protease was extremely efficient cleaving 100% of 
the p55 polyprotein after 90 minutes. All the mutants were able to cleave the initial p2-NC 
cleavage site at varying rates. The intermediate 9Mut variants were much slower but were 
still able to process the multiple cleavage sites in the polyprotein. Overall, all protease 
variants were able to process substrates, with the highly mutated and abundant 10Mut 





Figure 3.2 Time course cleavage of full-length gag polyprotein, p55, by HIV-1 protease 





3.3.3 Accumulation of mutations progressively increases DRV resistance  
The enzyme inhibition constant, Ki, of DRV was measured against WT and the 
selected protease variants using an established assay with an optimized fast-cleaving 
substrate90. Wild type protease is highly susceptible to DRV with a Ki in single digit pM 
range below the assay limit of reliable detection (Ki < 0.005 nM), as we previously 
reported136. Against 1Mut, 2Mut, and 4Mut, DRV maintained picomolar inhibition, but with 
Ki increasing progressively 6–80 fold relative to WT [Figure 3.1C]. The 8Mut variant was 
significantly more resistant to DRV, with a 2,560-fold increase in resistance compared to 
WT (Ki = 12.8 nM). Addition of A71V mutation (9Mut-A71V) resulted in a ~2-fold further 
increase in resistance (Ki = 23.2 nM). In contrast, addition of L76V (9Mut-L76V) caused 
an order of magnitude increase in DRV resistance (Ki = 172.7 nM), indicating that the 
distal L76V mutation contributes a significant level of resistance. The 10Mut variant 
harboring both distal mutations exhibited 9Mut-L76V-like inhibition (Ki = 156.4 nM). 
Addition of I54L in 11Mut resulted in dramatic DRV resistance, with a 152,000-fold 
decrease in inhibition compared to WT (Ki = 759.2 nM). Active site mutations alone do 
not account for the high levels of resistance seen in the highly mutated variants, as only 
with the addition of distal mutations the protease was able to exhibit nanomolar-level 






Figure 3.3 The relationship between DRV inhibition and enzyme catalytic efficiency of 
HIV-1 protease variants with increasing number of mutations. 
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3.3.4 Double mutant cycle reveals the interdependency of A71V and L76V 
Only the 8Mut to 10Mut variants were observed in viral passaging, thus the addition 
of A71V and L76V mutations individually were examined as well as the double-mutant 
cycle analysis [Figure 3.1D] to elucidate the interdependency of these two distal 
mutations which cause 12-fold increase in resistance. The change in free energy of 
inhibitor binding (estimated from ΔG = RTln[Ki ])137 between the reference variant 8Mut 
and 10Mut (ΔΔG10Mut) was calculated. This was then compared to the sum of individual 
changes for 9Mut-A71V and 9Mut-L76V relative to 8Mut (ΔΔG9Mut-A71V + ΔΔG9Mut-L76V). 
When the two mutations are independent, the two values are equal (ΔΔG10Mut = ΔΔG9Mut-
A71V + ΔΔG9Mut-L76V). The sum of free energy changes for the 9-Mut intermediates were 
more than that for 10Mut [Figure 3.1D]. ΔΔG9Mut-A71V was 0.35 ± 0.07 kcal/mol and 
ΔΔG9Mut-L76V was 1.55 ± 0.10 kcal/mol, summing up to 1.90 ± 0.12 kcal/mol; however, 
ΔΔG10Mut was 1.45 ± 0.05 kcal/mol. Thus the double mutant cycle analysis shows that 
A71V and L76V are interdependent137 in conferring DRV resistance.  
3.3.5 Crystal structures show resistance mutations reduce vdW contacts with 
DRV 
To elucidate the changes in inhibitor binding and molecular mechanisms of 
resistance, we determined cocrystal structures of DRV bound to the wild type HIV-1 
protease of the NL4-3 strain, as well as all eight mutated variants at high resolution (1.9–
2.2 Å). Structure of DRV bound to WT protease and the I84V variant were previously 
determined37 and the 2Mut crystallized in the same space group (P212121), which 
contained one homodimer in the asymmetric unit and one inhibitor bound in a single 
orientation, allowing direct comparison. The variants containing four or more mutations 
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had a different preferred crystallographic lattice and were solved in the P61 space group. 
For reliable and direct comparison with these variants, WT protease structure was also 
determined in the hexagonal space group. These structures were also solved containing 
one homodimer in the asymmetric unit with one inhibitor bound in a single orientation 
[Table 3.2]. Structures of protease variants were overall similar to that of WT protease, 
with 0.3–0.4 Å overall RMSD [Figure 3.4]. Following established convention, throughout 
this analysis the B chain that contacts the aniline moiety of DRV will be denoted the prime 
(') chain, while the A chain will remain non-prime. The crystal structures determined 
provided insights into changes in the overall structure and protein–inhibitor interactions 
due to the accumulating resistance mutations. 
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Table 3.2 X-Ray Crystallography Statistics  




L76V 10MUT 11MUT 
INHIBITOR DRV DRV DRV DRV DRV DRV DRV DRV DRV DRV 
PDB ID 6DGX 6DH0 6OPT 6OPS 6OPU 6OPV 6OPW 6OPX 6OPY 6OPZ 
RESOLUTION (Å) 2.00 1.90 1.96 2.08 1.94 1.91 2.10 2.03 2.13 2.20 
SPACE GROUP P212121 P212121 P212121 P61 P61 P61 P61 P61 P61 P61 
TWIN LAW    h,-h-k,-l h,-h-k,-l h,-h-k,-l h,-h-k,-l h,-h-k,-l h,-h-k,-l h,-h-k,-l 
A (Å) 51.0 51.1 50.8 62.3 61.5 61.7 62.1 61.9 62.1 61.8 
B (Å) 58.3 58.1 57.9 62.3 61.5 61.7 62.1 61.9 62.1 61.8 
C (Å) 61.9 61.8 61.5 82.3 81.3 81.2 82.3 81.5 82.6 82.4 
COMPLETENESS 98.1 99.9 96.5 97.0 97.9 99.7 99.9 99.5 97.0 99.8 
TOT. REFLECTIONS 84332 181306 252365 104283 126710 135511 110972 127376 53059 92665 
UNIQ. REFLECT. 12758 15103 13103 10660 12722 13672 10571 11470 9912 9120 
AVG. I/SIGMA 31.1 41.1 53.2 24.0 48.5 43.7 37.1 33.8 29.7 37.2 
REDUNDANCY 6.6 12.0 19.3 9.8 10.0 9.9 10.5 11.1 5.4 10.2 
R-MERGE (LINEAR) 0.057 0.057 0.056 0.086 0.045 0.052 0.064 0.077 0.048 0.059 
RMSD BONDS 0.003 0.003 0.003 0.003 0.002 0.006 0.004 0.003 0.006 0.004 



























Figure 3.4 Deviation of internal Cɑ distances in protease variant crystal structures relative 








Resistance mutations selected under DRV selective pressure are expected to 
directly or indirectly perturb inhibitor binding and result in reduced potency. To elucidate 
alterations in inhibitor packing at the active site, we calculated vdW contacts of DRV with 
the protease residues from the crystal structures [Table 3.3]. Compared to WT protease, 
the common multidrug resistance mutation I84V resulted in a loss of 1.2 and 1.8 kcal/mol 
in vdW contacts of residue 84 and 84', respectively [Figure 3.5A, Table 3.3]. Similarly, 
all remaining variants, which also contain this mutation, had 1–2.5 kcal/mol losses in vdW 
contacts at these two residues. In the presence of single I84V mutation, the location of 
the other active site mutation, V82, had a compensatory gain in vdW contacts in chain B, 
which was progressively alleviated as the mutations were added. Overall, V82F exhibits 
a minor gain in vdW contacts (0.2 kcal/mol on average), but the larger nonpolar side chain 
significantly shifts Arg8' away from DRV resulting in 0.6–1.1 kcal/mol loss in vdW contacts. 
Addition of flap mutations K45I and M46I caused reduced vdW contacts of I50 in 4Mut 
variant, and a net loss in total vdW contacts which correlate with reduced potency [Figure 
3.5B, Table 3.3]. The highly resistant 8Mut variant structure continued the trend, 
exhibiting a net reduction in vdW contacts. Notably, although the V32I mutation results in 
a larger amino acid at the edge of the active site, vdW contacts with DRV were reduced 
0.4–0.6 and 0.5–1.0 kcal/mol due to the orientation of the additional methyl group away 
from the inhibitor [Figure 3.5A, Table 3.3]. The combination of I13V, L33F and V32I 
exacerbated losses of vdW contacts at residues I84V and I84V' by 0.2 and 0.7 kcal/mol, 
respectively. Each mutation, both proximal and distal, either directly or indirectly reduced 
vdW contacts with the inhibitor, thereby destabilizing inhibitor binding.  
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Table 3.3 A) Protease–DRV per residue vdW contacts for all crystal structures. Darker red indicates more contacts. B) 
Difference in per residue protease–DRV vdW contacts relative to WT cocrystal structure in the same space group. Positive 
numbers and cooler colors indicate reduced vdW contacts and negative numbers and warmer colors indicate increased 
vdW contacts, relative to WT structure.  
A           B WT-P2 WT-P6 
 WT   WT   9Mut 9Mut        9Mut 9Mut   
  (P2) I84V 2Mut  (P6) 4Mut 8Mut A71V L76V 10Mut 11Mut  I84V 2Mut 4Mut 8Mut A71V L76V 10Mut 11Mut 
A23 -1.0 -1.0 -1.1 -1.1 -0.9 -1.0 -0.8 -0.9 -1.2 -1.2  0.1 0.0 0.2 0.2 0.3 0.2 -0.1 -0.1 
A27 -3.8 -3.6 -3.8 -4.3 -3.9 -3.9 -4.0 -3.9 -4.0 -3.7  0.2 0.1 0.3 0.3 0.2 0.3 0.3 0.5 
A28 -5.4 -5.6 -5.6 -5.4 -5.2 -5.2 -5.0 -5.1 -5.2 -5.5  -0.2 -0.2 0.2 0.2 0.4 0.3 0.2 -0.1 
A29 -4.2 -4.2 -4.2 -4.1 -3.9 -3.9 -4.1 -3.6 -4.1 -4.0  0.0 0.0 0.2 0.1 -0.1 0.5 0.0 0.0 
A30 -3.8 -3.8 -3.0 -3.0 -3.0 -3.1 -2.7 -3.0 -3.0 -3.5  0.0 0.8 -0.1 -0.1 0.2 0.0 -0.1 -0.6 
A32 -1.2 -1.2 -1.1 -1.2 -1.1 -0.6 -0.7 -0.5 -0.7 -0.8  0.0 0.1 0.1 0.5 0.5 0.6 0.5 0.4 
A47 -1.5 -2.7 -2.6 -2.0 -1.7 -2.1 -1.7 -1.7 -1.8 -1.9  -1.2 -1.1 0.3 -0.1 0.2 0.3 0.2 0.1 
A48 -2.1 -2.7 -2.5 -2.6 -2.3 -2.3 -2.7 -2.1 -2.3 -2.3  -0.6 -0.4 0.3 0.2 -0.1 0.5 0.3 0.3 
A49 -2.9 -3.3 -3.0 -3.2 -3.2 -2.9 -3.1 -2.7 -2.9 -2.4  -0.4 -0.1 0.0 0.4 0.1 0.5 0.3 0.9 
A50 -6.1 -5.8 -5.7 -5.7 -6.3 -5.5 -5.6 -6.1 -5.3 -4.9  0.3 0.4 -0.6 0.2 0.1 -0.4 0.4 0.8 
A81 -0.5 -0.5 -0.7 -0.6 -0.7 -0.9 -1.3 -0.9 -0.9 -0.9  0.0 -0.1 -0.2 -0.3 -0.8 -0.3 -0.3 -0.4 
A82 -1.1 -1.2 -0.6 -1.4 -1.7 -1.6 -1.6 -1.7 -1.6 -1.6  -0.1 0.5 -0.3 -0.2 -0.2 -0.3 -0.2 -0.2 
A84 -3.1 -2.0 -2.0 -2.8 -1.6 -1.4 -1.3 -1.3 -1.5 -1.9  1.2 1.1 1.2 1.4 1.5 1.5 1.4 0.9 
B8 -1.4 -1.2 -0.7 -1.6 -0.9 -0.6 -1.0 -0.9 -0.7 -0.9  0.2 0.7 0.8 1.1 0.6 0.7 1.0 0.7 
B23 -1.5 -0.8 -1.3 -1.5 -1.2 -1.3 -1.2 -1.3 -1.3 -1.3  0.7 0.2 0.2 0.2 0.3 0.1 0.1 0.2 
B27 -2.8 -2.8 -2.8 -2.7 -2.7 -3.1 -3.3 -2.9 -2.7 -2.9  0.0 0.0 0.0 -0.3 -0.6 -0.2 0.0 -0.2 
B28 -4.4 -3.5 -3.9 -4.8 -4.3 -4.3 -4.2 -4.2 -4.6 -4.6  0.9 0.4 0.4 0.5 0.6 0.5 0.1 0.2 
B29 -1.6 -1.4 -1.6 -1.8 -1.5 -1.6 -2.4 -2.0 -2.1 -1.8  0.1 -0.1 0.3 0.2 -0.6 -0.2 -0.3 0.0 
B30 -2.1 -2.1 -2.1 -2.5 -2.3 -2.5 -2.5 -2.7 -2.8 -2.7  0.1 0.1 0.2 0.0 0.0 -0.2 -0.3 -0.3 
B31 -0.5 -0.4 -0.4 -0.5 -0.5 -0.4 -0.3 -0.3 -0.4 -0.3  0.0 0.0 -0.1 0.1 0.2 0.1 0.0 0.1 
B32 -1.7 -2.1 -2.0 -1.7 -1.8 -1.0 -0.8 -0.8 -1.2 -1.0  -0.3 -0.3 -0.1 0.7 1.0 0.9 0.5 0.7 
B47 -3.2 -2.9 -3.1 -2.2 -2.0 -1.9 -1.4 -1.6 -1.7 -1.7  0.3 0.1 0.2 0.3 0.8 0.6 0.5 0.5 
B48 -1.8 -1.7 -1.8 -1.7 -1.5 -1.8 -1.7 -1.9 -1.7 -1.7  0.1 0.0 0.2 -0.1 0.0 -0.2 0.0 0.0 
B49 -1.8 -1.8 -1.8 -2.1 -2.4 -2.5 -2.6 -2.6 -2.1 -2.0  0.0 0.0 -0.3 -0.4 -0.6 -0.5 -0.1 0.1 
B50 -3.6 -3.5 -3.4 -4.3 -4.4 -4.5 -5.1 -4.7 -4.7 -4.4  0.2 0.2 -0.1 -0.2 -0.8 -0.4 -0.3 0.0 
B76 -0.6 -0.5 -0.6 -0.5 -0.5 -0.4 -0.3 -0.1 -0.2 -0.1  0.1 0.0 0.0 0.1 0.2 0.4 0.3 0.4 
B81 -1.6 -1.6 -1.6 -1.6 -1.8 -2.0 -1.9 -1.9 -2.0 -1.7  0.0 0.0 -0.2 -0.4 -0.3 -0.3 -0.4 -0.1 
B82 -2.2 -3.2 -2.9 -2.4 -2.8 -2.4 -2.0 -2.7 -2.5 -2.3  -1.0 -0.7 -0.4 -0.1 0.4 -0.3 -0.1 0.0 
B84 -4.0 -2.3 -2.4 -4.2 -2.7 -2.1 -1.8 -2.3 -2.1 -1.9  1.8 1.6 1.5 2.2 2.5 1.9 2.1 2.4 
                    




Figure 3.5 A,B) Comparison of WT (black) and 8Mut (purple) variants, focusing on 
the active site, core, and flaps. C) 8Mut (purple) and 9Mut-L76V (green) variants, 
focusing on the hydrophobic packing at base of the flaps. D) 10Mut (orange) and 
11Mut (red) variants, which differ at I54L mutation, focusing on the hydrophobic 
packing upon P79.  
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Although the 9Mut variants were not observed in viral passaging, determining 
the structures of these complexes highlighted the interdependent structural 
changes of the mutations at residue 71 and 76 connecting the 8Mut and 10Mut 
variants. The A71V mutation, located on the distal “70’s loop”, is a well-known 
compensatory mutation that restores catalytic activity of protease variants 
containing I50V mutation. The mean differences in internal Cɑ distances [Figure 
3.6], also known as distance difference matrices, were calculated to quantify the 
structural alterations. Comparing the 8Mut and 9Mut-A71V structures, the A71V 
mutation pushes the flexible “70s loop” outward up to 0.61 and 0.63 Å for residues 
67 and 68', respectively. This outward shift can perturb the beta strand (residues 
69-76) that directly interacts with the neighboring beta strand extending up to the 
flaps (residues 53-65). Although there are very few changes in the internal Cɑ 
distances of 8Mut and 9Mut-L76V, when comparing 8Mut and 10Mut the changes 
in distances reflect an additivity of the differences between the 8Mut versus the 





Figure 3.6 Internal Cɑ distance differences in crystal structures mapped onto HIV-
1 protease structure. Warmer colors and larger putty thickness indicate larger 
differences between the variants compared.  
 
 
 Comparing the complexes of 10Mut and 11Mut helps explain the 5-fold 
reduction in potency. The longer side chain resulting from the I54L mutation 
pushed against Pro79 creating a mean difference of 0.36 Å at residues 54 and 54' 
and 0.20 Å at residues 79 and 79' [Figure 3.6]. This widening at the active site 
may destabilize flap closing, and most notably resulted in reduced vdW contacts 
at residues 49 and 50 of 0.9 and 0.8 kcal/mol, respectively. 11Mut–DRV cocrystal 
structure had the lowest total intermolecular vdW contacts, correlating with the 
highest DRV resistance.  
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3.3.6 Resistance mutations perturb packing in the hydrophobic core  
Many of the mutations observed were changes from one hydrophobic side 
chain to another, located in the hydrophobic core of the protein, that considerably 
change the packing between hydrophobic side chains. K45I results in a side chain 
rotamer that increases hydrophobic packing with residues I47, V56, L76 at the 
base of the flaps [Figure 3.5B]. While I84V may only bridge the gap between V82F 
and V32I [Figure 3.5A], V32I is involved in both the L76V cluster (also including 
K45I, I47, and V56) [Figure 3.5C] and the I54L cluster (also including I47, I50, and 
V56) [Figure 3.5D]. Mutations that perturb the packing of these clusters may also 
affect “hydrophobic sliding” and thus conformational dynamics of the protease52, 
138.  
3.3.7 Resistance mutations increase protease fluctuations 
Despite 5 orders of magnitude increase in the inhibition constant (Ki) of the 
11Mut variant relative to WT protease, DRV displayed only minor conformational 
differences in the cocrystal structures, and MD simulations were performed to 
better interrogate these structures. Starting from the cocrystal structures of the 
DRV complexes with WT protease and the resistant variants, three replicates of 
fully hydrated 100 ns MD simulations were performed for each complex. All 
simulations reached convergence [Figure 3.7]. The protein backbone dynamics 
were compared via root-mean-square fluctuations (RMSF) of Cɑ atoms [Figure 
3.8]. In WT–DRV complex, the entire backbone was stable, including the flaps (50s 
region) that close upon the bound inhibitor. In I84V variant, the flaps are slightly 
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more mobile but the active site remains stable. Relative to I84V, the 2Mut 
(I84V/V82F) protease has reduced flaps fluctuations [Figure 3.9]. The addition of 
flap mutations K45I and M46I in the 4Mut resulted in higher fluctuations at chain A 
flap and residues 79-82. Chain B flap and residues 79'-82' had WT-like fluctuations, 
remaining stable throughout the MD simulations. Overall, the backbone flexibility 
of the highly mutated 8Mut, 9Mut-A71V, 9Mut-L76V and 10Mut variants were 
similar to WT complex, except increased fluctuations at residue 65' in 10Mut. 
11Mut variant, bearing flap mutation I54L, displayed extremely large fluctuations 
at both flaps (residues 42-55 and 45'-52'), increasing more than 0.6 and 0.5 Å in 
chain A and B, respectively, relative to WT protease. In addition, 11Mut protease 
had increased fluctuations at residues 79-82 and 78'-80' as well as residues 26-28 
in the active site. Thus, the addition of I54L mutation resulted in considerable 
increase in protease backbone fluctuations at the active site and flaps. 
 






Figure 3.8 Root Mean Square Fluctuation (RMSF) of Cɑ atoms for WT, 8Mut, 
9Mut-A71V, 9Mut-L76V, 10Mut, and 11Mut from MD simulations.  
 
 
Figure 3.9 Root Mean Square Fluctuation (RMSF) of Cɑ atoms for WT, 1Mut, 2Mut, 




To compare the dynamic ensemble of DRV-bound variants, mean internal Cɑ 
distances from MD simulations were compared, similar to the comparison of crystal 
structures [Figure 3.10]. In this analysis, the internal distances between all Cɑ 
carbons were measured for every frame of the trajectory and an average was 
taken. Comparing 8Mut to 9Mut-A71V, changes were mostly localized to the 70s 
beta-sheets and residues 15–20 in both chains, with small changes at the flap 
elbows [Figure 3.10A]. Comparing 8Mut to 9Mut-L76V, changes were located in 
both flaps and the flap elbows. The 80s loop (residues 78 to 82) also had slight 
changes. In addition, the B chain 70s beta-sheet was affected while the A chain 
beta-sheet showed very little change [Figure 3.10B]. As was observed with the 
crystal structures, alterations in the two 9-Mut variants were additive when 10Mut 
was compared to 8Mut. The exception was that changes at residues 78-82 were 
attenuated when A71V and L76V were simultaneously present [Figure 3.10C]. To 
complete the cycle, the two 9Muts were compared with 10Mut. Similar to the 
effects noted earlier, A71V induced changes at the 70s beta-sheets and residues 
15–20, while L76V distally affected the flaps and flap elbows [Figure 3.10D-E]. 
These alterations in the dynamic ensemble were consistent with the comparison 
of crystal structures [Figure 3.6]. However, alterations in the 11Mut variant were 
accentuated in the conformational dynamics in the MD simulations, with large 
structural changes at both flaps and the active site [Figure 3.10F]. Compared to 
other variants, the flaps of 11Mut were more open as indicated by the increasing 
distance between the Cɑ atoms of I50-V84' and I50'-V84 [Figure 3.11]. Thus, I54V 
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mutation in 11Mut resulted in destabilization and increased fluctuations of the 






Figure 3.10 Mean internal Cɑ distance differences between (A) 8Mut and 9Mut-
A71V, (B) 8Mut and 9Mut-L76V, (C) 8Mut and 10Mut, (D) 9Mut-A71V and 10Mut, 
(E) 10Mut and 9Mut-L76V, and (F) 10Mut and 11Mut protease variants from MD 
simulations plotted onto protease structure. In all panels, DRV is shown as sticks 
in the active site. Putty thickness and color indicate distance difference where hot 






Figure 3.11 Distance between the Cɑ atoms of A) I50-V84' and B) I50'-V84 from 





3.3.8 Inhibitor fluctuations increase and interactions are destabilized due to 
resistance mutations 
In the cocrystal structures, conformation of DRV was highly similar with the 
most notable alterations occurring at the P1' moiety [Figure 3.12]. To investigate 
how the dynamics of DRV may vary, the RMSF of every DRV heavy atom from the 
MD simulations was calculated and grouped according to the four DRV moieties 
[Figure 3.13]. In complex with WT protease DRV was stable, with RMSF below 
0.75 Å except for the P1' moiety. In 1Mut, 2Mut and 4Mut variants fluctuations of 
DRV moieties were similar to those in WT complex, with few minor exceptions at 
the P1' and P1 moieties (data not shown). When bound to all the highly mutated 
variants, DRV had increased flexibility, especially at the P1 and P2 moieties 
[Figure 3.13]. In 10Mut complex, the P2 bis-THF moiety had high RMSF compared 
to WT and all other variants. This moiety makes several hydrogen bonds to 
protease active site residues and contributes significantly to the high potency of 
DRV. In complex with the 11Mut variant, the entirety of DRV experienced 
significant flexibility with the P1 moiety showing the greatest RMSF. Overall, 
resistance mutations in the protease variants resulted in increased flexibility and 
higher fluctuations of DRV, suggesting the inhibitor binding and intermolecular 





Figure 3.12 Alignment of DRV from crystal structures bound to WT (grey), 8Mut 






Figure 3.13 A) Root-mean-square fluctuation (RMSF) of DRV atoms grouped by 
moiety monitored during MD simulations bound to WT and resistant HIV-1 
protease variants (color scheme as in Figure 1). B) Packing around DRV in 
complex with WT protease and resistant variants. Total per atom protease–DRV 
vdW contact energies mapped onto the respective DRV crystal structure, with red 




Underlying the high potency of DRV against WT HIV-1 protease is an 
extensive hydrogen bonding network and strong vdW interactions with active site 
residues. In highly mutated variants these interactions may be perturbed, as 
suggested by increased DRV fluctuations. The vdW packing around DRV in 
complex with 8Mut, 9Mut-A71V, 9Mut-L76V, and 10Mut decreased slightly around 
the P2 bis-THF moiety compared to WT [Figure 3.13B]. In 11Mut variant, packing 
around DRV was significantly reduced at the P1 phenyl, P1' isobutyl, and P2' 
aniline moieties. In the cocrystal structure bound to WT protease, DRV makes a 
number of hydrogen bonds with the protease backbone and a water-mediated 
hydrogen-bonding network with the flaps [Figure 3.14A]. All these hydrogen bonds 
were stable and highly conserved throughout the MD simulations [Figure 3.14B]. 
In the highly mutated variants, frequency of hydrogen bonds during the MD 
simulations decreased relative to WT complex, with a severe loss in the hydrogen 
bond between D25' and the central hydroxyl of DRV. In 8Mut and 9Mut-A71V 
variants, DRV hydrogen bonds with P2 bis-THF and flaps destabilized 8–17%, and 
frequency of the hydrogen bond between P2' aniline and backbone nitrogen of 
D30' decreased 18%. In 9Mut-L76V and 10Mut variants there was a further 
decrease in the frequency of these hydrogen bonds. In 11Mut variant, water-
mediated hydrogen bonding network with the flaps was severely impacted, where 
two hydrogen bonds were completely lost and the other two maintained only 25% 
during the MD simulations. The hydrogen bond between D25 and the central 
hydroxyl was reduced to 62% where it was previously maintained at 83–99% for 
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WT and all other resistant variants. Additionally, the P2' aniline hydrogen bond with 
D30' was significantly reduced to only 9%, an 85% decrease compared to WT. 
Thus, the impact of distal mutations in these highly mutated and resistant variants 
propagated to the active site to destabilize inhibitor vdW and hydrogen bonding 





Figure 3.14 Resistant HIV-1 protease variants lose hydrogen bonding with 
inhibitor DRV. A) Hydrogen bonds with DRV (green sticks) indicated as black 
dashed lines on the WT protease crystal structure. The “flap water” molecule is 
depicted as a red sphere. Numbers correspond to hydrogen bonds shown in panel 
B. B) Hydrogen bonding frequencies from MD simulations. The water-mediated 
hydrogen-bonding network between the protease flaps and DRV is severely 





3.3.9 Protease–DRV cross-correlations of fluctuations are lost with 
increasing resistance 
Cross-correlation of collective motions between a ligand and target protein 
can distinguish tight and weak binders, as we previously reported55, 104, 139. For 
HIV-1 protease, tight binding inhibitors have greater correlation of fluctuations with 
proximal protease residues, namely the active site and flaps. Contrary to tight 
binders, weak binding inhibitors lose correlations with these residues 
corresponding to disrupted intermolecular interactions104. Cross-correlations 
between the fluctuations of DRV and protease residues were calculated from the 
MD simulation trajectories. As expected, DRV fluctuations were highly correlated 
with catalytic residues especially at chain A, flaps tips (49-51/49'-51'), and residues 
26-31 adjacent to the catalytic D25 [Figure 3.15A]. DRV also had moderate 
correlations with residues 81–87, while the flap elbows and 70’s beta-sheets were 
anti-correlated. In 8Mut, DRV maintained correlation with residues 49'-50' but 
decoupled from chain A flap tip and the active site residues [Figure 3.16]. While 
9Mut-A71V restored the lost correlations of DRV with the catalytic residues, the 
flap tips became further decoupled. In 9Mut-L76V and 10Mut, DRV fluctuations 
were further decoupled from the flap tips, but in both variants DRV somewhat 
maintained correlation with catalytic residues [Figure 5]. In 11Mut variant, positive 
correlations with DRV were almost completely lost, and the inhibitor established 
anti-correlations with various regions of the protein (chain B flap, S2' subsite, chain 
B 70’s beta-sheet and 80’s loop). Disruptions in the correlations between DRV and 
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11Mut fluctuations are consistent with increased resistance and weaker 





Figure 3.15 Cross-correlation of fluctuations between HIV-1 protease and DRV 
from MD simulations. A) Mean cross-correlation coefficient for each residue 
mapped onto protease structure, shown as cartoon putty for WT, 10Mut, and 
11Mut variants. B) Cross-correlations for WT, 10Mut, and 11Mut plotted. As 







Figure 3.16 Cross-correlation of DRV fluctuations with 8Mut, 9Mut-A71V, or 9Mut-L76V from MD simulations. Mean 




3.3.10 Distal mutations impact the dynamic ensemble to confer resistance 
The existing paradigm reasons that distal mutations play a compensatory 
role in HIV-1 protease, acting to restore catalytic efficiency lost by the accumulation 
of mutations. However, while certain distal mutations indeed play a compensatory 
role, they also confer resistance as demonstrated above. We reported previously 
that distal mutations may propagate their effects to the active site via altering the 
conformational dynamics of the inhibitor–protease complex, via hydrophobic 
sliding52, 138 and the internal hydrogen bonding network54. Here we used Jensen-
Shannon divergence (JSD) to analyze perturbations in the dynamic ensemble in 
response to mutations, where protein backbone and side chain dihedral angles 
were compared between variants during MD simulations. We focused on the 
impact of 3 additional non-active site mutations, from 8Mut to 11Mut, which results 
in almost 60-fold increase in resistance. 
Consistent with the Cɑ distance difference analysis, A71V caused only local 
perturbations in the dynamic ensemble in the 70’s beta-sheets [Figure 3.17A]. 
L76V also perturbed the dynamics of the 70’s loop (chain B) but also had distal 
effects on the dihedrals of residues in both flaps [Figure 3.17B]. In combination 
the effects of A71V and L76V were mostly additive, but together they also 
perturbed the side chain dihedrals of catalytic D25/25' residues (ɸ of D25 and χ2 
of D25') [Figure 3.17C]. However, the alterations in D25/D25' were subtle and did 
not significantly change the hydrogen bonds with DRV [Figure 3.14]. Comparison 
of 9Mut variants with 10Mut confirmed the earlier observation that addition of L76V 
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mostly impacted the flaps [Figure 3.17D], while A71V had local effects on the 
proximal 70’s beta-sheets [Figure 3.17E]. Lastly, addition of I54L in 11Mut caused 
considerable changes to the dynamic ensemble compared to 10Mut, both proximal 
and distal. Most noticeably, side chain dihedrals of catalytic residues were 
impacted (Ѱ and χ2 of D25 and χ2 of D25'), which is consistent with decreasing 
hydrogen bonding between the catalytic residues and the central hydroxyl of DRV 
[Figure 3.14]. In addition to changes at the active site, the dynamic ensemble of 
the flaps and 80’s loop of chain B were affected. These results indicate that distal 
resistance mutations propagate their effects throughout the protein structure, 






Figure 3.17 Comparison of protease dynamics via Jensen-Shannon divergence 
of dihedral angles between (A) 8Mut and 9Mut-A71V, (B) 8Mut and 9Mut-L76V, 
(C) 8Mut and 10Mut, (D) 9Mut-A71V and 10Mut, (E) 9Mut-L76V and 10Mut, and 
(F) 10Mut and 11Mut from MD simulations, mapped onto protease structure. Tube 
thickness and warmer colors indicate larger perturbation of the dynamic ensemble. 
Residues in white had no significant difference between the two variants. Arrows 






Drug resistance occurs when the target evolves and gains mutations to 
thwart inhibition while still maintaining biological function. We investigated a highly 
evolved and mutated variant of HIV-1 protease that accumulated 11 mutations to 
confer high-level resistance to DRV. We systematically dissected the mutations in 
this variant by generating 8 different subset variants, including separating active 
site mutations from distal mutations and leveraging a double mutant cycle analysis 
[Figure 3.1A]. Integrating activity and inhibition assays, high-resolution crystal 
structures, and molecular dynamics simulations, we determined how active site 
and distal mutations contribute to drug resistance. Our results show that resistance 
progressively increased as the mutations were added, while catalytic activity was 
maintained. Mutations were selected both inside and outside the active site where 
the inhibitor binds. We found that the distal mutations play a pivotal role in 
conferring drug resistance, as proximal mutations alone cannot explain the 
observed near µM resistance. Double mutant cycle analysis revealed that two such 
distal mutations are interdependent, with A71V restoring catalytic activity while 
L76V decreasing inhibition. Our findings challenge the convention that distal 
mutations are merely compensatory and have secondary or minimal contribution 
to resistance. On the contrary, we demonstrated that distal mutations act 




In addition to avoiding inhibition, the mutated protease needs to continue 
processing viral substrates to allow viral replication. The highly mutated variants 
(8Mut, 10Mut, 11Mut) detected from viral passaging had somewhat compromised 
enzymatic activity relative to WT protease, although still allowed for robust viral 
replication. Unlike the detectable variants, both 9Mut-A71V and 9Mut-L76V 
variants had severely compromised catalytic activity. The protease must evolve 
through one of the 9Mut intermediates en route from 8Mut to 10Mut variant, but 
the virus cannot efficiently replicate to populate detectable levels. A71V is a well-
known compensatory mutation that is often observed together with I50V and was 
reported to restore catalytic activity lost due to this primary mutation76, 91. The 8Mut 
variant does not contain I50V, and when added to the 8Mut variant A71V actually 
obliterated catalytic activity (9Mut-A71V). In the presence of the L76V mutation 
though the catalytic activity was restored (10Mut). Thus, the effect of A71V on 
catalytic activity is context dependent, and may be beneficial or detrimental 
depending on the background mutation(s).  
While resistance due to primary active site mutations are rather 
straightforward to explain especially using the substrate envelope, how 
combinations of mutations including distal mutations act interdependently to confer 
resistance requires further investigations. The crystal structures showed 
consistent losses in protein-inhibitor vdW contacts, differences in internal 
distances, and subtle alterations in the binding conformation of DRV. However, 
given the high levels of resistance and orders of magnitude change in inhibition 
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constants, we expected further and amplified impact on the conformational 
dynamics of the protease–inhibitor complex. MD simulations highlighted the extent 
of unfavorable protease–DRV interactions with increasing mutation accumulation. 
Highly mutated variants resulted in increased protein and inhibitor fluctuations and, 
most importantly, reduced cross-correlated motions. We previously found that the 
loss in correlated inhibitor–target fluctuations correlated with reduced inhibitor 
potency for HCV NS3/4A protease104 and analogous inhibitors binding to WT HIV-
1 protease55. We find here that the same loss exists for highly mutated and 
resistant variants of HIV-1 protease. In addition, the hydrogen bonds and vdW 
interactions that contribute to DRV’s pM potency in WT HIV protease were greatly 
diminished. Alterations in the dynamics of the protease–inhibitor complex are 
crucial in the molecular mechanisms of resistance, and thus the molecular 
dynamics need to be investigated in addition to static crystal structures structural 
to elucidate how the effect of distal mutations can be propagated to cause 
alterations in inhibitor binding. 
Here we develop an alternative approach to previously explored methods to 
elucidate how distal mutations propagate dynamic changes throughout the 
protease. Expanding upon hydrophobic sliding52, 138 and internal hydrogen bonding 
networks54, quantitative comparison of protein dihedral angles can be used to 
examine dynamic structural changes. As dihedral angles from MD simulations 
comprise highly similar probability distributions, a rigorous statistical analysis 
involving Jensen-Shannon divergence implementation is needed to determine 
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distinct changes. This approach previously quantified differences in long-range 
dynamics of proteins with and without a ligand bound140. Dihedral angle 
comparison illustrated the propagation of dynamic effects due to distal mutations 
throughout the protein, including impact of A71V/L76V on the catalytic residues. In 
the most mutated and most resistant variant 11Mut, addition of I54L mutation 
conferred many additional changes to the active site and flaps while also 
propagating changes throughout the protease structure. This analysis 
demonstrated how mutations cause dynamic changes that propagate to distal 
regions of the protein, and thus how considering local changes to the static 
structure is not sufficient to elucidate molecular mechanisms of drug resistance. 
Our work provides evidence that distal mutations do indeed contribute to drug 
resistance through complex dynamic processes, significantly altering protease 
dynamics and perturbing inhibitor binding. In other HIV-1 protease variants and, 
perhaps more significantly, other drug targets where distal mutations are observed 
in clinically relevant resistant variants, the possibility that distal mutations directly 
confer resistance cannot be ignored. This also has the implication that drug design 
needs to consider both structural and dynamic changes to the protein–inhibitor 
complex to be able to effectively target these variants. The increasing threat of 
drug resistance in many clinically relevant systems highlights the need to 
characterize resistance mutations, including distal mutations and combinations of 





3.5.1 Protease Gene Construction.  
Protease gene construction was carried out as previously described40, 104. In 
short, the WT and 10Mut protease variant genes were purchased on a pET11a 
plasmid with codon optimization for protein expression in E. coli (Genewiz). The 
remaining variants were constructed using QuikChange site-directed mutagenesis 
(Genewiz). A Q7K mutation was included to prevent autoproteolysis101.  
3.5.2 Protein Expression and Purification 
The expression, isolation, and purification of WT and mutant HIV-1 proteases 
used for all assays and crystallization were carried out as previously described40, 
99. Briefly, the gene encoding the desired HIV protease was subcloned into the 
heat-inducible pXC35 expression vector (ATCC) and transformed into E. coli TAP-
106 cells. Cells grown in 6 L of Terrific Broth were lysed with a cell disruptor twice, 
and the protein was purified from inclusion bodies102. The inclusion body 
centrifugation pellet was dissolved in 50% acetic acid followed by another round 
of centrifugation at 19K rpm for 30 minutes to remove impurities. Size exclusion 
chromatography was carried out on a 2.1-L Sephadex G-75 superfine (Sigma 
Chemical) column equilibrated with 50% acetic acid to separate high molecular 
weight proteins from the desired protease. Pure fractions of HIV protease were 
refolded into a 10-fold dilution of refolding buffer [0.05 M sodium acetate at pH 5.5, 
5% ethylene glycol, 10% glycerol, and 5 mM DTT]. Folded protein was 
concentrated down to 0.5–3 mg/mL and stored. The stored protease was used in 
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KM and Ki assays. For crystallography, an additional purification step was 
performed with a Pharmacia Superdex 75 FPLC column equilibrated with refolding 
buffer. Protease fractions purified from the size exclusion column was 
concentrated to 1–2 mg/mL using an Amicon Ultra-15 10-kDa device (Millipore) for 
crystallization. 
3.5.3 KM Assay  
KM values were determined as previously described37, 89-90. Briefly, a 10-
amino acid substrate containing the natural MA/CA cut site with an 
EDANS/DABCYL FRET pair was dissolved in 8% DMSO at 40 nM and 6% DMSO 
at 30 nM. The 30 nM substrate was 4/5 serially diluted from 30 nM to 6 nM. HIV 
protease was diluted to 120 nM and, using a PerkinElmer Envision plate reader, 
and 5 µL were added to the 96-well plate to obtain a final concentration of 10 nM. 
KM assays were conducted in triplicate. The fluorescence was observed with an 
excitation at 340 nm and emission at 492 nm and monitored for 200 counts, for 
approximately 23 minutes. FRET inner filter effect correction was applied as 
previously described103. Data corrected for the inner filter effect was analyzed with 
Prism7. Fluorescence over time was used to calculate initial velocities by fitting the 
data to the one-phase association equation. Initial velocities were then fit by non-
linear regression to the Michaelis-Menten equation to determine kcat and KM and 
the standard error of the mean (SEM) was calucated. The error from these two 
measurements was propagated to calculate the overall error of kcat/KM.  
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3.5.4 Ki Assay 
Enzyme inhibition constants (Ki values) were determined as previously 
described37, 89-90. Briefly, in a 96-well plate, DRV was 3/5 serially diluted from 2000 
nM for 8Mut, 1000 nM for 9Mut-A71V, 5000 nM for 9Mut-L76V, 5000 nM for 10Mut, 
or 10,000 nM for 11Mut. All samples were incubated with 5 nM protein for 1 hour. 
A 10-amino acid substrate containing an optimized protease cut site90, purchased 
from BAchem, with an EDANS/DABCYL FRET pair was dissolved in 4% DMSO at 
120 mM. Using a PerkinElmer Envision plate reader, 5 µL of the 120 mM substrate 
were added to the 96-well plate to a final concentration of 10 mM. Fluorescence 
was observed with an excitation at 340 nm and emission at 492 nm and monitored 
for 200 counts. Data was analyzed with Prism7, as described in Chapter 2. 
3.5.5 Gag Polyprotein Cleavage Assay 
The pET28a plasmid containing full length Pr55Gag-TEV-His construct was a 
kind gift from Maria Bewley and John Flanagan. Protein expression and purification 
was done as described by Bewley et al. (Protein Expr Purif, 2017; 130:137-145) 
and consists of the removal of DNA and ammonium sulfate precipitation. On the 
day of the assay, ammonium sulfate pellets were dissolved in resuspension buffer 
(10 mM HEPES pH 7.5, 500 mM NaCl, 0.1 mM TCEP and 0.1 mM EDTA) and 
diluted 1:5 with the same buffer without NaCl. The final solution was centrifuged at 
20k x g for 20 min. Cleavage of Pr55Gag polyprotein by HIV-1 protease was 
monitored by SDS-PAGE of cleavage products visualized by Coomassie staining. 
Samples were taken from the reaction mixture at designated time points, and the 
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cleavage reaction was quenched by adding gel running buffer containing SDS and 
boiling for 2 min.  
3.5.6 Crystallography 
Discovery of the condition producing hexagonal cocrystals of DRV bound to 
a highly mutated variant (8Mut) without seeding was achieved using the Protein 
Complex Suite Screen (Qiagen), in well G5, consisting of 1 M ammonium sulfate 
and 1 M potassium chloride and 0.1 M HEPES buffer at pH 7 with a protease 
concentration of 1.2 mg/mL and 5-fold molar excess of DRV. With previously 
generated orthorhombic and hexagonal cocrystals in hand, reproducible cocrystals 
of DRV bound to all variants were achieved as previously described37. Briefly, all 
cocrystals were grown at room temperature by hanging drop vapor diffusion 
method in 24-well VDX hanging-drop trays (Hampton Research) with protease 
concentrations between 1.0 to 2.4 mg/mL with 3, 5, or 10-fold molar excess of DRV. 
Crystallization drops were set with the reservoir solution consisting of 18–26% (w/v) 
ammonium sulfate and 0.1 M bis-Tris-methane buffer at pH 5.5 set with 2 mL of 
well solution and 1 mL protein and microseeded with a cat whisker. Crystal 
morphology and space group was entirely dependent on the microseeds. 
Diffraction quality crystals were obtained within 1 week. As data was collected at 
100 K, cryogenic conditions contained the precipitant solution supplemented with 
25% glycerol. For direct structural analysis without possible crystal lattice contact 
bias, structure of WT protease bound to DRV was also generated and determined 
in the hexagonal space group. 
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3.5.7 Data Collection and Structure Solution 
Diffraction data were collected and solved as previously described37, 40, 104. 
Diffraction quality crystals were flash frozen under a cryostream when mounting 
the crystal at our in-house Rigaku Saturn944 X-ray system. The data for 10Mut 
cocrystal structure was collected at the Advanced Photon Source at the Argonne 
National Laboratory, beamline 19-ID. All cocrystal diffraction intensities were 
indexed, integrated, and scaled using HKL3000105. Structures were solved using 
molecular replacement with PHASER106. Model building and refinement were 
performed using Coot107 and Phenix108. During refinement, all crystals utilized 
optimized stereochemical weights and non-crystallographic symmetry operators. 
Hexagonal crystals grew as pseudo-merohedral twins and were solved with a twin 
law applied (h,-h-k,-l). Ligands were designed in Maestro and the output sdf file 
was used in the Phenix program eLBOW109 to generate the cif file containing 
atomic positions and constraints necessary for ligand refinement. Iterative rounds 
of crystallographic refinement were carried out until convergence was achieved. 
To limit bias throughout the refinement process, 5% of the data were reserved for 
the free R-value calculation110. MolProbity111 was applied to evaluate the final 
structures before deposition in the PDB. Structure analysis, superposition, and 
figure generation were performed using PyMOL141. X-ray data collection and 
crystallographic refinement statistics are presented in Table 3.2.  
 
 116 
3.5.8 Internal Distance Analysis of Crystal Structures 
Distance-difference matrices were generated as previously described113 to 
reveal structural changes between inhibitor–protease pairs.  
3.5.9 Intermolecular vdW Contact Analysis of Crystal Structures 
To calculate the intermolecular van der Waals (vdW) interaction energies the 
crystal structures were prepared using the Schrodinger Protein Preparation 
Wizard114. Hydrogen atoms were added, protonation states determined and the 
structures were minimized. The protease active site was monoprotonated at D25. 
Subsequently, forcefield parameters were assigned using the OPLS2005 force 
field115. Interaction energies between the inhibitor and protease were estimated 
using a simplified Lennard-Jones potential, as previously described in detail116. 
Briefly, the vdW energy was calculated for pairwise interactions depending on the 
types of atoms interacting and the distance in-between. For each protease residue, 
the change in vdW interactions relative to a WT complex in the same space group 
was also calculated for each mutant structure.  
3.5.10 System Preparation 
High-resolution crystal structures were prepared using the Protein 
Preparation Wizard from Maestro within the Schrodinger Suite114 as previously 
described85. Briefly, cocrystallized phosphates were removed, missing atoms were 
added using Prime142, and PROPKA143-144 was used to determine the protonation 
state of side chains at pH 7.0. Lastly, the structure was minimized to a convergence 
criterion of 0.3 Å using Impref145. 
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3.5.11 Molecular Dynamics Simulations 
The prepared systems were placed in a cubic TIP3P water box measuring 
12 Å on each side. MD simulations were carried out as previously described85 
using Desmond software suite within Schrodinger146. Briefly, chloride ions were 
used to neutralize the system and 0.15 M salt were added using sodium and 
chloride ions. The OPLS3 force field was used to parameterize the ligand and 
protein. Prior to starting the 100 ns MD simulations, the solvated system was 
minimized using the stepwise procedure described previously85. Triplicates of 100 
ns simulations for WT, I84V, 2Mut, 4Mut, 8Mut, 9Mut-A71V, 9Mut-L76V, 10Mut, 
and 11Mut each with a randomized velocity were started using the protocol 
previously developed85. The root-mean-square deviation (RMSD) and root-mean-
square fluctuation (RMSF) of Cɑ atoms were calculated by utilizing the simulation 
interactions diagram from Maestro within the Schrodinger Suite. 
3.5.12 Intermolecular vdW Contact Analysis of MD Trajectories 
Intermolecular vdW interactions were calculated using a previously published 
protocol utilizing Lennard-Jones potential40, 147. The force field is not optimized for 
a sulfur violating the octet rule such as that found in the P2' moiety of DRV. As 
such, the packing around the P2' sulfur was calculated by averaging the vdW 
packing of the four adjacent atoms.  
3.5.13 Cross-Correlations of Protease/DRV Fluctuations 
The cross-correlation coefficients between the protease Cɑ atoms and DRV 
heavy atoms were calculated using a previously published protocol55. Briefly, the 
 
 118 
atom fluctuations were determined for each MD simulation. The cross-correlation 
between atom pairs, such as atoms i and j, was determined according to 




where ΔRi and ΔRj are the positional changes of atom i and j, respectively, 
and the angle brackets denote an ensemble average. The cross-correlation 
coefficient ranges from -1 to 1, where -1 represents complete anticorrelation 
between the atom pair, zero represents no correlation, and 1 represents complete 
correlation. The cross-correlation values were calculated using an in-house script 
and mapped onto the protease structure by replacing the B-factors in the PDB 
coordinate file, using PyMOL141. 
3.5.14 Distance-Difference Matrices 
The distances between all Cɑ atom pairs for a given structure were calculated 
as a 198×198 matrix for all frames in the trajectory. The distance was calculated 
for each Cɑ atom pair, giving the mean distance over the trajectory. The distance 
difference matrix was produced by subtracting each mean distance in the 
reference structure from the corresponding mean distance in the given structure. 
The overall difference for each residue was then calculated by taking the average 
of the absolute values of all the 198 distance differences involving that residue. 
PyMOL141 was used for visualization of distance differences where the protease 
backbone was represented as a cartoon-putty with increasing thickness and 
warmer color for increasing deviation. 
 
 119 
3.5.15 Jensen-Shannon Divergence Analysis of Dihedral Angles 
Over the MD simulations, all the ɸ, ѱ, χ dihedral angles of protease residues 
were measured. These dihedral angle measurements were used as input for the 
MutInf software package140. Utilizing this package, the Jensen-Shannon 
divergence (JSD), which analyzes the difference between two probability 
distributions, was calculated. An ɑ of 0.05 was used as a threshold to filter out non-
statistically significant differences in distributions, where a p-value > ɑ was 
considered non-statistically significant. In such cases, the JSD was set to zero. For 
visualization purposes, using PyMOL141, if a residue had multiple dihedral angles 
with a calculated JSD, the greatest value was selected. 
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 CHAPTER 4: 
HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2′ Ligands 
to Optimize Hydrogen Bonding in the Substrate Envelope   
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4.1 Abstract  
A structure-guided design strategy was used to improve the resistance profile of 
HIV-1 protease inhibitors by optimizing hydrogen bonding and van der Waals interactions 
with the protease while staying within the substrate envelope. Stereoisomers of 4-(1-
hydroxyethyl)benzene and 4-(1,2-dihydroxyethyl)benzene moieties were explored as P2′ 
ligands providing pairs of diastereoisomers epimeric at P2′, which exhibited distinct 
potency profiles depending on the configuration of the hydroxyl group and size of the P1′ 
group. While compounds with the 4-(1-hydroxyethyl)benzene P2′ moiety maintained 
excellent antiviral potency against a panel of multidrug-resistant HIV-1 strains, analogues 
with the polar 4-(1,2-dihydroxyethyl)benzene moiety were less potent, and only the (R)-
epimer incorporating a larger 2-ethylbutyl P1′ group showed improved potency. Crystal 
structures of protease-inhibitor complexes revealed strong hydrogen bonding interactions 
of both (R)- and (S)-stereoisomers of the hydroxyethyl group with Asp30′. Notably, the 
(R)-dihydroxyethyl group was involved in a unique pattern of direct hydrogen bonding 
interactions with the backbone amides of Asp29′ and Asp30′. The SAR data and analysis 






4.2 Introduction  
The HIV-1 protease is a major target for developing antiviral therapies against HIV-
1. Drug discovery efforts, aided by structure-based drug design, have led to the 
development of nine FDA-approved HIV-1 protease inhibitors (PIs).148 All approved HIV-
1 PIs are competitive inhibitors, and most contain different dipeptide isosteres as 
transition state mimetics.149 In addition to extensive hydrophobic interactions, PIs mainly 
rely on a number of direct and water-mediated hydrogen bonds with the protease for 
potency. The clinical efficacy of HIV-1 PIs has significantly improved since this drug class 
was first introduced in the mid-1990s. The development of second-generation PIs with 
improved potency, tolerability, and pharmacokinetic profiles, and the introduction of low-
dose ritonavir as a pharmacokinetic booster in PI-based antiretroviral therapy (ART) has 
led to improved clinical outcomes. Moreover, PIs allow exceedingly high level of viral 
inhibition at clinical concentrations due to cooperative dose-response curves with high 
slopes.150-151 These transition-state mimetic inhibitors represent the most potent anti-HIV-
1 drugs.  
Despite much success, PI-based therapies are associated with drawbacks that limit 
their effectiveness, including major side effects, unfavorable pharmacokinetics, and the 
acquisition of many viable multidrug-resistant (MDR) protease variants.89, 152 Drug 
resistance remains a major issue, as the prevalence of PI resistance mutations increases 
with duration of ART and is much higher among PI-experienced patients.153-154 Even the 
most effective PI-based regimens have been reported to select multiple resistance 
mutations in the protease, resulting in reduced virologic response.153-156 Moreover, the 
prevalence of transmitted drug resistance continues to increase, which is an added 
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challenge in the treatment of HIV infections.157-158 The emergence of MDR protease 
variants presents a challenge to structure-based drug design (SBDD), as the target is not 
a single protein but an ensemble of closely related proteases. The new PIs must maintain 
activity not only against existing MDR protease variants, but also against future variants 
that may emerge. These challenges require developing new SBDD strategies to optimize 
PI potency while avoiding resistance. 
The design strategy to maximize interactions in the HIV-1 protease active site, 
particularly with the protein backbone atoms, has been quite successful leading to the 
development of the FDA-approved drug darunavir.159-160 Darunavir (DRV, 1) is a highly 
potent inhibitor of HIV-1 protease with a low pM inhibition constant (Ki) and a high genetic 
barrier to resistance. The key structural feature that distinguishes DRV from previous 
generation HIV-1 PIs is the bis-tetrahydrofuran (bis-THF) moiety at the P2 position 
[Figure 4.1] that makes strong hydrogen bonding interactions with the backbone NH of 
Asp29 and Asp30 in the protease active site.148, 159, 161 The application of the design 
strategy to maximize interactions with the backbone atoms of HIV-1 protease has recently 
led to the discovery of DRV analogues that maintain exceptional potency against MDR 






Figure 4.1 Structures of HIV protease inhibitors DRV (1), P2′ 4-(1-
hydroxymethyl)benzene analogues (2–4) and designed compounds with 
stereochemically defined P2′ 4-(1-hydroxyethyl)benzene and (12–17) and 4-(1,2-
dihydroxyethyl)benzene (22–27) moieties. The canonical nomenclature for inhibitor 







Among the strategies proposed to rationally design PIs against drug-resistant HIV-
1 variants, the substrate envelope model provides a more comprehensive framework to 
incorporate drug resistance considerations into SBDD.166-168 This structure-guided design 
strategy aims to optimize hydrogen bonding and van der Waals (vdW) interactions with 
the protease to improve potency against MDR protease variants, while constraining 
inhibitors within the substrate envelope to avoid resistance.169 We previously used the 
substrate envelope-guided design strategy to develop a series of highly potent DRV 
analogues that maintained excellent antiviral potencies against a panel of clinically 
relevant MDR HIV-1 strains.169 The X-ray cocrystal structures confirmed that the designed 
PIs optimally fill the substrate envelope and make enhanced vdW contacts and hydrogen 
bonding interactions with HIV-1 protease.169-170 
Among these PIs, compounds 3 and 4 [Figure 4.1] with the 4-
(hydroxymethyl)benzene P2′ moiety were identified as promising lead compounds due to 
distinct polar interactions of the benzylic hydroxyl group with the protease. Cocrystal 
structures of PIs 3 and 4 bound to wild-type HIV-1 protease revealed that the P2′ benzylic 
hydroxyl group is positioned close to the backbone NH of Asp29′ and Asp30′ in the S2′ 
subsite. The hydroxyl group makes a direct hydrogen bond only with the backbone NH of 
Asp30′, which is slightly closer than the NH of Asp29′ [Figure 4.2].169-170 We reasoned 
that introduction of a small hydrophobic group such as a methyl at the benzylic position 
could shift the resulting secondary hydroxyl group closer to the backbone NH of Asp29′, 
allowing polar interactions with both residues, as well as additional vdW contacts in the 
S2′ subsite. Similarly, a hydroxymethyl group at the benzylic position could serve the 
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same purpose, with the primary hydroxyl group making additional polar interactions in the 
S2′ subsite of HIV-1 protease [Figure 4.1]. Optimal polar interactions of the P2′ moiety 
with the backbone NH of Asp29′ and Asp30′ could potentially mimic the strong hydrogen 
bonding interaction of the P2 bis-THF moiety, further improving potency against MDR 
HIV-1 variants. Previous efforts to identify an optimal P2′ moiety have only been partially 
successful, and none of the reported P2′ moieties make direct hydrogen bonding 









Figure 4.2 Comparison of hydrogen bonding network of (A) DRV (1) (PDB 6DGX) and 
(B) parent compound 4 (PDB 6OXQ). Hydrogen bonding pattern is similar throughout the 
active site except in the S2′ subsite. DRV makes a direct hydrogen bond with the 
backbone carbonyl of Asp30′ and water-mediated interactions with the side chain 
carboxylate group of the same residue. In contrast, inhibitor 4 makes a direct hydrogen 
bond with the backbone NH of Asp30′ and water-mediated hydrogen bonding with the 




On the basis of insights from the structural analysis and modeling, modifications of 
the P2′ moiety of PIs 3 and 4, in combination with variations at the P1′ group, were 
explored to enhance inhibitor interactions in the S1′ and S2′ subsites. Here, we describe 
the substrate envelope-guided design, synthesis, evaluation of biochemical and antiviral 
potency, and crystal structure analysis of a series of novel HIV-1 PIs. The inhibitors were 
designed by incorporating stereoisomers of the 4-(1-hydroxyethyl)benzene and 4-(1,2-
dihydroxyethyl)benzene moieties as novel P2′ ligands to enhance hydrogen bonding 
interactions in the S2′ subsite of HIV-1 protease. Structure-activity relationship (SAR) 
studies identified a number of compounds with improved potency profiles compared to 
DRV and the parent compounds against highly drug-resistant HIV-1 strains representing 
the spectrum of clinically relevant MDR viruses. We also report high-resolution crystal 
structures of all new compounds bound to wild-type HIV-1 protease revealing key 
interactions of the chiral 4-(1-hydroxyethyl)benzene and 4-(1,2-dihydroxyethyl)benzene 
moieties in the protease active site. A unique pattern of hydrogen bonding interactions 
was observed for compounds incorporating the (R)-4-(1,2-dihydroxyethyl)benzene as P2′ 
ligand, where both P2 and P2′ moieties make direct hydrogen bonds with the backbone 





The synthesis of HIV-1 PIs with the (S)- and (R)-(1-hydroxyethyl)benzene moieties 
at the P2′ position is outlined in Scheme 4.1. We envisioned generating both 
stereoisomers of the hydroxyethyl group at the P2′ moiety from the corresponding 4-
acetylbenzene derivatives by enantioselective reduction of the acetyl group using the 
Corey–Bakshi–Shibata (CBS) catalyst.174 The 4-acetylbenzenesulfonamide 
intermediates 8a–c were prepared from the commercially available epoxide 5 in two steps. 
Ring opening of the chiral epoxide 5 with selected amines provided the amino alcohols 
6a–c, which were reacted with 4-acetylbenzenesulfonyl chloride 7 using Na2CO3 as a 
base under biphasic conditions to afford the 4-acetylbenzenesulfonamide intermediates 
8a–c in excellent yield. Reduction of the acetyl group using BH3-THF in the presence of 
the chiral catalyst (R)-CBS-Me provided the required intermediates with the (S)-(1-
hydroxyethyl)benzene moiety 9a–c with excellent enantioselectivity. After purification by 
flash chromatography, the products were recrystallized from a mixture of EtOAc and 
hexanes to ensure chiral purity. Removal of the Boc protecting group with TFA and 
reaction of the resulting amine salts with the bis-THF activated carbonate 11 provided the 
target compounds 12, 14 and 16 with the (S)-4-(1-hydroxyethyl)benzene moiety at the 
P2′ position. Inhibitors with the corresponding (R)-4-(1-hydroxyethyl)benzene at the P2′ 
position were prepared similarly using the (S)-CBS-Me as the catalyst during the 




Scheme 4.1 Synthesis of protease inhibitors incorporating (S)- and (R)-4-(1-
hydroxyethyl)benzene as P2′ ligands.  
 
Reagents and conditions: (a) RNH2, EtOH, 70 °C, 3 h, 79–91%; (b) Na2CO3, EtOAc, H2O, 
RT, 18 h, 98–100%; (c) R-CBS-Me, BH3-THF (1 M), THF, 0 °C to RT, 3 h, 57–85%; (d) 
TFA, CH2Cl2, RT, 1 h; (e) DIEA, CH3CN, RT, 24 h, 73–91%; (f) S-CBS-Me, BH3-THF (1 
M), THF, 0 °C to RT, 3 h, 47–87%. 
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The protease inhibitors with the (R)- and (S)-4-(1,2-dihydroxyethyl)benzene 
moieties at the P2′ position were prepared from the corresponding styrene derivatives by 
Sharpless asymmetric dihydroxylation using the AD-mix catalyst175-176 as outlined in 
Scheme 4.2. Briefly, reactions of amino alcohols 6a–c with 4-vinylbenzenesulfonyl 
chloride 18 using Na2CO3 as a base under biphasic conditions provided the 4-
vinylbenzenesulfonamide intermediates 19a–c. The asymmetric dihydroxylation reaction 
using AD-mix-β as a chiral catalyst proceeded smoothly and provided the required 
intermediates with the (R)-4-(1,2-dihydroxyethyl)benzene moiety 20a–c. In all cases the 
(S)-epimer was not detected by 1H NMR; however, the products were recrystallized to 
provide enantiomerically pure intermediates 20a–c. Analogous to the compound series 
with the 4-(1-hydroxyethyl)benzene P2′ moiety, Boc deprotection and the reaction of the 
resulting amine salts with the bis-THF carbonate 11 provided the target compounds 22, 
24 and 26 with the (R)-4-(1,2-dihydroxyethyl)benzene moiety at the P2′ position. 
Inhibitors with the corresponding (S)-4-(1,2-dihydroxyethyl)benzene moiety at the P2′ 
position were prepared in a similar fashion using the AD-mix-α as the chiral catalyst in 




Scheme 4.2 Synthesis of protease inhibitors incorporating (S)- and (R)-4-(1,2-
dihydroxyethyl)benzene as P2′ ligands.  
 
Reagents and conditions: (a) Na2CO3, EtOAc, H2O, RT, 18 h, 75–94%; (b) AD-mix-β, t-
BuOH, H2O, RT, 4 h, 68–87%; (c) TFA, CH2Cl2, RT, 1 h; (d) DIEA, CH3CN, RT, 24 h, 33–




4.4 Results and Discussion 
Our goal was to improve potency of PIs against MDR HIV-1 variants by optimizing 
hydrogen bonding interactions in the S2′ subsite of HIV-1 protease. Specifically, we 
explored the possibility of additional hydrogen bonding interactions between the hydroxyl 
group of the P2′ moiety and the backbone amide NH of Asp29′ and Asp30′ on the basis 
of an analysis of 3- and 4-bound HIV-1 protease structures and molecular modeling. 
Addition of a methyl group to the hydroxymethyl substituent was expected to shift the 
hydroxyl group closer to the backbone NH of Asp29′, while increasing vdW interactions 
with residues in the S2′ subsite. Similarly, replacement of the hydroxymethyl group with 
a more polar 1,2-dihydroxyethyl was intended to enhance polar interactions; particularly 
the second hydroxyl group was expected to replace the water-mediated interactions 
between the P2′ moiety and the Asp30′ side chain. However, due to the free rotation of 
the hydroxyethyl and dihydroxyethyl groups, modeling did not provide clear distinction 
which of the two stereoisomers would provide optimal polar and vdW interactions. Thus, 
both (R)- and (S)-stereoisomers of 4-(1-hydroxyethyl)benzene and 4-(1,2-
dihydroxyethyl)benzene moieties were explored as P2′ ligands in combination with three 
P1′ groups of varying size and hydrophobicity.  
4.4.1 Enzyme Inhibition Assays 
The binding affinity of HIV-1 PIs has reached a level where assessing the inhibition 
of wild-type protease using standard FRET-based assays is quite difficult. Accurate 
measurement of inhibition constants in the low pM range remains a challenge even with 
the recently reported highly sensitive fluorogenic assay.177 Due to these limitations, two 
drug-resistant protease variants, I84V and I50V/A71V were selected to assess the 
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potency of new PIs. I84V is a common drug resistance mutation that reduces 
susceptibility to all FDA-approved PIs, while I50V/A71V mutations arise in response to 
therapy with APV and DRV-based regimens, resulting in reduced susceptibility to these 
PIs. The enzyme inhibition constants (Ki) were determined against the I84V and 
I50V/A71V protease variants using the highly sensitive FRET assay177; DRV was used 





Table 4.1 Protease inhibitory activity of PIs 12–17 and 22–27 against drug-resistant 
variants. 
Inhibitor Structure Ki (nM) I84V I50V/A71V 
12 
 
0.048 ± 0.004 0.057 ± 0.008 
13 
 
0.109 ± 0.007 0.092 ± 0.008 
14 
 
0.111 ± 0.008 0.093 ± 0.013 
15 
 
0.095 ± 0.005 0.132 ± 0.014 
16 
 
0.020 ± 0.002 0.102 ± 0.010 
17 
 
0.028 ± 0.003 0.107 ± 0.014 
22 
 
0.098 ± 0.008 0.090 ± 0.008 
23 
 





0.216 ± 0.011 NT 
25 
 
0.504 ± 0.039 NT 
26 
 
0.057 ± 0.004 0.074 ± 0.006 
27 
 
0.134 ± 0.007 0.220 ± 0.011 
3 
 
0.010 ± 0.003 0.080 ± 0.006 
4 
 
0.005 ± 0.002 0.055 ± 0.004 
DRV  0.025 ± 0.006 0.075 ± 0.006 





DRV retained excellent potency against the I84V and I50V/A71V protease variants 
(Ki = 25 pM and 75 pM, respectively) compared to that reported for wild-type protease (Ki 
= 5–16 pM).159, 169, 177 Compound 3, which incorporates a 4-(hydroxymethyl)benzene 
moiety as P2′ ligand and (S)-2-methylbutyl group at the P1′ position, showed better 
potency against the I84V protease but was equipotent to DRV against the I50V/A71V 
variant. Analogue 4 with a larger 2-ethylbutyl group at the P1′ position was more active 
than DRV against both the I84V and I50V/A71V protease variants. The corresponding 
analogue 2 with the isobutyl P1′ group was previously reported which was equipotent to 
DRV against wild-type protease but exhibited relatively lower antiviral potency, 
presumably due to reduced hydrophobicity.159, 178 Thus, as we have previously shown, 
PIs with 4-(hydroxymethyl)benzene as the P2′ moiety in combination with larger, more 
hydrophobic (S)-2-methylbutyl and 2-ethylbutyl P1′ groups maintained potency against 
drug-resistant protease variants. 
Replacement of the 4-(hydroxymethyl)benzene P2′ moiety of PIs 2–4 with (S)- and 
(R)-4-(1-hydroxyethyl)benzene resulted in pairs of diastereoisomers epimeric at P2′. The 
P2′ hydroxyethyl analogues 12–17 showed excellent inhibitory potencies against the I84V 
and I50V/A71V protease variants with Ki values ranging between 20 to 132 pM. In each 
case, both diastereoisomers were relatively less potent than the corresponding parent 
hydroxymethyl compound, particularly against the I84V protease variant. However, no 
major difference in inhibitory potency was observed between P2′ epimeric compounds. 
Only compounds with the isobutyl P1′ group showed minor differences in inhibitory 
potencies between the P2′ epimers, as diastereoisomer 12 with (S)-configuration of the 
hydroxyethyl group was slightly more potent than the corresponding (R)-epimer 13. While 
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this work was underway, Ghosh et al. reported the synthesis of PIs 12 and 13 using a 
much longer reaction sequence; both compounds were tested against wild-type HIV-1 
protease, and only compound 13 was evaluated for antiviral activity.81  
Diastereoisomers 14 and 15 with the (S)-2-methylbutyl P1′ group showed similar 
potencies against the I84V and I50V/A71V protease variants, and both were less potent 
than the parent 3. Similarly, no difference in inhibitory potency was observed between 
diastereoisomers 16 and 17 incorporating the 2-ethylbutyl P1′ group. However, 
analogues 16 and 17 were more potent against the I84V protease (Ki = 20 and 28 pM, 
respectively) and exhibited overall potency profiles comparable to that of DRV. Together, 
these data demonstrate that minor modifications to the P1′ and P2′ moieties result in 
distinct potency profiles. 
In contrast to the 4-(1-hydroxyethyl)benzene P2′ series, compounds with the 4-(1,2-
dihydroxyethyl)benzene P2′ moiety showed clear differences in inhibitory potency 
between the P2′-epimers. Compounds incorporating the (R)-4-(1,2-
dihydroxyethyl)benzene P2′ moiety were 2–3-fold more potent than the corresponding 
(S)-epimers. Diastereoisomer 22, with the isobutyl group at the P1′ position and (R)-
configuration of the dihydroxyethyl group, exhibited excellent inhibitory potency against 
the I84V and I50V/A71V proteases, while the corresponding (R)-epimer 23 was about 3-
fold less active against the I84V protease. A similar trend was observed for 
diastereoisomers 24 and 25 incorporating the (S)-2-methylbutyl P1′ group, though both 
compounds were 2-fold less active against the I84V protease than the corresponding 
isobutyl P1′ analogues 23 and 24. The analogue 26 incorporating the larger 2-ethylbutyl 
P1′ group and (R)-configuration of the dihydroxyethyl group was the most potent in this 
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series, with enzyme potency against the I50V/A71V protease variant comparable to that 
of DRV. Again, the corresponding P2′ (S)-epimer 27 was 2–3-fold less potent against the 
protease variants tested. Thus, shape of the hydrophobic group at P1′ and the 
configuration of the dihydroxyethyl group at P2′ affected inhibitor potency against drug-
resistant protease variants. 
4.4.2 Antiviral Assays 
The potency and resistance profiles of PIs were evaluated using a cell-based 
antiviral assay against wild-type HIV-1 and three representative MDR variants selected 
from a panel of clinically relevant multi-PI resistant recombinant clones [Table 4.3-4.4].179 
Relative to the wild-type HIV-1 strain NL4-3 (with a near consensus protease sequence), 
the MDR variants contain 19, 20 and 24 amino acid substitutions in the protease and are 
named SLK19, VSL20, and KY24, respectively. All three variants show high-level 
resistance and cross-resistance to multiple PIs including DRV, as determined by the 
Monogram Biosciences (South San Francisco, CA) PhenoSense assay.179 Accordingly, 
in antiviral assays, the MDR variants exhibited increasingly high-level resistance to DRV: 
compared to wild-type HIV-1, DRV was 6-fold less potent against SLK19, 58-fold less 
potent against VSL20, and 210-fold less potent against KY24. Thus, the three selected 





Table 4.2 Antiviral potency of PIs 12–17 and 22–27 against WT HIV-1 and drug-resistant 
variants 
Inhibitor cLogPa 
Antiviral EC50 (nM) (fold change)b 
WT SLK19 VSL20 KY24 
12 2.885 4.7 31 (7) 117 (25) 352 (75) 
13 2.885 7.5 100 (13) 148 (20) 360 (48) 
14 3.414 4.6 49 (11) 281 (61) 490 (107) 
15 3.414 4.2 91 (22) 291 (69) 342 (81) 
16 3.943 4.4 26 (6) 112 (25) 196 (45) 
17 3.943 5.1 32 (6) 420 (82) 345 (68) 
22 1.673 176 NT NT NT 
23 1.673 189 NT NT NT 
24 2.202 80 NT NT NT 
25 2.202 92 NT NT NT 
26 2.731 40 116 (3) 100 (3) 507 (13) 
27 2.731 41 151 (4) 417 (10) 1154 (28) 
3 3.105 5.7 52 (9) 310 (54) 1087 (191) 
4 3.634 4.2 36 (9) 426 (101) 495 (118) 
DRV 2.387 5.5 33 (6) 320 (58) 1157 (210) 
acLogP values were calculated using ChemDraw 18. bThe multidrug-resistant HIV-
1variants SLK19, VSL20 and KY24 contain the following amino acid substitutions in HIV-
1 protease compared to the WT NL4-3 strain: SLK19 (L10I, V11I, I13V, K14R, A22V, 
E35D, M36I, N37D, G48M, F53L, I54V, I62V, L63P, A71V, T74S, V82A, I84V, T91S, 
Q92K); VSL20 (L10I, K20R, L33F, E34A, E35D, M36I, N37D, K43T, M46I, G48V, I50V, 
I54T, I62V, L63P, A71V, I72V, V77I, V82A, I85V, I93L); KY24 (L10V, T12V, I13V, I15V, 
K20M, V32I, L33F, K43T, M46I, I47V, I54M, D60E, Q61N, I62V, L63P, C67Y, H69K, A71I, 




Table 4.3 Antiviral potency of PIs 12–17 and 22–27 against WT HIV-1 and drug-resistant 
variants  
Inhibitor cLogP 
Antiviral EC50 (nM) (95% Cl: lower, upper) 
WT SLK19 VSL20 KY24 
12 2.885 4.7 (4.2, 5.2) 31 (23, 43) 117 (84, 162) 352 (311, 398) 
13 2.885 7.5 (6.4, 8.7) 100 148 (110, 200) 360 (278, 466) 
14 3.414 4.6 (4.0, 5.3) 49 (39, 62) 281 (215, 366) 490 (402, 599) 
15 3.414 4.2 (3.7, 4.8) 91 (48, 180) 291 (227, 372) 342 (246, 477) 
16 3.943 4.4 (3.8, 5.1) 26 (13, 50) 112 (78, 160) 196 (162, 238) 
17 3.943 5.1 (4.4, 6.3) 32 (26, 39) 420 (311, 566) 345 (294, 405) 
22 1.673 176 (154, 201) NT NT NT 
23 1.673 189 (181, 196) NT NT NT 
24 2.202 80 (69, 92) NT NT NT 
25 2.202 92 (88, 96) NT NT NT 
26 2.731 40 (7.2, 72) 116 (92, 145) 100 (74, 134) 507 (425, 605) 
27 2.731 41 (25, 57) 151 (100, 229) 417 (268, 649) 1154 (1017, 1311) 
3 3.105 5.7 (1.6, 9.9) 52 (37, 66) 310 (252, 382) 1087 (866, 1364) 
4 3.634 4.2 (3.4, 5.0) 36 (17, 54) 426 (330, 550) 495 (399, 615) 
DRV 2.387 5.5 (4.6, 6.5) 33 (30, 35) 320 (302, 340) 1157 (994, 1347) 





The 4-(hydroxymethyl)benzene P2′ analogues 3 and 4 were equipotent to DRV 
against wild-type HIV-1 with EC50 values of 5.7 and 4.2 nM, respectively. The two 
analogues retained potent activity against the SLK19 variant but were significantly less 
potent against the VSL20 variant, with EC50 values similar to that of DRV. Compared to 
DRV and compound 3, both of which showed similar potencies against the three MDR 
variants, analogue 4 retained 2-fold better potency against the KY24 variant. The slightly 
improved resistance profile of compound 4 is in agreement with previous results and 
indicates that optimizing vdW interactions in the S1′ pocket can improve potency against 
MDR viruses.169  
All compounds incorporating the 4-(1-hydroxyethyl)benzene P2′ moieties (12–17) 
potently inhibited wild-type HIV-1 with EC50 values similar to that of DRV and parent 
compounds 3 and 4. However, the three MDR HIV-1 variants showed distinct 
susceptibilities to each of these compounds, depending on the P1′ group and the 
configuration of the hydroxyethyl group at the P2′ moiety. Compound 12, with the isobutyl 
P1′ group and the (S)-4-(1-hydroxyethyl)benzene P2′ moiety, was equipotent to DRV 
against SLK19 but exhibited 2–3-fold better potency against the highly resistant MDR 
variants VSL20 and KY24, resulting in an overall improved resistance profile. The 
corresponding epimer 13, incorporating the (R)-4-(1-hydroxyethyl)benzene P2′ moiety, 
while showing a 3-fold lower potency against SLK19, retained similar potency as 12 
against VSL20 and KY24. Diastereoisomers 14 and 15 with the (S)-2-methylbutyl P1′ 
group exhibited similar potency profiles as the corresponding analogues 12 and 13, 
except for a 2-fold loss in potency against VSL20. Further improvement in overall potency 
profile was realized with analogue 16 incorporating a larger 2-ethylbutyl P1′ group and 
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the (S)-4-(1-hydroxyethyl)benzene P2′ moiety, which maintained similar potency against 
SLK19 as DRV but demonstrated about 3- and 6-fold increase in potency against VSL20 
and KY24, respectively. Moreover, compared to the parent compound 4, analogue 16 
demonstrated 4- and 2-fold improved potency against VSL20 and KY24. Compared to 16, 
the (R)-epimer 17 maintained similar potency against SLK19 but exhibited lower potency 
against VSL20 and KY24. While all compounds with the 4-(1-hydroxyethyl)benzene as 
P2′ ligands maintained excellent potency against MDR HIV-1 variants, each exhibited 
distinct resistance profile depending on the configuration of the hydroxyethyl group and 
size of the P1′ group. 
The introduction of a more polar 4-(1,2-dihydroxyethyl)benzene moiety as the P2′ 
ligand  resulted in significantly reduced potency against wild-type HIV-1, despite 
compounds 22–27 showing pM inhibitory activities in biochemical assays. The observed 
loss of potency in cellular assays is likely due to reduced hydrophobicity, as indicated by 
lower calculated partition coefficient (LogP) values compared to DRV [Table 4.1]. The 
cellular potency of HIV-1 protease inhibitors has been shown to strongly correlate with 
the hydrophobicity descriptor LogP, suggesting that membrane transport is a key factor 
affecting antiviral potency.180 
The observed antiviral potencies of the 4-(1,2-dihydroxyethyl)benzene containing 
compounds indeed correlate with their cLogP values [Figure 4.3]. In all cases both 
diastereoisomers exhibited similar antiviral potencies against wild-type HIV-1. 
Compounds 22 and 23 incorporating the isobutyl P1′ group showed significantly lower 
potency than DRV. Replacement of the isobutyl P1′ group with a slightly more 
hydrophobic (S)-2-methylbutyl group, providing analogues 24 and 25, resulted in further 
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improvement in antiviral potency. Compounds 26 and 27 incorporating a larger 2-
ethylbutyl P1′ group further increased hydrophobicity and resulted in a 2-fold 
improvement in potency compared to the (S)-2-methylbuty P1′ analogues 24 and 25. 
However, both diastereoisomers 26 and 27 were 8-fold less active than DRV against wild-
type HIV-1 despite 26 exhibiting similar potency in enzyme inhibition assays. Compared 
to DRV the P2′ (R)-epimer 26 maintained better potency against MDR variants VSL20 
and KY24 and exhibited much lower fold potency losses. The corresponding (R)-epimer 
27, though less active against SLK19, showed similar potency as DRV against VSL20 
and KY24. Thus, the combination of a more hydrophobic 2-ethylbutyl P1′ group and the 






Figure 4.3 Correlation of observed antiviral potencies of PIs against wild-type HIV-1 with 





4.4.3 Analysis of Protease-Inhibitor Complexes 
To explore molecular interactions of the chiral 4-(1-hydroxyethyl)benzene and 4-
(1,2-dihydroxyethyl)benzene P2′ moieties, we determined crystal structures of PIs 12–17 
and 22–27 bound to wild-type HIV-1 protease of the NL4-3 strain. The cocrystal structures 
of PIs 2–4 were also determined with the same protease enzyme, as the previously 
reported cocrystal structures of PIs 3 and 4 were with the wild-type protease of SF-2 
sequence, which is slightly different from NL4-3. The two variants differ by four amino 
acids which caused minor structural differences at the distal loops, but the active sites 
were nearly identical, including inhibitor binding and crystallographic waters. The 
crystallographic data collection and refinement statistics are summarized in Table 4.4. All 
15 high-resolution (1.86–2.03 Å) cocrystal structures were solved in the same P212121 
space group with one protease homodimer in the asymmetric unit, and only one 
orientation of the bound inhibitor in the protease active site, which was crucial for direct 




Table 4.4 X-ray data collection and crystallographic refinement statistics. 
Inhibitor 1 2 3 4 12 13 14 15 16 17 22 23 24 25 26 27 
PDB Code 6DGX 6OXO 6OXP 6OXQ 6OXR 6OXS 6OXT 6OXU 6OXV 6OXW 6OXX 6OXY 6OXZ 6OY0 6OY1 6OY2 
Resolution (Å) 2.00 2.00 1.97 1.89 2.03 1.99 1.86 1.86 1.99 1.98 1.96 1.96 1.96 2.00 2.00 1.99 
Space group P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 
Cell dimensions:                 
a (Å) 51.0 51.1 51.0 50.9 50.8 50.9 51.1 51.0 50.9 50.9 51.0 51.0 50.9 51.1 50.9 51.1 
b (Å) 58.3 58.4 58.0 58.1 58.6 59.0 58.1 58.0 58.8 58.9 57.9 58.2 57.7 58.1 57.8 58.2 
c (Å) 61.9 62.2 62.1 62.3 61.8 61.6 62.2 62.0 61.7 61.7 62.3 62.2 62.4 62.3 62.2 62.1 
β (°) 90 90 90 90 90 90 90 90 90 90 90 90 90 90 90 90 
Completeness 
(%) 98.1 99.7 94.5 96.8 95.8 97.8 95.4 95.1 99.6 95.3 96.8 97.1 95.4 98.1 92.7 95.0 
Total reflections 84332 86563 55435 104830 88407 84420 90485 84249 47857 86496 79161 62349 62708 82784 58994 61152 
Unique 
reflections 12758 13010 12890 14875 11816 12983 15390 15237 13165 12786 13311 13435 13109 12855 12065 12586 
Average I/σ 31.1 15.7 24.9 33.6 26.2 24.9 23.5 26.7 22.2 25.6 17.6 25.3 27.0 25.8 32.3 24.5 
Redundancy 6.6 6.7 4.3 7.0 7.5 6.5 5.9 5.5 3.6 6.8 5.9 4.6 4.8 6.4 4.9 4.9 
Rsym (%)a 5.7 10.4 5.3 5.5 7.5 7.1 8.3 6.9 5.6 6.8 8.8 5.9 5.9 7.2 5.1 6.4 
RMSDb in:                 
Bond lengths 
(Å) 0.003 0.002 0.004 0.009 0.002 0.003 0.003 0.008 0.007 0.003 0.005 0.005 0.003 0.003 0.008 0.002 
Bond angles (°) 0.590 0.547 0.689 0.971 0.553 0.657 0.703 0.904 0.956 0.608 0.784 0.767 0.640 0.766 0.913 0.584 
Rfactor (%)c 19.2 20.1 17.3 19.7 18.9 18.7 19.8 18.5 17.7 18.8 19.2 16.5 17.1 17.9 17.8 19.3 
Rfree (%)d 22.8 25.0 22.2 23.7 23.4 22.8 23.1 23.3 21.9 23.8 23.3 19.6 21.9 21.8 22.5 24.0 
 
aRsym = Σ | I − <I>|/ Σ I, where I = observed intensity, <I> = average intensity over symmetry equivalent; values in parentheses 
are for the highest resolution shell. 
bRMSD, root mean square deviation. 
cRfactor = Σ || Fo| − |Fc||/ Σ|Fo|. 
dRfree was calculated from 5% of reflections, chosen randomly, which were omitted from the refinement process.
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The overall binding conformations of all PIs incorporating the 4-
(hydroxymethyl)benzene (2–4), 4-(1-hydroxyethyl)benzene (12–17), and 4-(1,2-
dihydroxyethyl)benzene (22–27) P2′ moieties are similar to that of DRV [Figure 4.4A]. 
However, clear differences in contacts were observed in the binding of the P2′ moieties 
depending on the substituent at the 4-position of the benzene ring and the configuration 
of the hydroxyl group [Figure 4.4B, 4.4D]. Compared to DRV, all PIs with modified P2′ 
ligands maintain similar hydrogen bonding interactions with the protease, except in the 
S2′ subsite [Figures 4.5 and 4.6]. The cocrystal structures of PIs 2–4 in complex with 
protease showed minor changes in the conformation of the 4-(hydroxymethyl)benzene 
moiety compared to the 4-aminobenzene of DRV in the S2′ subsite [Figure 4.7]. In the 
DRV-bound protease structure, the amino group of the 4-aminobenzene P2′ moiety is 
involved in hydrogen bonding interactions with the main chain carbonyl of Asp30′ and 
water-mediated interactions with the side-chain carboxylate of Asp30′ [Figure 4.2]. The 
primary hydroxyl group of the 4-(hydroxymethyl)benzene P2′ moiety in compounds 2–4 
is oriented toward Asp29′ and Asp30′ backbone and makes a direct hydrogen bond with 
the backbone NH of Asp30′. Moreover, the hydroxyl group interacts with the backbone 
NH of Asp29′ and the side chain of Asp30′ through water-mediated hydrogen bonds. This 
network of hydrogen bonding interactions in the S2′ subsite likely underlie the improved 





Figure 4.4 Comparison of binding modes of protease inhibitors with 4-(1-
hydroxyethyl)benzene and 4-(1,2-dihydroxyethyl)benzene P2′ moieties in the active site 
of wild-type HIV-1 protease. The two protease monomers are in cyan (denoted as non-
prime) and magenta (denoted as prime). Superposition of protease complexes with DRV 
(1), parent compounds (2–4), and new analogues (12–17 and 22–27). The inhibitors are 
shown as sticks and HIV protease dimers are shown as ribbons. (B)  Zoomed-in active 
site of superimposed complexes. The inhibitors bind to wild-type HIV protease in similar 
conformations except minor variations in the S2′ subsite. (C) Fit of inhibitors within the 
substrate envelope. The substrate envelope is in blue space filling representation, and 
the superimposed inhibitors are displayed as sticks. There is minimal protrusion of 





Figure 4.5 Crystal structures of wild-type HIV-1 protease in complex with inhibitors (A) 
16, (B) 17, (C) 26, and (D) 27. Both (R)- and (S)-stereoisomers of the P2′ 4-(1-
hydroxyethyl)benzene moiety make direct hydrogen bonding interactions with the 
backbone NH of Asp30′ in the S2′ subsite (A and B). The (R)-stereoisomer of the P2′ 4-
(1,2-dihydroxyethyl)benzene moiety makes hydrogen bonding interactions with backbone 
NH of Asp29′ and Asp30′ (C). The (S)-stereoisomer of the P2′ 4-(1,2-
dihydroxyethyl)benzene moiety makes hydrogen bonding interactions with the backbone 





Figure 4.6 Comparison of binding interactions of representative PIs with modified P2′ 
moieties in the S2′ subsite of HIV-1 protease. Binding interactions of (A) DRV (PDB 
6DGX), (B) parent compound 4 (PDB 6OXQ) with the 4-(hydroxymethyl)benzene P2′ 
moiety, (C) inhibitor 16 with (S)-4-(1-hydroxyethyl)benzene P2′ moiety, (D) inhibitor 17 
with the (R)-configuration of the P2′ moiety, (E) inhibitor 26 with (R)-4-(1,2-
dihydroxyethyl)benzene P2′ moiety, and (F) inhibitor 27 with the (S)-configuration of the 




Figure 4.7 X-ray crystal structures of inhibitors superimposed with DRV showing shift of 
the benzene ring of the P2′ moiety. Superimposed structures of (B) parent compounds 
2–4; (C) analogues 12, 14 and 16; (D) 13, 15 and 17; (E) 22, 24 and 26; and (F) 23, 25 
and 27.  
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The PIs 12–17 with the 4-(1-hydroxyethyl)benzene moiety at the P2′ position were 
designed to better position the hydroxyl group between the backbone NH of Asp29′ and 
Asp30′. In addition, the methyl group was expected to make vdW interactions with the 
hydrophobic residues around the S2′ subsite. Similar to the parent compounds, PIs 12–
17 fit well within the substrate envelope [Figure 4.4C]. For both the (S)- and (R)-4-(1-
hydroxyethyl)benzene P2′ moieties only a portion of the hydroxyethyl substituent 
protrudes outside the envelope. The structures of PIs 12, 14 and 16 bound to protease 
superimpose very well with the corresponding parent compound structures with only 
subtle changes in the position and orientation of the (S)-4-(1-hydroxyethyl)benzene P2′ 
moiety. The differences in the conformation of the P2′ moiety are more evident for PIs 13, 
15 and 17 incorporating the (R)-4-(1-hydroxyethyl)benzene, which is shifted upward 
toward the Gly48 backbone with a slight change in the orientation of the benzene ring 
compared to the position in the corresponding epimers, likely to maintain polar 
interactions between the hydroxyl group and the backbone NH of Asp30′ [Figure 4.7]. 
Despite clear differences in the overall binding conformations of (S)- and (R)-4-(1-
hydroxyethyl)benzene P2′ moieties, the secondary hydroxyl group is oriented in the same 
direction of Asp29′ and Asp30′ backbone [Figure 4.6]. Instead, the orientation of the 
methyl group is altered. As a result, regardless of the configuration of the hydroxyl group, 
the PIs incorporating the 4-(1-hydroxyethyl)benzene moiety (12–17) make identical direct 
and water-mediated hydrogen bonding interactions in the protease active site as the 
parent compounds 2–4 [Figure 4.6]. In both configurations, the hydroxyl group is 
positioned between the backbone NH of Asp29′ and Asp30′. However, in all structures 
the hydroxyl group makes a direct hydrogen bond only with the backbone NH of Asp30′, 
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which is closer (3.0–3.2 Å) than the NH of Asp29′ (3.6–3.8 Å). The distance between the 
hydroxyl group and the backbone NH of Asp30′ is slightly shorter (3.0–3.1 Å) for 
compounds with the (S)-4-(1-hydroxyethyl)benzene P2′ moiety than the corresponding 
(R)-epimers (3.2 Å) [Table 4.5]. The hydroxyl group also interacts with the side chain of 
Asp30′, mostly through water-mediated hydrogen bonds but directly in case of compound 
14. In the 14-protease complex structure the side chain of Asp30′ is shifted toward the 
P2′ moiety, resulting in a strong, direct hydrogen bond between the hydroxyl and 
carboxylate groups. Moreover, the hydroxyl group makes water-mediated interactions 
with the backbone NH of Asp29′, which are not observed in DRV-protease complex. Thus, 
the hydroxyl group at the P2′ moiety is involved in a network of direct and water-mediated 
interactions in the protease active site [Figure 4.6]. 
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Table 4.5 Intermolecular hydrogen bonds between the protease and inhibitors in the cocrystal structures (distance in Å). 
Shorter distances are more red and longer distances are more blue (cutoff 3.5 Å). 
Residue D30 D29 D29 G27 D25 D25 D25' D25' I50 I50 I50' I50' D30' D30' D30' D30' D30' D29' D29' D29' D29' D29' 
Atom MC-N MC-N MC-N MC-O SC-O SC-O SC-O SC-O MC-N MC-N MC-N MC-N SC-O SC-O SC-O SC-O MC-N MC-N SC-O H2O MC-N SC-O 
Type Direct Direct Direct Direct Direct Direct Direct Direct Water Water Water Water Water Water Direct Direct Direct Direct Direct Water Water Water 
DRV 2.9 3.2 2.8 3.0 3.2 2.5 2.9 2.5 3.0 3.1 2.8 2.9 2.9 2.9         
2 3.0 3.2 2.7 3.1 3.1 2.5 2.8 2.4 2.9 3.1 2.5 3.1     3.1      
3 3.0 3.2 2.9 3.0 3.2 2.6 2.9 2.5 2.8 3.0 2.7 3.1 2.5 2.1   3.0   3.0 2.9  
4 3.0 3.1 2.8 3.0 3.3 2.6 2.9 2.4 2.7 3.0 2.8 3.0 2.7 2.8   2.9   3.2 2.9  
12 2.9 3.1 2.8 2.9 3.1 2.4 2.8 2.4 3.0 3.0 2.6 3.0 2.6 2.4   3.1   3.3 3.1  
14 2.9 3.1 2.8 3.0 3.3 2.6 2.9 2.5 2.8 2.9 2.6 3.0   3.0  3.0   3.1 2.8  
16 3.0 3.2 2.9 3.0 3.3 2.5 2.9 2.4 2.9 2.9 2.7 2.9 2.6 2.3   3.1   3.0 3.0 3.5 
13 2.9 3.1 2.8 3.0 3.2 2.4 2.9 2.5 2.9 3.0 2.6 3.0 2.4 2.6   3.2   3.3 3.0  
15 3.1 3.1 2.9 3.1 3.3 2.6 2.9 2.5 2.7 2.9 2.7 3.0 2.7 2.4   3.2   2.9 2.8  
17 2.9 3.2 2.8 3.0 3.2 2.5 2.8 2.3 2.9 2.9 2.6 3.0 2.5 2.5   3.2   3.3 3.1  
22 2.9 3.0 2.8 3.0 3.4 2.6 2.9 2.3 2.8 3.0 2.6 3.0   2.5  2.9 3.1 3.4    
24 2.9 3.1 2.8 3.0 3.4 2.6 2.8 2.4 2.9 3.0 2.6 3.0   2.4  2.9 3.1 3.3    
26 3.0 3.1 2.8 3.1 3.3 2.6 2.9 2.3 2.7 3.1 2.7 2.9   3.4  2.9 3.1 3.5    
23 3.0 3.2 2.9 3.0 3.3 2.6 2.9 2.4 2.8 3.1 2.6 3.1   3.2 2.5 3.2   3.3 3.1  
25 2.9 3.0 2.8 3.0 3.2 2.5 2.8 2.4 2.8 3.1 2.5 3.0   2.9 2.4 3.0      
27 3.0 3.1 2.8 2.9 3.2 2.5 2.8 2.4 3.0 3.0 2.5 2.9   3.1 3.0 3.0   3.3 3.0 3.4 
MC: Main chain; SC: side chain 
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Cocrystal structures were analyzed for vdW contacts, and compounds with 
the modified P2′ moieties showed enhanced vdW interactions with protease 
residues in the S2′ subsite compared to the corresponding parent PIs 2–4 [Figure 
4.8]. To evaluate the changes in vdW interactions, total vdW energies per residue 
were calculated for each protease-inhibitor complex and the corresponding values 
for parent compound subtracted [Figure 4.9]. The additional methyl group is 
oriented toward Ile47 in complexes with PIs 12, 14 and 16 incorporating the (S)-4-
(1-hydroxyethyl)benzene P2′ moiety and toward Val32 and Leu76 in the 
corresponding (R)-epimers 13, 15 and 17. Compounds with the same P1′ group 
show minor differences in vdW interactions with residues in the S2′ subsite 
depending on the configuration of the P2′ hydroxyl group. The methyl group of 
analogue 12 with the (S)-configuration of the hydroxyl group makes additional vdW 
interactions with the methylene portion of Asp30′ side chain compared to the 
parent compound 2. Surprisingly, there is no increase in vdW contacts with Ile47 
even though the methyl group of compound 12 is oriented toward this residue. The 
methyl group of the P2′ (R)-epimer 13 forms vdW contacts with Ile47 and Leu76. 
The corresponding analogues with the (S)-2-methylbutyl and 2-ethylbutyl P1′ 
groups showed largely similar interactions as observed for 12 and 13, respectively, 
but a slight shift in the benzene ring caused minor differences in the vdW contacts. 
As previously shown for parent compounds 3 and 4, larger (S)-2-methylbutyl and 
2-ethylbutyl P1′ groups result in increased vdW contacts in the S1′ subsite, 
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compared to the corresponding isobutyl group. Compounds with the same P1′ 
group show similar vdW contacts in the S1′ subsite. Thus, enhanced vdW 
interaction of PIs 12–17 in the S2′ subsite result from the additional methyl group 




Figure 4.8 Packing of inhibitors (A) 16, (B) 17, (C) 26, and (D) 27 in the S2′ subsite 
of HIV-1 protease. The protease residues are colored blue to red for increasing 
van der Waals (vdW) contact potentials with the inhibitor mapped onto the surface 







Figure 4.9 Differences in vdW interactions for PIs incorporating the modified P2′ 
moieties compared to the corresponding parent compound. Differences in per 
residue vdW interactions were calculated by subtracting the corresponding parent 




While compounds with the (S)- and (R)-4-(1-hydroxyethyl)benzene P2′ 
moieties show minor changes in vdW contacts in the S2′ subsite, both 
diastereoisomers make identical hydrogen bonding interactions with the protease 
because the orientation of the hydroxyl group is similar in both configurations. The 
largely similar overall binding interactions of P2′ epimeric compounds correlates 
with the similar enzyme inhibitory potencies observed between diastereoisomers. 
PIs with the (S)-4-(1-hydroxyethyl)benzene P2′ moiety showed improved antiviral 
potency against MDR variants likely due to stronger polar interactions with the 
backbone atoms without relying on contacts with side chains that could mutate to 
cause resistance. Overall, the cocrystal structures provided insights into the 
binding of these new PIs with modified P2′ moieties, revealing the structural basis 
for the observed inhibitory potencies. 
The cocrystal structures of PIs 22–27 incorporating the 4-(1,2-
dihydroxyethyl)benzene in complex with protease revealed a larger shift in the 
position of the P2′ moiety compared to DRV [Figure 4.7]. The benzene ring is 
moved toward the flaps, likely to accommodate the larger substituent at the 4-
position. With the (R)-configuration of the dihydroxyethyl group, the primary 
hydroxyl group in PIs 22, 24 and 26 is oriented toward the Asp29′ backbone and 
the S3′ subsite. As a result, these PIs fit very well within the substrate envelope 
[Figure 4.4C]. In contrast, the primary hydroxyl group in the corresponding (S)-
epimer compounds 23, 25 and 27 is oriented in the opposite direction, toward the 
Asp30′ and Leu76 side chains, and lie largely outside the substrate envelope. The 
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cocrystal structures of PIs 22–27 also showed subtle variations in the binding of 
the secondary hydroxyl group of the (R)- and (S)-4-(1,2-dihydroxyethyl)benzene 
P2′ moieties. Despite differences in the binding of the dihydroxyethyl 
stereoisomers, similar conformations of the benzene ring were observed for both 
(R)- and (S)-4-(1,2-dihydroxyethyl)benzene P2′ moieties. 
The hydrogen bonding patterns of compounds incorporating the 4-(1,2-
dihydroxyethyl)benzene as P2′ ligands varied considerably depending on the 
configuration of the secondary hydroxyl group [Figure 4.6]. In the cocrystal 
structures of PIs 22, 24, and 26 with the (R)-configuration of the dihydroxyethyl 
group, the secondary hydroxyl group makes a strong, direct hydrogen bond with 
the backbone NH of Asp30′. Another weaker but direct hydrogen bond connects 
the secondary hydroxyl group with the side chain carboxylate of Asp30′, replacing 
the water-mediated interactions observed for compounds with the 4-
(hydroxymethyl)- and 4-(1-hydroxyethyl)-benzene P2′ moieties. The primary 
hydroxyl group of the (R)-dihydroxyethyl moiety is oriented toward the protease 
backbone and forms a direct hydrogen bond with the backbone NH of Asp29′, 
displacing a water molecule observed in the parent compound structures [Figure 
4.10]. The primary hydroxyl group is also involved in weaker (3.3–3.5 Å), direct 
hydrogen bonding interactions with the side chain carboxylate of Asp29′. The 
unique pattern of polar interactions of the (R)-dihydroxyethyl group in the S2′ 
subsite, particularly involving the backbone NH of Asp29′ and Asp30′, mimics the 




Figure 4.10 Comparison of water networks in the S2′ subsite. Most 
crystallographic waters are conserved in protease cocrystal structures of inhibitors 
with similar P2′ moieties. (A) Water structure in DRV-protease complex. 
Superimposed structures of (B) parent compounds 2–4; (C) analogues 12, 14 and 
16; (D) 13, 15 and 17; (E) 22, 24 and 26; and (F) 23, 25 and 27.  
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The cocrystal structures of PIs 23, 25, and 27 with the (S)-configuration of 
the P2′ dihydroxyethyl group also revealed a unique network of hydrogen bonds 
between the hydroxyl groups and the protease. The secondary hydroxyl group 
forms two direct hydrogen bonds, one with the backbone NH of Asp30′ and another 
with the side chain carboxylate of the same residue. The secondary hydroxyl group 
is also positioned close to the backbone NH of Asp29′ (3.5–3.6 Å) and makes 
water-mediated interactions with both the backbone NH and side chain carboxylate 
of this residue. The primary hydroxyl group is oriented toward the side chain of 
Asp30′ and is involved in a direct hydrogen bonding interaction with the carboxyl 
group, replacing the water molecule observed in complexes with compounds 
incorporating the 4-(hydroxymethyl)- and 4-(1-hydroxyethyl)-benzene P2′ moieties. 
In this orientation, the dihydroxyethyl group forms an additional direct hydrogen 
bond with the protease replacing a water-mediated interaction.  
In addition, PIs 22–27 incorporating the 4-(1,2-dihydroxyethyl)benzene 
moieties as P2′ ligands form enhanced vdW contacts with the protease compared 
to the corresponding parent compounds 2–4. The altered position of the P2′ moiety 
places the benzene ring closer to Gly48′ in the flaps, resulting in an overall 
increase in vdW contacts for all PIs in this series. Minor changes in vdW 
interactions were observed between P2′ epimeric compounds, with additional 
subtle variations resulting from changes at the P1′ position [Figure 4.9]. In general, 
compounds with the (R)-configuration of the modified P2′ moiety (22, 24, and 26) 
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make enhanced vdW interactions with Asp29′, Pro81, and residues 47′–50′ in the 
flap region, but slightly reduced interactions with Val32 and Ile84 [Figure 4.8]. The 
corresponding (S)-epimers (23, 25, and 27) formed more vdW contacts with a 
different set of residues around the active site, including Asp30′, Lys45′, Ile47, and 
Leu76′, and weaker contacts with Asp30 and Ile50. However, few exceptions to 
these general trends were observed for compounds 24 and 25 that incorporate the 
(S)-2-methylbutyl group at the P1′ position, likely due to the asymmetric shape of 
the P1′ group [Figure 4.9]. Overall, for PIs incorporating the 4-(1,2-
dihydroxyethyl)benzene P2′ moieties, the increase in vdW interactions with 
specific protease residues mainly depend on the configuration of the 
dihydroxyethyl group. 
The cocrystal structures of PIs with the 4-(1,2-dihydroxyethyl)benzene P2′ 
moieties revealed unique hydrogen bonding patterns and vdW contacts that vary 
significantly, depending on the configuration of the modified P2′ moiety. The 
improved potency profiles of PIs with the (R)-4-(1,2-dihydroxyethyl)benzene P2′ 
moiety compared to the corresponding (S)-epimers likely result from enhanced 
backbone interactions with residues Asp29′ and Asp30′, as well as increased vdW 
contacts with the side chains of Asp29′ and residues in the flap region. Notably, 
these PIs also fit very well in the substrate envelope. Compound 26, with the 2-
ethylbutyl P1′ group, is a promising lead for exploring further modifications, 
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particularly in combination with more hydrophobic P1 and P2 groups, to further 
improve potency against MDR variants.  
4.5 Conclusions 
New HIV-1 protease inhibitors were designed by incorporating stereoisomers 
of the 4-(1-hydroxyethyl)benzene and 4-(1,2-dihydroxyethyl)benzene moieties as 
P2′ ligands to enhance hydrogen bonding interactions in the S2′ subsite. 
Compounds with the polar dihydroxyethyl group at the P2′ moiety were generally 
less potent than DRV while inhibitors with the hydroxyethyl group exhibited 
improved antiviral potency against MDR variants. Crystal structures of protease-
inhibitor complexes show that all PIs make enhanced hydrogen bonding and vdW 
interactions with the protease. The reduced cellular potency of PIs with the 
dihydroxyethyl group is likely due to their relatively low hydrophobicity, which can 
be counterbalanced with increased hydrophobicity at other positions such as P1. 
Overall, the PI potency profile was determined by the polar substituent at the 4-
position of the P2′ benzene ring, configuration of the secondary hydroxyl group, 
and the size of the P1′ group. Exploration of both stereoisomers of P2′ moiety 
revealed unique polar and vdW interactions, including a network of direct and 
water-mediated hydrogen bonding with the backbone and side chain atoms of 
Asp29′ and Asp30′. Notably, PIs with the (R)-4-(1,2-dihydroxyethyl)benzene 
moiety make hydrogen bonding interactions with the backbone NH of Asp29′ and 
Asp30′ in the S2′ subsite, mimicking the polar interactions of the P2 bis-THF moiety, 
and show improved potency and resistance profiles compared to the 
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corresponding (S)-epimers. In general, compounds that make increased hydrogen 
bonding interactions with the backbone and vdW contacts with invariant residues, 
and fit better within the substrate envelope maintain better potency against highly 
resistant MDR HIV-1 strains. These SAR data and structural insights may allow 
further optimization of these promising inhibitors. 
4.6 Experimental Section 
4.6.1 General 
All reactions were performed in oven-dried round- bottomed fitted with rubber 
septa under argon atmosphere unless otherwise noted. All reagents and solvents, 
including anhydrous solvents, were purchased from commercial sources and used 
as received. Flash column chromatography was performed on an automated 
Teledyne ISCO CombiFlash Rf+ system equipped with a UV-Vis detector using 
disposable Redisep Gold high performance silica gel columns, or manually using 
silica gel (230−400 mesh, EMD Millipore). Thin- layer chromatography (TLC) was 
performed using silica gel (60 F- 254) coated aluminum plates (EMD Millipore), 
and spots were visualized by exposure to ultraviolet light (UV), exposure to iodine 
adsorbed on silica gel, and/or staining with alcohol solutions of phosphomolybdic 
acid (PMA) and ninhydrin followed by brief heating. 1H NMR and 13C NMR spectra 
were acquired on Varian Mercury 400 MHz and Bruker Avance III HD 500 MHz 
NMR instruments. Chemical shifts are reported in ppm (δ scale) with the residual 
solvent signal used as reference, and coupling constant (J) values are reported in 
hertz (Hz). Data are presented as follows: chemical shift, multiplicity (s = singlet, d 
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= doublet, dd = doublet of doublet, dd = doublet of triplet, t = triplet, m = multiplet, 
br s = broad singlet), coupling constant in Hz, and integration. High-resolution 
mass spectra (HRMS) were recorded on a Thermo Scientific Orbitrap Velos Pro 
mass spectrometer coupled with a Thermo Scientific Accela 1250 UPLC and an 
autosampler using electrospray ionization (ESI) in the positive mode. The purity of 
final compounds was determined by analytical HPLC and was found to be ≥95% 
pure. HPLC was performed on an Agilent 1200 system equipped with a multiple 
wavelength detector and a manual injector under the following conditions: column, 
Phenomenex Hypersil-BDS-5u-C18 (5 μm, 4.6 mm × 250 mm, 130 Å); solvent A, 
H2O containing 0.1% trifluoroacetic acid (TFA); solvent B, CH3CN containing 0.1% 
TFA; gradient, 20% B to 100% B over 15 min followed by 100% B over 5 min; 
injection volume, 20 μL; flow rate, 1 mL/min. The wavelengths of detection were 
254nm and 280 nm. Retention times and purity data for each target compound and 
intermediate can be found online.   
4.6.2 Antiviral Assays 
293T and TZM-BL181 cells (NIH AIDS Research and Reference Reagent 
Program) were maintained in Dulbecco’s modified Eagle’s medium supplemented 
with 10% fetal calf serum in the presence of penicillin and streptomycin at 37 °C 
with 5% CO2. To determine the concentration of drugs achieving 50% inhibition of 
infection compared with the drug-free control, 4.5×106 293T cells were seeded 
onto a 10-cm plate 24 h before transfection. Cells were transfected with 8 µg of 
either the wild-type plasmid, infectious molecular clone pNL-CH derived from the 
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pNL4-3 clone of HIV-1, or each PI-resistant HIV-1 variant179 using FuGENE 6 
transfection reagent (Roche). The culture supernatant of 293T cells transfected 
with wild-type or PI-resistant HIV-1 variant was removed 18 h after transfection 
and the cells were washed with 1 × PBS. The 293T cells were collected and 
transferred to wells of a 24-well plate. Briefly, each drug was serially diluted in the 
culture medium and the dilutions were added to the wells of a 24-well plate. The 
293T cells (0.5 × 106 per well) collected from the transfection were added to wells 
containing various concentrations of drug. The culture supernatant containing virus 
particles was harvested 18 h after the 293T cells were reseeded in the presence 
of drug. This supernatant was filtered through a 0.45-µm-pore-size membrane 
(Millipore) to remove cell debris then used to infect 2 × 104 TZM-BL cells in a 96-
well plate following a procedure previously described.182 The culture supernatant 
was removed from each well 48 h post-infection, and the cells were washed with 
1 × PBS. For the luciferase assay, infected TZM-BL cells were lysed in 1× reporter 
lysis buffer (Promega) and the cells were kept at −80 °C. After one freeze-thaw 
cycle, the cell lysates were transferred into a 96-well assay plate (Costar), and 
luciferase activity was measured using a luminometer (Promega). The culture 
supernatant harvested from 293T cells reseeded in the absence of drugs was used 
as a drug-free control. EC50 was determined based on a dose-response curve 
generated using GraphPad Prism (version 7.0). 
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4.6.3 Protease Gene Construction 
Protease gene construction was carried out as previously described.183-184 
The NL4-3 strain has four naturally occurring polymorphisms in the protease 
relative to the SF2 strain.100  In short, the protease variant genes (I84V, I50V/A71V) 
were constructed using QuikChange site-directed mutagenesis (Genewiz) onto 
NL4-3 wild-type protease on a pET11a plasmid with codon optimization for protein 
expression in Escherichia coli. A Q7K mutation was included to prevent 
autoproteolysis.185  
4.6.4 Protein Expression and Purification 
The expression, isolation, and purification of WT and mutant HIV-1 proteases 
used for the kinetic assays and crystallization were carried out as previously 
described.183-184 Briefly, the gene encoding the HIV protease was subcloned into 
the heat-inducible pXC35 expression vector (ATCC) and transformed into E. coli 
TAP-106 cells. Cells grown in 6 L of Terrific Broth were lysed with a cell disruptor 
and the protein was purified from inclusion bodies.186 The inclusion body 
centrifugation pellet was dissolved in 50% acetic acid followed by another round 
of centrifugation to remove impurities. Size exclusion chromatography was used 
to separate high molecular weight proteins from the desired protease. This was 
carried out on a 2.1 L Sephadex G-75 superfine column (Millipore Sigma) 
equilibrated with 50% acetic acid. The cleanest fractions of HIV protease were 
refolded into a 10-fold dilution of 0.05 M sodium acetate at pH 5.5, 5% ethylene 
glycol, 10% glycerol, and 5 mM DTT. Folded protein was concentrated down to 
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0.7–2 mg/mL and stored. This stored protease was used in KM and Ki assays. For 
crystallography, a final purification was performed with a Pharmacia Superdex 75 
FPLC column equilibrated with 0.05 M sodium acetate at pH 5.5, 5% ethylene 
glycol, 10% glycerol, and 5 mM DTT. Protease fractions purified from the size 
exclusion column were concentrated to 1–2 mg/mL using an Amicon Ultra-15 10-
kDa device (Millipore) for crystallization. 
4.6.5 Enzyme Inhibition Assays 
The KM and Ki Assays were carried out as previously described.89, 177 In the 
KM assay, a 10-amino acid substrate containing the natural MA/CA cleavage site 
with an EDANS/DABCYL FRET pair was dissolved in 8% DMSO at 40 nM and 6% 
DMSO at 30 nM. The 30 nM of substrate was 4/5th serially diluted from 30 nM to 6 
nM, including a 0 nM control. HIV protease was diluted to 120 nM and, using a 
PerkinElmer Envision plate reader, 5 µL was added to the 96-well plate to obtain 
a final concentration of 10 nM. The fluorescence was observed with an excitation 
at 340 nm and emission at 492 nm and monitored for 200 counts, for approximately 
23 minutes. FRET inner filter effect correction was applied as previously 
described.187 Corrected data were analyzed with Prism7, as described in Chapter 
3.  
To determine the enzyme inhibition constant (Ki), in a 96-well plate, each 
inhibitor was 2/3 serially diluted from 3 nM to 52 pM, including a 0 pM control, and 
incubated with 0.35 nM protein for 1 hour. A 10-amino acid substrate containing 
an optimized protease cleavage site with an EDANS/DABCYL FRET pair was 
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dissolved in 4% DMSO at 120 µM. Using the Envision plate reader, 5 µL of the 120 
µM substrate was added to the 96-well plate to a final concentration of 10 µM. The 
fluorescence was observed with an excitation at 340 nm and emission at 492 nm 
and monitored for 200 counts, for approximately 60 min. Data was analyzed with 
Prism7, As described in Chapter 2.  
4.6.6 Protein Crystallization 
The condition reliably producing cocrystals of NL4-3 WT protease bound to 
PIs was discovered and optimized as previously described.188 Briefly, all cocrystals 
were grown at room temperature by hanging drop vapor diffusion method in a 24-
well VDX hanging-drop trays (Hampton Research) with a protease concentration 
of 1.0–1.7 mg/mL with 3-fold molar excess of inhibitors. Crystallization drops 1 µL 
protein-inhibitor solution and 2 µL reservoir solution consisting of 22–26% (w/v) 
ammonium sulfate with 0.1 M bis-Tris-methane buffer at pH 5.5. Drops were micro-
seeded with a cat whisker. Diffraction quality crystals were obtained within 1 week. 
As data were collected at 100 K, cryogenic conditions contained the precipitant 
solution supplemented with 25% glycerol.  
4.6.7 X-Ray Data Collection and Structure Solution 
X-ray diffraction data were collected and solved as previously described.184, 
188-189 Diffraction quality crystals were flash frozen under a cryostream when 
mounting the crystal at our in-house Rigaku_Saturn944 X-ray system. The 
cocrystal diffraction intensities were indexed, integrated, and scaled using 
HKL3000.190 Structures were solved using molecular replacement with 
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PHASER.191 Model building and refinement were performed using Coot192 and 
Phenix.193 Ligands were designed in Maestro and the output sdf files were used in 
the Phenix program eLBOW109 to generate cif files containing atomic positions and  
constraints necessary for ligand refinement. Iterative rounds of crystallographic 
refinement were carried out until convergence was achieved. To limit bias 
throughout the refinement process, five percent of the data were reserved for the 
free R-value calculation.110 MolProbity194 was applied to evaluate the final 
structures before deposition in the PDB. Structure analysis, superposition and 
figure generation was done using PyMOL.195 X-ray data collection and 
crystallographic refinement statistics are presented in the Supporting Information 
[Table 4.4].  
4.6.8 Molecular Modeling 
Molecular modeling was carried out using MacroModel.196 Briefly, inhibitors 
were modeled into the active site of wild-type HIV-1 protease using the protease-
3 and protease-4 co-complex structures (PDB code: 3O9B and 3O9G).169 
Structures were prepared using the Protein Preparation tool in Maestro 11.196 2D 
chemical structures were modified with the appropriate changes using the Build 
tool in Maestro. Once modeled, molecular energy minimizations were performed 
for each inhibitor–protease complex using the PRCG method with 2500 maximum 
iterations and 0.05 gradient convergence threshold. PDB files of modeled 
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Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-
Tetrahydrofuran in a Pseudo-symmetric Dipeptide Isostere   
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5.1 Abstract  
Drug discovery efforts against HIV-1 protease have focused mainly on exploring 
darunavir (DRV) analogues with similar sulfonamide-based dipeptide isosteres and 
P2/P2′ moieties. The conformationally constrained P2 bis-tetrahydrofuran (bis-THF) of 
DRV and related ligands have not been extensively explored in other dipeptide isosteres. 
In this study, we investigated HIV-1 protease inhibitors (PIs) containing bis-THF in a 
pseudo-C2-symmetric dipeptide isostere and characterized their binding using 
experimental and computational methods. Specifically, series of hybrid PIs were designed 
by incorporating bis-THF on either side of the Phe-Phe isostere of lopinavir in combination 
with hydrophobic amino acids on the opposite P2/P2′ position. Enzyme inhibition and 
antiviral data indicated that the bis-THF moiety can be attached at either the P2 or P2′ 
position without significantly affecting potency. In contrast, the moiety on the opposite P2 
or P2′ position had a dramatic effect on potency depending on the size and shape of the 
hydrophobic amino acid. Cocrystal structures of inhibitors with wild-type HIV-1 protease 
revealed the bis-THF moiety retained similar interactions as observed in the DRV-
protease complex regardless of position on the Phe-Phe isostere. Analyses of cocrystal 
structures and molecular dynamics simulations provide insights for optimizing HIV-1 PIs 




5.2 Introduction  
Combinations of drugs targeting HIV-1 enzymes essential for viral replication have 
been highly effective in reducing viral load in infected individuals and significantly 
increasing their life expectancy.152 HIV-1 protease inhibitors (PIs) remain essential 
components of combination antiretroviral therapy (cART) for AIDS patients. There are 
nine HIV-1 PIs currently approved by the US FDA; however, clinical use of most of these 
has diminished over the years due to side effects, unfavorable pharmacokinetics, and 
drug resistance. Currently only three PIs, darunavir (DRV), lopinavir (LPV), and 
atazanavir (ATV) [Figure 5.1] – boosted with small doses of ritonavir (RTV) – are being 







Figure 5.1 Structures of HIV-1 protease inhibitors darunavir (DRV) (1), lopinavir (LPV) 
(2), atazanavir (ATV) (3), previously reported hybrid compounds 4 and 5, and new hybrid 
compounds designed by incorporating the bis-THF moiety of DRV into the pseudo-
symmetric Phe-Phe dipeptide isostere of LPV at the P2 (12a–h) or P2′ position (15a–c), 
in combination with an ATV-like hydrophobic amino acid moiety at the P2′ or P2 position, 





HIV-1 protease is a C2-symmetric homodimer with a pair of catalytic aspartic acid 
residues and a series of subsites forming the active site along the dimer interface. The 
protease recognizes and cleaves a variety of substrates, which adopt a conserved shape 
when bound in the active site defined as the substrate envelope.43 A series of diverse 
amino acid sequences can be recognized as specific substrates due to dynamic subsite 
interdependence within the active site.197 Most HIV-1 PIs are substrate-based 
peptidomimetics containing a hydroxyl group as a transition state mimetic and diverse 
moieties that target the S1/S1′ and S2/S2′ subsites.27, 148 Of these PIs, DRV is the most 
potent with the highest barrier to resistance and efficacy against multidrug-resistant HIV-
1 strains.78 The excellent potency and resistance profile of DRV is attributed to the bis-
tetrahydrofuran (bis-THF) moiety, which forms strong hydrogen bonding interactions with 
the main-chain NH of Asp29 and Asp30 in the S2 subsite of the enzyme.198 Moreover, 
the extensive van der Waals (vdW) interactions of the bis-THF moiety, along with the 
sulfonamide-based Phe-Leu dipeptide isostere and the 4-aminobenzene group, also 
significantly contribute to the potency of DRV [Figure 5.1].161 
Efforts to improve potency, pharmacokinetics, and resistance profiles of HIV-1 PIs 
have led to the discovery of exceptionally potent compounds exhibiting a wide range of 
properties.148, 199-201 The classical design approaches of elaborating existing drugs and 
combining pharmacophores to form new hybrid scaffolds while employing structural 
insights from crystal structures have been the primary tools used to design these new 
inhibitors.148, 202 In recent years, drug discovery efforts against HIV-1 protease have 
focused mainly on sulfonamide-based compounds similar to DRV. As such, many 
analogues of DRV containing sulfonamide-based dipeptide isosteres with modifications 
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at P1/P1′ and P2/P2′ positions have been explored extensively, including novel bis-THF 
analogues with improved hydrogen bonding and vdW interactions with the protease.80, 148, 
203-204 Moreover, detailed structural analyses informing structure-based design of 
inhibitors with the DRV scaffold have been reported numerous times.148, 161, 166 However, 
very few inhibitors containing the bis-THF moiety combined with other isosteres, in 
particular the pseudo-C2-symmetric dipeptide isosteres of LPV and ATV, have been 
explored.205  
The variety of dipeptide isosteres and P2/P2′ moieties in HIV-1 PIs hitherto 
developed suggest that protease subsites can be targeted with diverse ligands but may 
require careful consideration of subsite interdependence. The bis-THF moiety of DRV has 
emerged as a privileged ligand for targeting the S2 subsite especially when incorporated 
into the (R)-(hydroxyethylamino)sulfonamide isostere.206 Despite the unique binding 
characteristics of bis-THF, only a few attempts have been made to use this ligand in 
combination with other dipeptide isosteres. Chen and colleagues at Abbott Laboratories 
explored PIs with bis-THF on either side of the pseudo-C2-symmetric Phe-Phe dipeptide 
isostere of LPV,205 while Cannizzaro and coworkers at Gilead Sciences designed similar 
analogues using the aza-dipeptide isostere of ATV.207 Although some of the Phe-Phe 
isostere-based compounds, such as 4 and 5 [Figure 5.1], exhibited significant antiviral 
activity against wild-type HIV-1, in the absence of direct comparison, it is unclear if their 
potency is similar to that of DRV.205 The stereochemical preference for the bis-THF moiety 
has been clearly established, with the same (3R)-stereoisomer preferred in the Phe-Phe 
isostere as in the DRV scaffold.208 However, due to limited structure-activity relationship 
studies, the S2/S2′ subsite preference of the bis-THF moiety in the context of Phe-Phe 
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isostere remains unclear,205, 208 as is the identity of an optimal moiety for targeting the 
opposite S2/S2′ subsite.205 Furthermore, no cocrystal structures of such hybrid PIs have 
been reported, limiting opportunities for structure-guided design and optimization. 
The active site of HIV-1 protease exhibits subsite interdependence in substrate 
recognition and inhibitor binding,55, 197 but this feature of the protease has rarely been 
considered in inhibitor design. While identifying optimal moieties for targeting each of the 
subsites in the protease active site is important, understanding the subsite 
interdependence and selection of the best combination of moieties are also crucial to 
achieving higher potency especially against drug-resistant variants.203 The bis-THF 
moiety potentially can be incorporated in diverse dipeptide isosteres in combination with 
suitable ligands targeting the other subsites. Here, we explored a series of hybrid HIV-1 
PIs incorporating the bis-THF moiety of DRV on either side of the pseudo-C2-symmetric 
Phe-Phe dipeptide isostere of LPV in combination with ATV-like hydrophobic P2/P2′ 
ligands of varying size and shape [Figure 5.1]. The hybrid PIs were tested for inhibitory 
activity against wild-type and two drug-resistant variants and for antiviral activity in cellular 
assays. We also determined high-resolution X-ray crystal structures of all designed hybrid 
compounds (and 4) bound to wild-type HIV-1 protease, and characterized the binding 
interactions of bis-THF in the context of the Phe-Phe isostere. In addition, molecular 
dynamics simulations were utilized to assess the stability of protease-inhibitor interactions 
in solution. The comprehensive structural and dynamic analyses of hybrid PIs have 




The synthesis of hybrid PIs incorporating the bis-THF moiety at either the P2 or P2′ 
position is outlined in Scheme 5.1. The required Phe-Phe dipeptide isostere core 
intermediate 7 was synthesized from phenylalanine following previously reported 
methods with minor modifications.209 Reaction of the dipeptide isostere 7 with bis-THF 
activated carbonate 8 in the presence of DIEA provided intermediate 9. Debenzylation of 
9 using ammonium formate and 10% palladium on activated carbon in methanol gave the 
corresponding deprotected amine 10, which was subsequently coupled with the amino 
acid derivatives 11a–h using HATU and DIEA to provide the target compounds 12a–h 
with bis-THF at the P2 position. While N-(methoxycarbonyl)-protected amino acid 
derivatives 11a and 11e were commercially available, intermediates 11b–d and 11f–h 
were prepared from the corresponding amino acids by reaction with methyl chloroformate 
under basic conditions following a reported procedure.210 
The PIs 15a–c with the bis-THF at the P2′ position were synthesized using a similar 
reaction sequence. Coupling of the dipeptide isostere 7 with acids 11a–c under HATU 
peptide coupling conditions gave the corresponding intermediates 13a–c. Catalytic 
debenzylation of compounds 13a–c followed by coupling with bis-THF activated 
carbonate 8 in the presence of DIEA provided the target compounds 15a–c. A pair of 
previously reported PIs 4 and 5 containing the dimethylphenoxy acetate and bis-THF 
moieties as the P2 and P2′ ligands in the Phe-Phe isostere were also synthesized using 





Scheme 5.1 Synthesis of Protease Inhibitors Incorporating Bis-Tetrahydrofuran in a 




Reagents and conditions: (a) K2CO3, KOH, BnCl, H2O, 100 °C, 5 h; (b) NaNH2, CH3CN, 
MTBE, 0 °C, 2 h, then BnMgCl (2 M in THF), RT, 14 h; (c) NaBH4, MsOH, i-PrOH, EGDME, 
0 °C, 12 h; (d) NaBH4, TEA, DMA, 0–15 °C, 2 h; (e) DIEA, CH3CN, RT, 24 h; (f) Pd/C, 
HCO2NH4, MeOH, 50 °C, 12 h; (g) N-(methoxycarbonyl)-capped amino acid, HATU, DIEA, 
DMF, RT, 4 h. 
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5.4 Results and Discussion 
We explored hybrid HIV-1 PIs containing the bis-THF moiety of DRV in the Phe-Phe 
isostere of LPV, with the goal to characterize the binding interactions of this P2 ligand in 
the context of a pseudo-C2-symmetric dipeptide isostere. The bis-THF moiety was used 
in combination with diverse N-(methoxycarbonyl)-capped amino acid derivatives similar 
to the P2/P2′ moiety of ATV to optimize hydrogen bonding and vdW interactions in both 
the S2 and S2′ subsites of HIV-1 protease. To explore subsite preference for the bis-THF 
moiety, pairs of compounds were synthesized with the bis-THF moiety attached at either 
the distal (P2) (12a–c) or proximal (P2′) (15a–c) position with respect to the central 
hydroxyl group of the Phe-Phe isostere. Considering potential subsite interdependence, 
incorporating a relatively small and conformationally flexible moiety at the other P2/P2′ 
position was expected to allow the P2/P2′  bis-THF moiety to optimally interact with the 
backbone atoms in the S2/S2′ subsite, likely improving overall inhibitor binding with the 
protease. Structure-activity relationships were explored by incorporating hydrophobic 
amino acids of varying size and shape to identify an optimal ligand for targeting the other 
S2/S2′ subsite. 
5.4.1 Enzyme Inhibition and Antiviral Assays 
The potency of PIs was assessed using biochemical and antiviral assays. The 
enzyme inhibition constants (Ki) were determined against wild-type protease and two 
drug-resistant variants (I84V and I50V/A71V) using a highly sensitive fluorogenic assay 
[Table 5.1].90 For a subset of compounds, antiviral potencies (EC50) were determined 
against wild-type HIV-1 (NL4-3 strain) using a cell-based antiviral assay. DRV was used 
as a control in all assays. 
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Table 5.1 Inhibitory Activity of PIs against WT HIV-1 Protease and Drug-Resistant 
Variants 
Inhibitor Structure 
Ki (nM)  EC50 (nM) 
















0.005  39 
12b 
 
46 ± 3 236 ± 39 484 ± 70  NT 
15b 
 




























































0.055 NT  16 
LPV 
 
< 0.005 0.051 ± 0.004 
0.061 ± 
0.011  12 
DRV 
 
< 0.005 0.025 ± 0.006 
0.075 ± 
0.006  5 
NT = Not Tested 
  
Compounds 12a and 15a, with the bis-THF moiety at the P2 (distal) and P2′ 
(proximal) position, respectively, and the N-(methoxycarbonyl)-tert-leucine at the 
opposite P2/P2′ position, showed excellent inhibitory potencies against wild-type 
protease and the drug resistant variants. Compared to DRV and LPV, both compounds 
were less active, particularly against the I84V variant. Interestingly, compounds 12a and 
15a exhibited similar Ki values, though the latter was 4-fold more active against the 
I50V/A71V variant, indicating no clear S2/S2′ subsite preference for the bis-THF moiety. 
However, in antiviral assays compound 12a was 3-fold more potent than 15a against wild-
type HIV-1. The distal compound 12a, with the bis-THF moiety at the P2 position, 
exhibited excellent antiviral potency (EC50 = 11 nM) comparable to that of LPV (EC50 = 
12 nM) and DRV (EC50 = 5 nM). A similar trend was observed for previously reported 
compounds 4 and 5 containing the bis-THF and the dimethylphenoxy acetate moieties as 
the P2 and P2′ ligands. Compound 5 exhibited 2-fold better antiviral potency than 4, 
indicating a reverse subsite preference for the bis-THF moiety relative to the 12a/15a pair. 
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The small variation in the antiviral potencies of compounds 12a/15a and 4/5 indicate that 
the position of the bis-THF moiety with respect to the central hydroxyl group of the Phe-
Phe isostere, though not critical for binding, may affect potency in cellular assays.  
Although the potency of the hybrid compounds was not particularly sensitive to the 
position of the bis-THF moiety, compounds with different hydrophobic amino acid 
derivatives at the opposite P2/P2′ position showed markedly different inhibitory potencies. 
The compounds with the cycloleucine moiety, 12b and 15b, were significantly less active 
(>2500-fold and 560-fold, respectively) than the corresponding tert-leucine analogues 
12a and 15a. The dramatic loss of potency is likely due to the altered shape and flexibility 
of the hydrophobic amino acid moiety. This was further supported by the fact that the 
corresponding cyclopentylglycine analogues 12c and 15c, though also an order of 
magnitude less active than 12a and 15a, still exhibited sub-nanomolar to low nM potency 
against wild-type protease and drug-resistant variants. Together these data confirm that 
the hydrophobic amino acid moiety at the opposite P2/P2′ position significantly influence 
potency in both biochemical and antiviral assays. 
Since potency of the compounds with bis-THF moiety attached to the Phe-Phe 
isostere largely depended on the hydrophobic amino acid moiety at the opposite side of 
the core scaffold, we investigated size and shape requirements for optimally targeting the 
S2′ subsite. Analogues of compound 12a were synthesized with diverse hydrophobic 
amino acid derivatives as P2′ ligands while keeping the bis-THF moiety at the P2 position. 
The alanine analogue 12d exhibited excellent inhibitory potency with Ki values against 
resistant variants comparable to that of LPV and DRV. The corresponding valine 
analogue 12e was 4-fold less active against wild-type protease but maintained similar 
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inhibitory potency as 12a against the resistant variants. However, compared to 12a 
compounds 12d and 12e were 6- and 5-fold less active in antiviral assays, respectively, 
indicating that factors other than binding affinity are responsible for lower antiviral potency. 
The cyclopropyl analogue 12f was considerably less active than 12a, with Ki values 
similar to the cyclopentyl analogue 12c, strongly suggesting that cyclic moieties at the 
P2/P2′ position are unfavorable. Replacement of tert-leucine with an isoleucine 
(compound 12g) or alloisoleucine (compound 12h) moiety at the P2′ position also resulted 
in slightly lower activity against wild-type protease but similar or better potency against 
resistant variants. This further confirmed earlier findings that the P2/P2′ group opposite 
to the bis-THF moiety on the Phe-Phe core has a significant impact on potency. These 
results are in contrast to the sulfonamide-based dipeptide isostere of DRV, where diverse 
P2′ modifications result in relatively minor changes in potency.78 The identity of the P2/P2′ 
moiety opposite to the bis-THF on the Phe-Phe core considerably impacts potency in both 
biochemical and antiviral assays. 
5.4.2 Analysis of Protease-Inhibitor Complexes 
To characterize protease-inhibitor molecular interactions, twelve high-resolution 
(1.8–2.0 Å) crystal structures of hybrid PIs and compound 4 bound to wild-type HIV-1 
protease of the NL4-3 strain were determined. A cocrystal structure of LPV was also 
determined bound to the same protease enzyme for direct comparison. The 
crystallographic data collection and refinement statistics are summarized in Table 5.2. 
Following convention, protease chains were assigned chain A (non-prime) or chain B 
(prime) depending on the interactions between the central hydroxyl group of the Phe-Phe 
isostere and the catalytic aspartates Asp25/Asp25′. 
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Table 5.2 X-ray data collection and crystallographic refinement statistics. 
Inhibitor DRV LPV 4 12a 12b 12c 12d 12e 12f 12g 12h 15a 15b 15c 
PDB Code 6DGX 6PJB 6PJC 6PJD 6PJE 6PJF 6PJG 6PJH 6PJI 6PJK 6PJL 6PJM 6PJN 6PJO 
Resolution (Å) 2.00 1.98 1.95 1.89 1.92 1.94 1.80 1.85 1.90 1.99 1.99 1.93 1.98 1.95 
Space group P212121 P212121 P1211 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121 
Cell dimensions:               
a (Å) 51.0 51.4 51.7 51.3 51.4 51.3 51.3 51.5 51.1 51.3 51.5 51.3 51.3 51.4 
b (Å) 58.3 57.8 62.5 58.3 58.5 58.1 58.6 58.7 58.6 58.8 58.2 58.8 58.9 58.6 
c (Å) 61.9 62.3 59.8 62.1 61.9 61.5 62.0 62.0 61.7 61.9 61.7 61.8 61.8 61.7 
β (°) 90 90 98.175 90 90 90 90 90 90 90 90 90 90 90 



























Total reflections 84332 91123 113979 60549 88652 93472 90337 80091 88965 47555 64344 86288 79533 74054 
Unique reflections 12758 13342 26144 15065 14780 14151 17695 16774 15198 12050 12967 14564 13515 13293 

























































RMSDb in:               
Bond lengths (Å) 0.003 0.003 0.009 0.008 0.005 0.004 0.011 0.005 0.008 0.011 0.007 0.003 0.003 0.003 
Bond angles (°) 0.590 0.537 1.282 0.928 0.796 0.699 1.230 0.853 1.044 1.270 1.029 0.673 0.647 0.719 
Rfactor (%)c 19.2 19.7 23.9 17.0 18.2 20.7 18.1 18.5 18.8 17.9 20.0 17.4 17.6 18.9 
Rfree (%)d 22.8 22.5 27.4 21.9 22.8 24.6 21.5 21.9 22.5 23.7 23.1 21.5 22.2 23.9 
aRsym = Σ | I − <I>|/ Σ I, where I = observed intensity, <I> = average intensity over symmetry equivalent; values in parentheses are for 
the highest resolution shell. 
bRMSD, root mean square deviation. 
cRfactor = Σ || Fo| − |Fc||/ Σ|Fo|. 
dRfree was calculated from 5% of reflections, chosen randomly, which were omitted from the refinement process. 
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LPV and DRV achieve low picomolar affinity to wild-type HIV-1 protease by making 
a number of hydrogen bonds and vdW interactions with the active site residues [Figure 
5.2]. The interactions of the transition state mimetic secondary hydroxyl group with the 
catalytic aspartates, together with the vdW interactions of the adjacent P1/P1′ moieties, 
are critical for overall inhibitor binding. Together these interactions determine the 
positions of the P2/P2′ moieties in the active site, which in turn determine the patterns of 
hydrogen bonding and vdW interactions of these moieties with the protease. DRV 
contains a sulfonamide-based Phe-Leu dipeptide isostere core with the (R)-configuration 
of the secondary hydroxyl group, whereas LPV has a pseudo-C2-symmetric Phe-Phe 
dipeptide isostere with the (S)-configuration of the hydroxyl group. Though chemically 
quite distinct, the core scaffolds of LPV and DRV make largely similar hydrogen bonding 
and vdW interactions with the protease. These inhibitors, however, differ in their 





Figure 5.2 Binding mode of parent compounds (A) LPV and (B) DRV, and (C) ATV. 




The bis-THF moiety of DRV forms direct hydrogen bonds with the main-chain NH of 
Asp29 and Asp30 in the S2 subsite, while the 4-aminobenzene makes a direct hydrogen 
bond with the main-chain carbonyl of Asp30′ as well as a water-mediated hydrogen bond 
with the side-chain carboxylate of the same residue in the S2′ subsite [Figure 5.2]. The 
cyclic urea moiety of LPV makes direct hydrogen bonds with the main-chain NH and side-
chain carboxylate of Asp29. The same moiety also makes water-mediated hydrogen 
bonds with the main-chain carbonyl of Gly27 and the side-chain carboxylate of Asp29 in 
the S2 subsite. However, in contrast to the P2′ moiety of DRV, the dimethylphenoxy 
acetate moiety of LPV only makes hydrophobic interactions in the S2′ subsite [Figure 
5.2]. The hybrid compounds combine the pseudo-C2-symmetric Phe-Phe isostere of LPV 
with the bis-THF moiety of DRV and an ATV-like amino acid moiety to enhance direct 
hydrogen bonding and vdW interactions in the S2 and S2′ subsites. 
The cocrystal structures of hybrid compounds revealed similar binding 
conformations of the Phe-Phe isostere and the bis-THF moiety as observed in the 
protease complexes with LPV and DRV, respectively [Figure 5.3]. Importantly, the bis-
THF moiety is positioned to interact with the main-chain NH of residues Asp29 and Asp30, 
mimicking the binding interactions of DRV [Figure 5.4]. This binding conformation is 
maintained in all hybrid compounds including 4 regardless of the position of the bis-THF 
moiety. As a result, within the distal and proximal compound series (with the bis-THF 
moiety at the P2 and P2′ position respectively), the structures aligned well with variations 





Figure 5.3 Overlays of protease cocrystal structures bound to LPV (grey, top) and DRV 
(brown, bottom) with compounds 12a (green), 15a (orange), and 4 (salmon) revealed 
similar binding conformations of the Phe-Phe isostere and the bis-THF moiety as 
observed in the protease complexes with LPV and DRV, respectively. Note that DRV is 





Figure 5.4 Crystal structures of wild-type HIV-1 protease in complex with (A) LPV and 
hybrid compounds (B) 4, (C) 12a, and (D) 15a. The bis-THF moiety maintains the 
hydrogen bonding interactions with the main-chain NH of Asp29/Asp29′ and 
Asp30/Asp30′ in the S2/S2′ subsites regardless of the its position on the Phe-Phe core. 





Figure 5.5 Superposition of HIV-1 protease complexes with (A) distal compounds 12a–
12h and (B) proximal compounds 15a–15c, showing similar binding conformations of the 
bis-THF moiety regardless of the position, minor differences at the Phe-Phe isostere, but 
major differences at the P2/P2′ amino acid moiety. The protease active site is shown in a 






In all complexes, the central hydroxyl group of the Phe-Phe core maintains the key 
hydrogen bonds with the side-chain carboxylates of the catalytic residues Asp25/Asp25′. 
Nevertheless, subtle differences in hydrogen bonding and vdW interactions were 
observed between the Phe-Phe cores in LPV and the hybrid compounds. Notably, one of 
the four water-mediated interactions with the flap residue Ile50 is consistently longer (2.9–
3.4 Å) than what is observed in the LPV structure (2.7 Å) [Table 5.3]. The two amide NH 
groups on each side of the Phe-Phe core could potentially interact with the backbone 
carbonyl of Gly27 and Gly27′, but in the LPV structure only the Gly27 is close enough to 
form a hydrogen bond (2.9 Å versus 3.9 Å) [Figure 5.4]. This phenomenon is also 
observed in the protease complex with compound 4 (2.9 Å versus 3.7 Å) indicating that 
the large hydrophobic P2′ moiety prevents the additional hydrogen bond from occurring 
with Gly27′. In contrast, in all hybrid compound structures the core NH groups are within 
3.5 Å from the backbone carbonyls of Gly27 and Gly27′ [Table 5.3], although 
simultaneous interactions with both Gly27/Gly27′ may not be stable. Nevertheless, the 
combination of bis-THF and a flexible, hydrophobic amino acid moiety allow both core NH 
groups to interact with the main-chain carbonyls of residues Gly27/Gly27′.  
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Table 5.3 Intermolecular hydrogen bonds between the protease and inhibitors in the cocrystal structures (distance in Å). 
Shorter distances are more red and longer distances are more blue (cutoff 3.5 Å). 
 





The Phe-Phe isostere in hybrid compounds, in addition to maintaining key hydrogen 
bonding interactions with the protease, makes a number of favorable vdW interactions 
with the hydrophobic residues that make up the S1/S1′ subsites. Despite the same 
phenylalanine side chains at the P1 and P1′ positions, there are a few notable differences 
in vdW contacts with the protease [Figure 5.6]. Compared to LPV, the P1/P1′ phenyl 
group adjacent to the amino acid moiety is shifted towards Val82 resulting in increased 
vdW contacts with that residue, particularly for compounds with larger P2/P2′ amino acid 
moieties. These localized gains in vdW contacts are slightly lower for proximal 
compounds (15a–c) than their distal counterparts (12a–c). The shift of the P1/P1′ phenyl 
group towards Val82, creating more vdW contacts, resulted in a nearly equal and opposite 
loss of contacts with Ile50 in the same subsite. The packing of the phenyl group adjacent 
to the bis-THF moiety resulted in a small increase in vdW contacts with the 80’s loop 
(residues 81, 82 and 84) but decrease in contacts with flap residue Gly49. In the proximal 
compounds, gains in vdW contacts are smaller and the losses are greater. Overall, 
despite localized losses and gains in vdW interactions for both distal and proximal 





Figure 5.6 Comparison of per residue vdW contacts of the Phe-Phe core compared to 
LPV. Negative numbers indicate that the designed compounds are making better contacts 




The cocrystal structures of hybrid compounds (and 4) also revealed similar binding 
interactions of the bis-THF moiety as in DRV-protease complex regardless of the position, 
with the two ring oxygen atoms positioned to form hydrogen bonds with the main-chain 
NH of Asp29 and Asp30. However, there is a subtle differences in the position and 
puckering of the bis-THF rings, causing the carbamate-linked THF ring oxygen atom to 
slightly shift away from the backbone NH of Asp30 compared to DRV (3.1–3.4 Å versus 
2.9 Å) [Figure 5.7]. Whereas the oxygen atom of the other THF ring maintains a similar 
distance to the backbone NH of Asp29 (2.7–2.9 Å versus 2.8 Å) [Table 5.3]. For distal 
compounds, these subtle changes in the bis-THF moiety arise from the differences in the 
binding of core isosteres, where the P1 benzyl group and the carbamate are shifted 
towards the B-chain compared to their position in DRV. This is likely due to the additional 
carbon in the core or to accommodate the larger P1′ group. In the proximal compounds, 
the core scaffold from the central hydroxyl to the bis-THF moiety is identical. However, 
the opposite stereochemistry of the central hydroxyl causes a subtle shift preventing the 
bis-THF moiety from optimally interacting with Asp30′ [Figure 5.7]. The minor differences 
in the position and puckering of the bis-THF moiety in hybrid compounds result in weaker 





Figure 5.7 Comparison of the binding conformations of the bis-THF moiety and protease-
inhibitor hydrogen bond distances with the main-chain NH of Asp29 and Asp30 in the 
S2/S2′ subsite of HIV-1 protease. As observed the DRV-protease complex, the bis-THF 
moiety retained similar interactions with the protease in complexes with compound 4 (top), 
the most potent hybrid compounds 12a and 15a (middle), and the least potent hybrid 




The bis-THF moiety of DRV is critical to its potency, not only for the hydrogen 
bonding interactions with Asp29 and Asp30, but also vdW packing with residues in the 
S2 subsite, particularly Val32 and Ile47. In hybrid compounds, the minor change in the 
position and puckering of the bis-THF moiety causes reduced vdW interactions with Ala28 
and Asp30, but increased contacts with Ile47 and Gly48 [Figure 5.8]. The main-chain 
carbonyl of Gly48 is oriented towards the hydrophobic region of bis-THF, so increased 
contacts with this residue may be unfavorable. In contrast, compounds 4, 15a and 15b 
do not make these unfavorable contacts with Gly48. With the exception of enhanced 
interactions with Ile47, the bis-THF moiety in most hybrid compounds make less optimal 





Figure 5.8 Comparison of per residue vdW contacts of the bis-THF moiety compared to 
DRV. Negative numbers indicate that the designed compounds are making better 
contacts with those residues.  
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The major difference between the hybrid compounds and the previously reported 
Phe-Phe core-based bis-THF containing PIs 4 and 5 is the introduction of an ATV-like 
amino acid moiety to target the opposite S2/S2′ subsite. The amino acid side chain 
interacts with hydrophobic protease residues, while the N-(methoxycarbonyl)-capping 
group allows for additional hydrogen bonding interactions with the protease. As already 
noted, LPV’s P2′ moiety does not form any hydrogen bonds, and DRV’s P2′ moiety makes 
one direct and one water-mediated hydrogen bond in the S2′ subsite [Figure 5.2]. In most 
hybrid compounds, the carbonyl oxygen of the carbamate makes one direct hydrogen 
bond with the backbone NH of Asp29′ (Asp29), and the carbamate NH makes another 
direct hydrogen bond with the backbone carbonyl of Gly48′ (Gly48) in the flaps [Figure 
5.9]. There are also a number of coordinated water molecules that allow for additional 
water-mediated interactions. The carbonyl oxygen of the carbamate coordinates the 
same water-mediated hydrogen bonds as the cyclic urea moiety of LPV, with the 
backbone carbonyl of Gly27′ (Gly27) and the side-chain carboxylate of Asp29′ (Asp29) 
[Figure 5.9]. This network of polar interactions is maintained by all amino acid moieties 





Figure 5.9 Comparison of protease-inhibitor direct and water-mediated hydrogen bond 
interactions in the S2/S2′ subsites for the cyclic urea moiety of LPV (A), N-
(methoxycarbonyl)-tert-leucine of ATV (B), and the N-(methoxycarbonyl)-capped amino 
acid moieties of hybrid compound 15a (C), 12a (D), 15b (E), and 12b (F). Hydrogen bonds 




The carbamate of the distal compound 12b is flipped relative to all other inhibitors 
losing the direct hydrogen bond to flap residue Gly48′ [Figure 5.9F]. This flip positions 
the carbonyl oxygen of the carbamate close to the carbonyl oxygen of Gly48′ (3.3 Å), 
creating a very unfavorable interaction and preventing compound 12b from utilizing the 
same water-mediated hydrogen bonds as LPV and most hybrid compounds. Instead 12b 
forms a hydrogen bond with a “backside” water in the S2′ subsite, creating a water-
mediated interaction with the main-chain carbonyl and NH of Asp30′ [Figure 5.9F]. The 
marked changes in the hydrogen bonding interactions in the S2/S2′ subsite likely underlie 
the greatly reduced potency of 12b compared to all other hybrid compounds. Unlike 12b, 
the P2 carbamate group in compound 15b maintained a similar conformation as in the 
tert-leucine analogue 15a but with a slight change in the position of the carbonyl oxygen 
away from Asp29. This shift resulted in increased hydrogen bond distance between the 
P2 carbamate carbonyl and the main-chain NH of Asp29 compared to 15a (3.3 Å versus 
2.9 Å). However, the reduced potency of 15b could not result from minor differences in 
hydrogen bonding interactions alone, underlying the significance of non-polar interactions 
for potency.  
The protease-inhibitor vdW interactions in the S2/S2′ subsite varied significantly 
depending on the size and shape of the hydrophobic amino acid moiety [Figure 5.10]. 
Compounds 12a and 15a with the tert-leucine make highly distributed vdW contacts with 
a number of residues. In contrast, compared to tert-leucine, the cycloleucine side chain 
in 12b predominantly interacts with Ile50 and I84V, while losing significant contacts with 
residues 28–30 [Figure 5.11]. The cycloleucine side chain of 15b packs in the same 
hydrophobic area but makes less vdW contacts than 12b. Compound 12c with the 
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cyclopentyl glycine also has increased vdW contacts with Ile50 but without experiencing 
losses at other resides as observed for 12b. In general, the cyclic hydrophobic amino acid 
derivatives make more localized vdW interactions in the S2/S2′ subsite while the acyclic 
moieties make more distributed contacts. Thus, in addition to altered polar interactions, 
the differences in vdW contacts due to the size and shape of the hydrophobic amino acid 





Figure 5.10 Comparison of per residue vdW contacts in the S2/S2’ subsite between 
hybrid compounds and the best compounds (12a/15a). Negative numbers indicate that 




Figure 5.11 Comparison of binding conformation (A) and van der Waals packing with 
residues in the S2′ subsite for the most and least potent inhibitors 12a (B, green sticks) 
and 12b (C, blue sticks). Compound 12a makes more extensive contacts with the 
protease as estimated by relative vdW contact energy compared to 12b (–91 versus –86 
kcal/mol), with major difference occurring at the S2′ subsite (–27 versus –23 kcal/mol). 




5.4.3 Molecular Dynamics (MD) Simulations 
Starting from the cocrystal structures, molecular dynamics (MD) simulations were 
utilized to interrogate the stability of protease-inhibitor interactions in the dynamic 
ensemble of the complexes. Three replicates of fully hydrated 100 ns MD simulations 
were performed on each protease-inhibitor complex. All simulations reached 






Figure 5.12 Root-mean-square deviation (RMSD) analysis of the molecular dynamics 




The protease active site and flaps dynamics were analyzed by measuring Cα 
distances between specific residues. The analysis focused on the most and least potent 
of both the distal and proximal compounds (12a, 15a, 12b and 15b) compared to LPV. 
The cocrystal structures suggested the flaps and the 80’s loops surrounding the inhibitor 
may be perturbed when bound to different compounds. To monitor dynamics of the flaps, 
distance distributions between Cα atoms of Ile50–Ile84′, Ile50′–Ile84 and Ile50–Ile50′ were 
calculated during the MD trajectories. Distances for Ile84–Ile84′ and Pro81–Pro81′ were 
used to probe the expansion or narrowing of the “lower” and “upper” side wall of the active 
site, respectively [Figure 5.13]. In protease complexes with hybrid compounds, the active 
site remained largely unchanged in the “lower” part of the active site as indicated by a 
single, narrow distribution of Ile84–Ile84′ distance centered around 15.2 Å. However, 
compared to LPV the shift in the Pro81–Pro81′ distance distribution with compounds 12a, 
15a, 12b, and 15b indicated the active site was narrower in the “upper” portion close to 
the flaps. In addition, the active site was asymmetrically longer (Ile50′–Ile84 or Ile50–
Ile84′), sampling bimodal distance distributions, suggesting the sampling of a semi-open 
conformation of the flaps. This was supported by the Ile50–Ile50′ distance distribution, 
with one major peak around 5.3 Å (closed flaps) and another ∼10 Å corresponding to 
semi-open flaps with compounds 15a and 15b [Figure 5.13]. Increased distance between 
residues Ile50 and Ile50′ in the relatively short time (nanoseconds) during MD simulations 
has been previously suggested to indicate flap opening.211-212 Thus, perturbed flaps 
dynamics and narrowing of the active site may indicate unfavorable binding of these 




Figure 5.13 Distance distribution between (A) Cα atoms of active site residues which can 
be used to estimate the height, width, and diagonal distance distribution of the active site 
over a molecular dynamics simulation. Distance distributions of (B) Ile84–Ile84′ and (C) 
Pro81–Pro81′ represent the width of the bottom- and top-half of the active site, 
respectively. Distance distributions of (D) Ile50–Ile84′ and (E) Ile50′–Ile84 aid in 
visualizing diagonal motion of the flaps. Finally, the distance distribution of (F) Ile50–Ile50′ 




Next, the stability of inhibitor binding was analyzed by calculating root-mean-square 
fluctuations (RMSF) of each atom [Figure 5.14]. In all complexes, the bis-THF moiety 
often displayed the lowest RMSF amongst all moieties, regardless of its position on the 
Phe-Phe core. Notably, even in the least active compounds with nanomolar potency (12b 
and 15b), the bis-THF moiety showed fluctuations similar to that observed in 12a and 15a. 
Moreover, despite the pseudo-symmetric nature of the Phe-Phe core, the phenylalanine 
side chain adjacent to the bis-THF moiety displayed lower RMSF compared to the distal 
phenylalanine side chain. The P2/P2′ amino acid moieties showed varying RMSF profiles, 
independent of the size or shape of the hydrophobic side chain. The phenylalanine 
adjacent to the amino acid moiety consistently displayed greater RMSF, with the 
exception of 12e. The varying fluctuations of the P1/P1′ moiety depending on the size and 
shape of the P2/P2′ moiety indicate interdependence between the S1/S1′ and S2/S2′ 
subsites. The P2/P2′ amino acid moiety also affected the fluctuations of the bis-THF 
moiety but to a much lesser extent. This data suggests that in hybrid compounds the bis-
THF moiety and the adjacent P1/P1′ moiety remain relatively stable in the protease active 
site regardless of the position on the Phe-Phe core. In contrast, the fluctuations of the 
amino acid and the adjacent P1/P1′ moieties appear to destabilize overall inhibitor binding. 
Thus, due to interdependence between the S1/S1′ and S2/S2′ subsites, the optimization 
of the bis-THF containing hybrid PIs, would require modification of the amino acid moiety 





Figure 5.14 Inhibitor root-mean-square fluctuation (RMSF) of each non-hydrogen atom 
of DRV, LPV, and hybrid compounds mapped onto their crystal structure. Warmer colors 




The relationship between inhibitor and protease conformational dynamics was 
examined via simultaneous monitoring of inhibitor bond rotations and protease residue 
distances. The dihedral angles of all inhibitor rotatable bonds were calculated throughout 
the MD simulations. Given the bimodal sampling of the flap distances (Ile50–Ile50′, Ile50–
Ile84′ and Ile50′–Ile84), we examined whether the semi-open conformation of flaps was 
associated with certain inhibitor bond rotations. In protease complexes with compounds 
12a and 15a, the two most potent inhibitors, the separation of the flap tips (Ile50–Ile50′) 
was associated with the conformational sampling of the dihedral controlling the amino 
acid moiety [Figure 5.15]. In this semi-open flap conformation, the Ile50/Ile50′ residues 
at the top of the flaps also lost intra-protease vdW contacts with residues 32, 47–49 and 
84 [Figure 5.16]. Loss of intra-protease vdW interactions could result in a less stable 





Figure 5.15 The dihedral angle (φ5) responsible for conformational sampling of the tert-





Figure 5.16 Intra-protease van der Waals interactions between Ile50/Ile50′ and 
neighboring residues.    
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In addition, protein dynamics were compared by calculating the root-mean-square 
fluctuations (RMSF) of Cα atoms. Consistent with our observations from the distance 
distributions, there were significant increases in fluctuations at the flaps and 80’s loop 
[Figure 5.17]. In complex with LPV, the flaps and active site show little fluctuations, 
comparable to DRV. However, the proximal hybrid compounds showed increased 
fluctuations at both flaps, with fluctuations asymmetrically greater at the B chain flap, 
contacting the amino acid moiety. The increased protein fluctuation could impact the 





Figure 5.17 Protein root-mean-square fluctuation (RMSF) of the (A) distal and (B) 




In the cocrystal structures, the hybrid compounds make a number of direct and 
water-mediated hydrogen bonds with the protease active site, including the central 
hydroxyl with catalytic residues, coordinated water with Ile50/50′, the Phe-Phe core 
nitrogen atoms with Gly27, bis-THF with Asp29 and Asp30, carbamate with Asp29 and 
Gly48, and the coordinated S3′ water with Gly27′ and Asp29′. To assess if the increased 
protein and ligand fluctuations impact hydrogen bonding stability, the patterns and 
frequencies of these hydrogen bonds were monitored throughout the MD simulations 
[Figure 5.18-5.19]. In MD simulations, LPV and the hybrid compounds did not maintain 
all hydrogen bonds observed in the cocrystal structures. LPV and all distal compounds (4 
and 12a–h) maintained a hydrogen bond with Asp25′ (66–99% frequency) but did not 
form a hydrogen bond with Asp25. Whereas proximal compounds 15a and 15b formed 
the hydrogen bonds with Asp25 and Asp25′ at roughly 100% and 50% frequency, 
respectively. In contrast, the hydrogen bond between proximal compound 15c and Asp25 
was unstable, while the hydrogen bond with Asp25′ was highly stable (92% frequency). 
Hybrid compounds maintained the water-mediated hydrogen bonding network with the 
main-chain NH of Ile50 and Ile50′ at varying stability. The interactions with Ile50 were 
observed to be less stable compared to the ones with Ile50′ (21–65% versus 49–78%). 
For most of the hybrid compounds, the hydrogen bonds between the Phe-Phe core NH 
groups and the main-chain carbonyls of Gly27/Gly27′ were either not observed or were 





Figure 5.18 Protease-inhibitor hydrogen bond frequencies from MD simulations mapped 
onto the cocrystal structures of compounds (A) 12a, (B), 12b, (C), 15a, and (D) 15b. The 
protease side chains and inhibitors are shown as sticks; chains A and B are colored cyan 





Figure 5.19 (A) Protease-inhibitor hydrogen bonds are indicated as black dashed lines 
on the cocrystal structures of 12a and 15a. Hydrogen bonding frequencies from MD 





The bis-THF moiety in all hybrid compounds maintained two hydrogen bonds with 
the main-chain NH of Asp29/Asp29′ and Asp30/Asp30′ at high frequency, regardless of 
the position on the Phe-Phe isostere [Figure 5.18-5.19]. In contrast, the P2/P2′ amino 
acid moiety had varying effects on hydrogen bonding interactions in the S2/S2′ subsite. 
The carbamate nitrogen of both distal and proximal compounds formed a hydrogen bond 
with the backbone carbonyl of Gly48′ at moderate to high frequency, but this interaction 
was not observed for the least potent compound 12b and was less stable for 15b. The 
carbonyl oxygen of the P2′ amino acid moiety in distal compounds formed relatively stable 
water-mediated interactions with the sidechain of Asp30′. In contrast, the carbonyl oxygen 
of the P2 moiety in proximal compounds 15a and 15c formed three low-frequency (14–
39%) water-mediated hydrogen bonds, bridging the main-chain carbonyl of Gly27 and the 
side-chain carboxylate of Asp29. These data suggest that for most hybrid compounds the 
key hydrogen bonding interactions of the bis-THF moiety and the Phe-Phe isostere with 
protease remain relatively stable. In addition, the size and shape of the P2/P2′ amino acid 
moiety not only influences the interactions in the S2/S2′ subsites but can also propagate 
changes in the water-mediate interactions between the inhibitors and Ile50/Ile50′. 
5.5 Conclusions 
We have explored hybrid HIV-1 PIs containing the bis-THF moiety of DRV on either 
side of the Phe-Phe dipeptide isostere of LPV to ascertain whether this moiety could 
maintain key interactions with the protease and improve potency against wild-type and 
primary drug-resistant variants of the enzyme. Most of the hybrid compounds retained 
picomolar biochemical potency irrespective of the position of bis-THF relative to the 
central hydroxyl group, likely due to the pseudo-C2-symmetric nature of the Phe-Phe 
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isostere. But in both distal and proximal compound series the identity of the other P2/P2′ 
moiety significantly affected potency, favoring relatively flexible, hydrophobic moieties. 
The cocrystal structures of hybrid compounds revealed that the bis-THF moiety maintains 
the key hydrogen bonding interactions with the protease in the S2/S2′ subsite as 
observed in the DRV-protease complex regardless of its position on the Phe-Phe isostere. 
In contrast, the binding of the hydrophobic amino acid moiety in the other S2/S2′ subsite 
was greatly influenced by the size, shape, and flexibility of the hydrophobic group, which 
affected hydrogen bonding and vdW interactions with the protease. Moreover, this moiety 
appears to influence binding of the adjacent P1/P1′ group as well as the water-mediated 
interactions between the inhibitor and flap residues, indicating dynamic interdependence 
between the protease subsites. This is further supported by the relatively stable binding 
interactions of the bis-THF moiety and the adjacent P1/P1′ group. The dynamic 
interdependence between subsites in the protease active site can be exploited to optimize 
inhibitor potency against drug-resistant protease variants. The detailed structural 
characterization of hybrid HIV-1 PIs containing bis-THF in non-sulfonamide dipeptide 
isosteres offers opportunities for structure-guided optimization of these promising 
inhibitors.  
5.6 Experimental Section 
5.6.1 General 
All reactions were performed in oven-dried round-bottom flasks fitted with rubber 
septa under argon atmosphere unless otherwise noted. All reagents and solvents, 
including anhydrous solvents, were purchased from commercial sources and used as 
received. Flash column chromatography was performed on an automated Teledyne ISCO 
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CombiFlash Rf+ system equipped with a UV-vis detector using disposable Redisep Gold 
high performance silica gel columns or was performed manually using silica gel (230−400 
mesh, EMD Millipore). Thin- layer chromatography (TLC) was performed using silica gel 
(60 F254) coated aluminum plates (EMD Millipore), and spots were visualized by exposure 
to ultraviolet light (UV), exposure to iodine adsorbed on silica gel, and/or staining with 
alcohol solutions of phosphomolybdic acid (PMA) and ninhydrin followed by brief heating. 
1H NMR and 13C NMR spectra were acquired on Varian Mercury 400 MHz and Bruker 
Avance III HD 500 MHz NMR instruments. Chemical shifts are reported in ppm (δ scale) 
with the residual solvent signal used as a reference and coupling constant (J) values are 
reported in hertz (Hz). Data are presented as follows: chemical shift, multiplicity (s = 
singlet, d = doublet, dd = doublet of doublet, dd = doublet of triplet, t = triplet, m = multiplet, 
br s = broad singlet), coupling constant in Hz, and integration. High-resolution mass 
spectra (HRMS) were recorded on a Thermo Scientific Orbitrap Velos Pro mass 
spectrometer coupled with a Thermo Scientific Accela 1250 UPLC and an autosampler 
using electrospray ionization (ESI) in the positive mode. The purity of final compounds 
was determined by analytical HPLC and was found to be ≥95% pure. HPLC was 
performed on an Agilent 1200 system equipped with a multiple wavelength detector and 
a manual injector under the following conditions: column, Phenomenex Hypersil-BDS-5u-
C18 (5 μm, 4.6 mm × 250 mm, 130 Å); solvent A, H2O containing 0.1% trifluoroacetic acid 
(TFA); solvent B, CH3CN containing 0.1% TFA; gradient, 20% B to 100% B over 15 min 
followed by 100% B over 5 min; injection volume, 20 μL; flow rate, 1 mL/min. The 
wavelengths of detection were 254 nm and 280 nm. Retention times and purity data for 
each target compound and intermediate can be found online.   
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5.6.2 Protease Gene Construction 
Protease gene construction was carried out as previously described.183-184 The NL4-
3 strain has four naturally occurring polymorphisms in the protease relative to the SF2 
strain.  In short, the protease variant genes (I84V, I50V/A71V) were constructed using 
QuikChange site-directed mutagenesis (Genewiz) onto NL4-3 wild-type protease on a 
pET11a plasmid with codon optimization for protein expression in Escherichia coli. A Q7K 
mutation was included to prevent autoproteolysis.185  
5.6.3 Protein Expression and Purification 
The expression, isolation, and purification of WT and mutant HIV-1 proteases used 
for the kinetic assays and crystallization were carried out as previously described.183-184 
Briefly, the gene encoding the HIV protease was subcloned into the heat-inducible pXC35 
expression vector (ATCC) and transformed into E. coli TAP-106 cells. Cells grown in 6 L 
of Terrific Broth were lysed with a cell disruptor and the protein was purified from inclusion 
bodies.186 The inclusion body centrifugation pellet was dissolved in 50% acetic acid 
followed by another round of centrifugation to remove impurities. Size exclusion 
chromatography was used to separate high molecular weight proteins from the desired 
protease. This was carried out on a 2.1 L Sephadex G-75 superfine column (Millipore 
Sigma) equilibrated with 50% acetic acid. The cleanest fractions of HIV protease were 
refolded into a 10-fold dilution of 0.05 M sodium acetate at pH 5.5, 5% ethylene glycol, 
10% glycerol, and 5 mM DTT. Folded protein was concentrated down to 1–2 mg/mL and 
stored. This stored protease was used in Ki assays. For crystallography, a final 
purification was performed with a Pharmacia Superdex 75 FPLC column equilibrated with 
0.05 M sodium acetate at pH 5.5, 5% ethylene glycol, 10% glycerol, and 5 mM DTT. 
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Protease fractions purified from the size exclusion column were concentrated to 1–2 
mg/mL using an Amicon Ultra-15 10-kDa device (Millipore) for crystallization. 
5.6.4 Enzyme Inhibition Assays 
The enzyme inhibition assays were carried out as previously described.90, 213 To 
determine the enzyme inhibition constant (Ki), in a 96-well plate, each inhibitor was 
serially diluted, including a no drug control, and incubated with 0.35 nM protein for 1 hour. 
A 10-amino acid substrate containing an optimized protease cleavage site with an 
EDANS/DABCYL FRET pair was dissolved in 4% DMSO at 120 µM. Using the Envision 
plate reader, 5 µL of the 120 µM substrate was added to the 96-well plate to a final 
concentration of 10 µM. The fluorescence was observed with an excitation at 340 nm and 
emission at 492 nm and monitored for 200 counts, for approximately 60 min. Data was 
analyzed with Prism7, as described in Chapter 2. DRV was used as a control in all assays. 
5.6.5 Antiviral Assays 
293T and TZM-BL181 cells (NIH AIDS Research and Reference Reagent Program) 
were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal 
calf serum in the presence of penicillin and streptomycin at 37 °C with 5% CO2. To 
determine the concentration of drugs achieving 50% inhibition of infection compared with 
the drug-free control, 4.5×106 293T cells were seeded onto a 10-cm plate 24 h before 
transfection. Cells were transfected with 8 µg of either the wild-type plasmid, infectious 
molecular clone pNL-CH derived from the pNL4-3 clone of HIV-1 using FuGENE 6 
transfection reagent (Roche). The culture supernatant of 293T cells transfected with wild-
type or PI-resistant HIV-1 variant was removed 18 h after transfection and the cells were 
washed with 1 × PBS. The 293T cells were collected and transferred to wells of a 24-well 
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plate. Briefly, each drug was serially diluted in the culture medium and the dilutions were 
added to the wells of a 24-well plate. The 293T cells (0.5 × 106 per well) collected from 
the transfection were added to wells containing various concentrations of drug. The 
culture supernatant containing virus particles was harvested 18 h after the 293T cells 
were reseeded in the presence of drug. This supernatant was filtered through a 0.45-µm-
pore-size membrane (Millipore) to remove cell debris then used to infect 2 × 104 TZM-BL 
cells in a 96-well plate following a procedure previously described.182 The culture 
supernatant was removed from each well 48 h post-infection, and the cells were washed 
with 1 × PBS. For the luciferase assay, infected TZM-BL cells were lysed in 1× reporter 
lysis buffer (Promega) and the cells were kept at −80 °C. After one freeze-thaw cycle, the 
cell lysates were transferred into a 96-well assay plate (Costar), and luciferase activity 
was measured using a luminometer (Promega). The culture supernatant harvested from 
293T cells reseeded in the absence of drugs was used as a drug-free control. EC50 was 
determined based on a dose-response curve generated using GraphPad Prism (version 
7.0). 
5.6.6 Protein Crystallization 
The condition reliably producing cocrystals of NL4-3 WT protease bound to PIs was 
discovered and optimized as previously described.188, 213 Briefly, all cocrystals were grown 
at room temperature by hanging drop vapor diffusion method in a 24-well VDX hanging-
drop trays (Hampton Research) with a protease concentration of 1.4–1.7 mg/mL with 3-
fold molar excess of inhibitors and mixed with the precipitant solution at a 1:2 ratio. The 
reservoir solution was 23–27% (w/v) ammonium sulfate with 0.1 M bis-Tris-methane 
buffer at pH 5.5, and the crystallization drops were set with 2 µL of well solution and 1 µL 
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of protein-inhibitor solution and micro-seeded with a cat whisker. Diffraction quality 
crystals were obtained within 1 week. As data were collected at 100 K, cryogenic 
conditions contained the precipitant solution supplemented with 25% glycerol.  
5.6.7 X-Ray Data Collection and Structure Solution 
X-ray diffraction data were collected and solved as previously described.184, 188, 213 
Diffraction quality crystals were flash frozen under a cryostream when mounting the 
crystals either at our in-house Rigaku_Saturn944 X-ray system or the Chicago APS 
Synchrotron Beamline 23-1D-D. The cocrystal diffraction intensities from the Rigaku 
system were indexed, integrated, and scaled using HKL3000.214 Structures were solved 
using molecular replacement with PHASER.106 Model building and refinement were 
performed using Coot107 and Phenix.108 Ligands were designed in Maestro and the output 
sdf files were used in the Phenix program eLBOW109 to generate cif files containing atomic 
positions and  constraints necessary for ligand refinement. Iterative rounds of 
crystallographic refinement were carried out until convergence was achieved. To limit bias 
throughout the refinement process, five percent of the data were reserved for the free R-
value calculation.110 MolProbity111 was applied to evaluate the final structures before 
deposition in the PDB. Structure analysis, superposition and figure generation was done 
using PyMOL.215 X-ray data collection and crystallographic refinement statistics are 
presented in the Supporting Information [Table 5.2]. 
The cocrystal structures of all new hybrid compounds were solved in the P212121 
space group with one protease homodimer in the asymmetric unit and only one 
orientation of the bound inhibitor in the active site, which was crucial for direct comparison 
of inhibitor structures. The cocrystal structure of compound 4 was solved in the P21 space 
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group with two protease homodimers in the asymmetric unit, and one inhibitor bound to 
each dimer in one orientation, allowing one P21 dimer to be directly compared to the 
crystal structures solved in the P212121 space group. Three structures (10a, 10b, 13c) 
had significant electron density at the flap tips (residues 50–51) indicating that the 
backbone atoms interacted in two conformations, as both hydrogen bond donors and 
acceptors. Figure generation and structural analysis calculations (distance differences, 
vdW, hydrogen bonds) were performed with the flap tips modeled in one conformation 
while the other conformation was excluded. Compound 5 formed cocrystals but were 
inadequate for X-ray data collection. 
5.6.8 Intermolecular vdW Contact Analysis of Crystal Structures 
To calculate the intermolecular vdW interaction energies the crystal structures were 
prepared using the Schrödinger Protein Preparation Wizard.216 Hydrogen atoms were 
added, protonation states were determined, and the structures were minimized. The 
protease active site was monoprotonated at Asp25. Subsequently, force field parameters 
were assigned using the OPLS3 force field.217 Interaction energies between the inhibitor 
and protease were estimated using a simplified Lennard-Jones potential, as previously 
described in detail.218 Briefly, the vdW energy was calculated for pairwise interactions 
depending on the types of atoms interacting and the distance between them. For each 
protease residue, the change in vdW interactions relative to a reference complex in the 
same space group was also calculated for each variant structure. 
5.6.9 Molecular Dynamics System Preparation 
High resolution crystal structures of LPV and the designed inhibitors bound to WT 
protease were prepared using the Protein Preparation Wizard using Maestro within the 
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Schrödinger Suite216 as previously described.219-220 Briefly, missing atoms were added 
using Prime221 and PROPKA222 was used to determine the protonation state of the side 
chains at pH 7.0. The catalytic aspartic acid with a pKa higher than 7.0 was protonated 
whereas the one with a pKa less than 7.0 was unprotonated. Co-crystallized fragments 
such as phosphate ions were removed. Lastly, the structure was minimized to a 
convergence criterion of 0.3 Å using Impref.223 
5.6.10 Molecular Dynamics Simulations 
The prepared systems were placed in a cubic TIP3P implicit water box measuring 
12Å on each side. Molecular dynamics simulations were carried out as previously 
described219 using Desmond within Schrödinger Suite.216 Briefly, chloride ions were used 
to neutralize the system and 0.15 M salt were added using sodium and chloride ions. The 
OPLS3 force field was used to parameterize the ligand and protein. Prior to starting the 
100 ns MD simulations, the solvated system was minimized using the stepwise procedure 
described previously.219 Triplicates of 100 ns simulations for LPV and the designed 
inhibitors in complex with WT protease each with a randomized velocity were started 
using a protocol previously developed.219-220 The root-mean-square deviation (RMSD) 
and root-mean-square fluctuation (RMSF) were calculated using tools within the 
Schrodinger Suite. 
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 CHAPTER 6: 








Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus that can cause 
severe paralytic neurologic disease and immune disorders as well as cancer. An 
estimated 20 million people worldwide are infected with HTLV-1, with prevalence reaching 
30% in some parts of the world. In stark contrast to HIV-1, no direct acting antivirals (DAAs) 
exist against HTLV-1. The aspartyl protease of HTLV-1 is a dimer similar to that of HIV-1 
and processes the viral polyprotein to permit viral maturation. We report that the FDA-
approved HIV-1 protease inhibitor darunavir (DRV) inhibits the enzyme with 0.8 µM 
potency and provides a scaffold for drug design against HTLV-1. Analogs of DRV that we 
designed and synthesized achieved sub-micromolar inhibition against HTLV-1 protease 
and inhibited Gag processing in viral maturation assays. Co-crystal structures of these 
inhibitors with HTLV-1 protease highlight opportunities for future inhibitor design. Our 







Human T-cell lymphotropic viruses type 1 and type 2 (HTLV-1/2) were the first 
human retroviruses described nearly 40 years ago.56-57 For decades HTLV-1 has been 
known to be highly carcinogenic and cause severe paralytic neurologic disease as well 
as immune disorders that can increase susceptibility to bacterial infections. HTLV-1 
infection can lead to adult T-cell leukemia/lymphoma (ATL), HTLV-associated 
myelopathy/tropical spastic paraparesis (HAM/TSP), uveitis and infective dermatitis.224-
225 HTLV-1 is transmitted via the same routes as HIV-1 (sexually, via blood or mother-to-
child) with significant HIV/HTLV co-infections reported in Europe, America, and Africa.58 
About 20 million people worldwide are infected with HTLV-1,59 reaching endemic rates of 
30% in some parts of the world. According to a recent report, up to 45% of the adult 
population among five Aboriginal communities in central Australia tested positive for 
HTLV-1.226 With global human movement, HTLV-1 infections are starting to expand into 
previously non-endemic regions as recently reported for Spain from Latin American 
immigrants.227 Unfortunately, there are no vaccines or direct acting antivirals (DAAs) 
against HTLV-1. 
In the absence of preventive vaccines and DAAs, treatment options for HTLV-1 
infected patients are scarce. For the estimated 3–5% of the HTLV-1 infected patients who 
develop ATL, chemotherapy is ineffective with very poor survival rates and relapse 
leading to death.60-61 Earlier studies with HIV-1 protease inhibitor ritonavir, although not 
very potent against HTLV-1, were promising against HTLV-1 induced ATL in cell lines 
and mouse models.228 In the clinic, a combination of zidovudine, an HIV-1 reverse 
transcriptase inhibitor, and IFN-ɑ significantly improved prognosis, indicating active 
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HTLV-1 replication in ATL patients that can be targeted by antiretrovirals. As with HIV-1 
infections, development of specific DAAs has a great potential to improve treatment 
outcomes. Such DAAs may also prove to be effective in all HTLV-1 associated human 
diseases, for pre-exposure prophylaxis (PrEP) especially in areas where the virus is 
endemic, and for preventing mother-to-child transmissions.229 
 HTLV-1 utilizes a similar viral machinery as HIV-1, and inhibiting the viral protease 
should prevent viral maturation. HIV-1 protease inhibitors are a success story of rational 
structure-based drug design, with the most recent FDA-approved drug, darunavir (DRV), 
having exceptional low-picomolar potency against wild type (WT) HIV-1 protease.78 As 
peptidomimetic transition-state analogues, protease inhibitors are the most potent among 
HIV-1 antivirals, as enzymes bind strongest to their transition-state as compared to 
substrates or products.230-231 Due to this potency and relatively high barrier to resistance, 
DRV has been tried as a monotherapy in patients with treatment-naïve HIV where the 
viral load and replication are relatively low.232 Success against HIV-1 protease suggests 
similar potency can be achieved against HTLV-1 protease.  
HTLV-1 protease is a 28 kDa homodimeric aspartyl protease that is 28% identical 
to HIV-1 protease with 45% identity between active site residues (Figure 6.1),62-63 yet 
HTLV-1 protease has considerably distinct substrate specificity (Table 6.1).63-67 The 
crystal structure of HTLV-1 protease was determined in 200565 and early attempts at 
inhibitor design involved peptide scanning with non-hydrolysable substrates.233 Iterations 
of this process incorporated unnatural amino acids234-235 and different capping 
moieties236-237 leading to the identification of allophenylnorstatin-based HTLV-1 protease 
inhibitors with low nanomolar potency.67 This inhibitor did not progress to clinic, likely due 
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to high peptidic character and large molecular weight. A few peptidic inhibitors were 
cocrystallized238 and deposited into the Protein Data Bank (PDB)69-70 providing valuable 
insights into inhibitor binding at the HTLV-1 active site. HIV-1 protease inhibitor indinavir 
(IDV), an FDA-approved drug, was also reported to weakly inhibit HTLV-1.68 More 
recently, pyrrolidine-based C2-symmetric non-peptidic inhibitors were investigated and 
achieved low nanomolar potency.239 Despite these efforts, there is still a need for 
exploring chemical scaffolds that will ultimately result in a clinically relevant HTLV-1 
protease inhibitor with sub-nanomolar potency.  
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Figure 6.1 Inhibitors tested against HTLV-1 protease. (A) Chemical structure of indinavir 
(IDV), darunavir (DRV) with P2–P2′ moieties labeled, and DRV analogs that exhibited 
improved potency. (B) Enzyme inhibition constants (Ki) for IDV, DRV, and DRV analogs 
against HTLV-1 protease. 
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Table 6.1 HIV-1 protease and HTLV-1 protease substrates/cleavage sites.  
Cleavage Site HIV-1 (P4-P1/P1′-P4′) 
HTLV-1 
(P4-P1/P1′-P4′) 
MA/CA SQNY/PIVQ PQVL/PVMH 
CA/NC - TKVL/VVQP 
Gag/PR SFNF/PQIT ASIL/PVIP 
PR/Pol TLNF/PISP PVIL/PIQA 
Pro/RT - PAVL/GLEL 





In this work, we tested the FDA-approved HIV-1 protease inhibitor DRV and our 
own novel DRV analogues against HTLV-1 protease. Several modifications to the DRV 
scaffold improved the inhibitors to low nanomolar potency, similar to the most potent 
HTLV-1 protease inhibitors to date. These compounds successfully inhibited maturation 
of viral-like particles (VLPs) by blocking the processing of viral Gag. Through the 
determination of co-crystal structures and comparison with analogous complexes in HIV-
1 protease we have additional insights into how to further increase potency and potentially 
develop the first direct acting antiviral against HTLV-1.  
6.3 Results and Discussion 
6.3.1 DRV and Analogs Inhibit HTLV-1 Protease  
We expressed and purified the 116-amino-acid construct of HTLV-1 protease for 
enzyme inhibition assays and crystallization. This protease construct has 9 amino acids 
removed from the C-terminus to facilitate crystallization,65 which does not affect catalytic 
activity.240 Utilizing a FRET-based enzymatic assay, the activity of HTLV-1 protease was 
tested using two peptide substrates based on HTLV-1 matrix/capsid (MA/CA) and 
capsid/nucleocapsid (CA/NC) cleavage sites (Table 6.2). The Michaelis-Menten constant 
(KM) was measured as 101.3 ± 1.9 µM and 31.6 ± 5.9 µM, consistent with previously 
reported values.241 HTLV-1 catalyzed cleavage of the MA/CA substrate an order of 
magnitude faster than that of CA/NC, with a catalytic efficiency of 0.21± 0.02 µM-1s-1. 




Table 6.2 Enzymatic activity of HTLV-1 protease measured using natural substrate 
sequences.  
 
Cleavage Site Sequence (P4-P1/P1′-P4’) KM (µM) kcat (s
-1) kcat / KM (µM-1s-1) 
MA/CA PQVL/PVMH 101.3 ± 1.9 21.6 ± 0.1 0.21 ± 0.02 
CA/NC TKVL/VVQP 31.6 ± 5.9 1.9 ± 0.1 0.06 ± 0.06 
 
 
The FDA-approved HIV-1 protease inhibitors IDV and DRV were tested against 
HTLV-1 protease (Figure 6.1 and Table 6.3). IDV weakly inhibited HTLV-1 protease (Ki 
= 62.7 µM), while DRV was two orders of magnitude more potent with a Ki of 0.8 µM. We 
previously found that modifications at the P1′ and P2′ positions of DRV improved potency 
against resistant variants of HIV-1 protease.45 These DRV analogues with larger 
hydrophobic P1′ moieties, increasing from an isobutyl to sec-butyl and isohexyl, were also 
tested against HTLV-1 protease. Some of the analogs had significantly improved potency, 
the best being UM6 with a Ki of 0.12 ± 0.01 µM, which is ~7-fold lower compared to DRV. 
In both UM1 and UM6, increasing the hydrophobicity at P1′ improved potency. However, 
modifications at the P2′ position did not further increase potency, indicating the aniline 






Table 6.3 Inhibition constant (Ki) against HTLV-1 protease.  
 
Code Inhibitor 2D Structure Ki (µM) 
IDV Indinavir 
 
63 ± 9 
DRV Darunavir 
 
0.8 ± 0.1 
UM1 UMass1 
 
0.28 ± 0.02 
UM6 UMass6 
 
0.12 ± 0.01 
UM7 UMass7 
 
1.2 ± 0.1 
UM8 UMass8 
 
1.9 ± 0.4 
UM9 UMass9 
 
0.4 ± 0.1 
PU6 P-UMass6 
 





Finally, we added a diethylphosphonate group via a methyloxy (O-CH2-O) linker to 
UM6 at the para position of the P1 phenyl (PU6) as this moiety had improved potency in 
a similar scaffold against highly drug resistant HIV-1 proteases.242 With this additional 
phosphonate modification, PU6 inhibited HTLV-1 protease 4-fold better than UM6 (Ki = 
0.03 ± 0.01 µM). Therefore, through exploration of a small panel of DRV analogues an 
HTLV-1 protease inhibitor with low-nM potency was identified with over 26-fold 
improvement over the FDA-approved inhibitor DRV.  
6.3.2 Inhibition of Gag Processing in HTLV-1 VLP’s 
 In addition to the biochemical enzymatic assays, DRV and the two analogs 
UM6/PU6 were tested for their ability to prevent Gag maturation (Figure 6.2). HTLV-1 
Gag expressed in Hek293T cells produced viral-like particles (VLPs), which were 
harvested, resolved by SDS-PAGE, and visualized using anti-capsid antibodies (see 
Methods for details). In the absence of any inhibitor, HTLV-1 protease rapidly processed 
Gag in VLPs to yield smaller fragments corresponding to cleavage products. DRV and 
both analogs effectively inhibited Gag cleavage and VLP maturation at as low as 1:1 ratio. 
Decreasing inhibitor concentration resulted in a dose-dependent response, as expected. 
Therefore, DRV analogs inhibit HTLV-1 protease thus Gag processing, which is required 







Figure 6.2 HTLV-1 Gag cleavage by protease in VPLs. (A) Gag cleavage by HTLV-1 
protease (1 µM) at 37° C without inhibitor as a function of time. Cleavage products 
visualized with anti-HTLV-1 p24 (capsid). (B) Gag cleavage after 60 min with decreasing 
molar ratio of inhibitor to protease. At a 1:1 ratio (1 µM), no Gag cleavage products are 
observed for any inhibitor, while below 1:10 ratio (100 nM inhibitor) some p24 capsid is 





6.3.3 Cocrystal Structures of DRV and Analogs Bound to HTLV-1 Protease 
To elucidate how the DRV scaffold binds to HTLV-1 protease, high-resolution 
cocrystal structures with DRV, UM6, and PU6 (2.05–2.29 Å) were determined (Table 6.4). 
The three complexes crystallized in the same space group (P6322), containing one 
homodimer in the asymmetric unit. For comparison, the structure of PU6 bound to HIV-1 
protease was also determined to 1.84 Å resolution (Table 6.4). Following established 
convention, the monomer that contacts the aniline side of DRV (P2′) is denoted the prime 
(′) or B chain, while the A chain that interacts with the bis-THF (P2) will remain non-prime. 
Starting from these crystal structures, a series of molecular dynamics (MD) simulations 
were performed to assess the stability of the inhibitor–protease interactions observed in 




Table 6.4 X-ray data collection and crystallographic refinement statistics. 
Protease-Inhibitor HTLV-DRV HTLV-UM6 HTLV-PU6 HIV-PU6 
PDB ID 6W6Q 6W6R 6W6S 6W6T 
Data Collection     
Space group P6322 P6322 P6322 P212121 
Cell dimensions:     
a (Å) 78.5 77.9 76.6 51.1 
b (Å) 78.5 77.9 76.6 58.0 
c (Å) 160.6 160.1 157.3 61.7 
α, β, γ (°) 90, 90, 120 90, 90, 120 90, 90, 120 90, 90, 90 
Resolution (Å) 40.1 - 2.10 (2.18 - 2.10) 
41.9 - 2.05 
(2.12 - 2.05) 
39.3 - 2.29 
(2.37 - 2.29) 
21.9-1.84 
(1.91-1.84) 
Unique reflections 17823 (1728) 18768 (1804) 12954 (1244) 16226 (1420) 
Total reflections 162887 (16621) 173500 (15456) 114508 (11155) 104007 (4828) 
Rmerge a 0.09 (2.00) 0.10 (3.49) 0.24 (3.89) 0.06 (0.29) 
Rpim 0.03 (0.68) 0.04 (1.25) 0.09 (1.36) - 
CC1/2 1.00 (0.37) 1.00 (0.23) 0.99 (0.15) - 
CC* 1.00 (0.73) 1.00 (0.62) 1.00 (0.50) - 
Completeness (%) 99.8 (100) 99.8 (99.6) 99.9 (99.9) 98.4 (88.0) 
Redundancy 9.1 (9.6) 9.2 (8.6) 8.8 (9.0) 6.4 (3.4) 
Average I/σ 12.6 (1.2) 12.2 (0.7) 5.9 (0.9) 22.7 (3.3) 
Wilson B-factors (Å2) 55.2 50.6 61.3 25.2 
Refinement     
Rfactor (%)c 22.9 22.1 26.6 20.0 
Rfree (%)d 26.2 24.3 30.5 22.7 
RMSDb in:     
Bond lengths (Å) 0.007 0.012 0.006 0.003 
Bond angles (°) 0.81 1.32 0.82 0.59 
Ramachandran:     
Favored 96.05 96.49 96.05 99.48 
Allowed 3.95 3.07 3.95 0.52 
Outliers 0.00 0.44 0.00 0.00 
 
aRsym = Σ | I − <I>|/ Σ I, where I = observed intensity, <I> = average intensity over symmetry 
equivalent; values in parentheses are for the highest resolution shell. 
bRMSD, root mean square deviation. 
cRfactor = Σ || Fo| − |Fc||/ Σ|Fo|. 
dRfree was calculated from 5% of reflections, chosen randomly, which were omitted from 






6.3.4 Interactions Lost in the Binding of DRV to HTLV-1 Versus HIV-1 Protease 
In the cocrystal structure determined, DRV was bound at the active site of HTLV-
1 protease with an overall conformation similar to that in HIV-1 protease (Figure 6.3). 
However, because of variations in the active site, evident in dramatically altered substrate 
specificity, certain key protease–inhibitor interactions were either lost or weakened in 
HTLV-1 protease.  As with all HIV-1 protease inhibitors, DRV is a transition state analogue: 
the central hydroxyl moiety interacts with the side chain oxygens of both catalytic 
aspartates at a distance of 2.5–3.2 Å between heavy atoms. In HTLV-1 protease, these 
distances increased to 2.8–3.5 Å. In addition, the more open active site in HTLV-1 
protease resulted limited packing of the inhibitor and the flaps, with no evidence of 
coordinated waters in the electron density maps. Finally, DRV is not large enough to keep 
optimal distance to the catalytic residues while coordinating bis-THF moiety interactions 
at the S2 subsite. In HIV-1 protease, the bis-THF oxygens have hydrogen bonds with the 
backbone nitrogen atoms of D29 and D30 [Figure 3B] within 2.8–3.2 Å while remaining 
3.5 Å away from the repulsive force of the carbonyl oxygen of D30. This binding also 
allows the NH atom of the carbamate linker to interact with the carbonyl oxygen of Gly27 
at a distance of 3.0 Å. In HTLV-1 protease, the bis-THF had a single hydrogen bond with 
the backbone nitrogen of D36 at a favorable distance of 2.9 Å. The nitrogen of M37 and 
carbonyl oxygen of Gly34 were both beyond hydrogen bonding distance (3.4–3.6 Å).  
Thus, these three major disruptions of hydrogen bonds in HTLV-1 protease (Figure 3B) 
between (1) the central hydroxyl and catalytic aspartates (which centers the inhibitor 
within the active site); (2) the loss of the tetrahedral network coordinating the inhibitor to 
the flaps through a conserved water; (3) the bis-THF moiety and backbone nitrogens in 
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the S2′ subsite, weaken the affinity with DRV as previously observed in highly DRV-







Figure 6.3 Comparison of DRV binding to HTLV-1 versus HIV-1 protease. (A) Cocrystal 
structures of DRV bound to HTLV-1 and HIV-1 protease (PDB IDs 6W6Q and 6DGX, 
respectively); (B) close-up view of bis-THF moiety in the S2 subsite; (C) close-up view of 
aniline moiety in the S2′ subsite; (D) inter-molecular hydrogen bonds between DRV and 
protease active site; (E) packing around DRV at the active site visualized through mean 
inter-molecular vdW interactions with protease during MD simulations, where yellow to 
red indicates increased packing. In all panels, the prime side monomer (chain A) 
interacting with the bis-THF moiety is in darker shade, and DRV is depicted as orange 
sticks in panels A-D. 
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The packing of DRV is dramatically different in HTLV-1 compared with HIV-1 
protease. In HTLV-1, the phenyl ring of P1 moiety does not pack well against the 
hydrophobic residues L30′, W98′, I100′, and L57 in the S1 subsite (Figure 6.3C) and the 
exposed ring coordinates a channel filled with water molecules. In contrast in HIV-1 
protease, the phenyl ring of P1 packs against the hydrophobic side chains in the 80s loop, 
especially V82 (Figure 6.3C). This reflects the substrate specificity of HIV protease where 
residues with aromatic rings (Phe and Tyr) naturally occur at the P1 position of cleavage 
sites [Table 6.1] and modifications to increase van der Waals (vdW) contacts at this site 
can greatly improve potency against resistant proteases.203, 242, 244 The cocrystal structure 
with HTLV-1 protease indicates modifications to the P1 moiety to either stack against the 
hydrophobic side chains in the S1 subsite or exploit the available space in the channel 
may increase potency. 
In homodimeric proteases, the S2′ subsite is symmetrically related to the S2 
subsite and made up of identical residues. In the S2′ subsite of HIV-1 protease, DRV P2′ 
aniline makes a direct hydrogen bond with the backbone oxygen of D30′ and a water-
mediated interaction with the side chain of D30′ [Figure 6.3D]. In our DRV analogs (UM7-
9), modifications to P2′ –including phenoxymethyl, hydroxymethylbenzene, 
benzo(1,3)dioxole– improved potency against resistant variants by establishing more 
favorable interaction with the backbone nitrogen of D30′.45 In contrast, DRV and analogs 
harboring the aniline moiety had the best potency among those tested against HTLV-1 
protease (Figure 6.1, Table 6.3). The cocrystal structure (Figure 6.3D) shows the aniline 
nitrogen is roughly equidistant from both the backbone oxygen and backbone nitrogen of 
residue M37′ but not within hydrogen bonding distance. The aniline benzene ring had a 
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slightly different rotation angle and S2’ subsite had a deeper hydrophobic pocket beyond 
V56′ toward F67′. These differences may underlie why the P2′ modifications did not 
increase potency toward HTLV-1 protease. 
When DRV bound to HTLV-1 protease, both P1 and P1′ moieties were largely 
exposed to channels occupied by water molecules (Figure 6.3C,D). These moieties are 
nestled in hydrophobic pockets in HIV-1 protease with favorable hydrophobic contacts. In 
HTLV-1 protease the favorable packing around these moieties was substantially 
decreased, which was also the case for the overall inhibitor due to the larger active site 
(Figure 6.3E). 
6.3.5 Structural Basis of Improved Potency of DRV Analogs Toward HTLV-1 
Protease 
Cocrystal structures of DRV analogs that had improved potency were determined 
with HTLV-1 protease. Both UM6 and PU6 have a larger isohexyl moiety at the P1′ 
position compared to DRV’s isobutyl. When bound to the protease, these aliphatic 
moieties had diverging conformations (Figure 6.4A) which could all be accommodated 
within the relatively large hydrophobic S1′ subsite (Figure 6.4B). The conformation of the 
P1′ moiety seemed to impact that of the P2′ aniline, suggesting subsite interdependence 
and the need to optimize these moieties simultaneously. The P1′ isohexyl moiety was not 
large enough to displace any water molecules in the extended S1’ channel. However, 
hydrophobic packing against S1′ residues (Ala59′ and Trp98) were enhanced (Figure 
6.1), likely underlying the improved potency of analogs with the larger P1′ moiety. Even 
larger P1′ moieties that pack against these hydrophobic moieties while extending into the 




Figure 6.4 Comparison of DRV and DRV analogs when bound to HTLV-1 protease. (A) 
Alignment of inhibitors. (B) Close-up view of P2′-P1′ moiety in the S2′-S1′ subsite. The P1′ 
moiety does not have a conserved binding conformation. (C) Close-up view of P2-P1 
moieties in the S2-S1 subsite. The phosphonate moiety extends into the S1 subsite, 






 On the flip side of the active site, the invariant P2 bis-THF and P1 benzene ring 
superimposed well with only minor conformational divergence (Figure 6.4A, C). The 
phosphonate added to the P1 ring in PU6 extended into the S1 channel, substantially 
increasing vdW contacts with Leu57, Trp98′, Arg10′ (Figure 6.5). These account for the 












 The phosphonate addition to the P1′ benzene ring has been reported for other HIV-
1 protease inhibitor scaffolds to increase potency against resistant variants by “solvent 
anchoring”.242 We determined the crystal structure of our PU6 inhibitor bound to HIV-1 
protease to both investigate the mechanism of increased potency and to compare with 
HTLV-1 protease (Figure 6.6). The conformation of the phosphonate moiety was 
completely different in the two cocrystal structures. In HIV-1 protease, one branch of the 
phosphonate moiety interacted with Pro81′ in the 80s loop while the other extended to 
the flaps. This suggests that rather than solvent interactions, the mechanism of improved 
potency against resistant HIV-1 protease variants is through interactions with the invariant 
Pro81′ and stabilization of the closed conformation of the flaps. In HTLV-1 protease, the 
phenyl ring intercalates between Leu57 and Trp98′, while Leu57 prevents the 
phosphonate group from interacting with the protease flaps. Instead, the phosphonate 





Figure 6.6 Comparison of PU6 when bound to HTLV-1 and HIV-1 protease. (A) The 
phosphonate moiety of PU6 sticks out into the S1 subsite in HTLV-1, whereas it binds up 
against the flaps in HIV-1 protease. (B) Residue L57 prevents the phosphonate from 




The crystal structures indicate that exploration of larger P1′ and P1 moieties to fill 
the water-occupied channels is highly promising. Our MD simulations indicate Ala59/59′ 
and Trp98/98′ are highly flexible (Figure 6.7). Modifications that increase interactions with 
Ala59/59′ to stabilize the flaps and with Trp98/98′ to lock the side chain conformer will 
likely further increase inhibitor potency. These tryptophan residues and phenylalanine 
(Phe67/Phe67′) in the S2/S2′ subsites also provide an opportunity for π-π stacking 
interactions between protease and inhibitor (Figure 6.8). Previously reported C2-
symmetric pyrrolidine-based inhibitors with P1/P1′ aromatic rings had π-π stacking 
interactions with Trp98, which improved potency.239 In our MD simulations, π-π stacking 
of P1 phenylalanine with Trp98 was maintained only about half of the time, and only PU6 
formed edge-to-face π-π stacking with Phe67′ again for about half of the simulation time. 
Stabilizing these stacking interactions may further increase potency. Overall, analysis of 
crystal structures suggests that DRV offers a promising scaffold for HTLV-1 protease 






Figure 6.7 Root-Mean-Square Fluctuation (RMSF) of Cɑ atoms for DRV, UM6 and PU6 
in complex with HTLV-1 protease from molecular dynamics simulations. 
 
 
Figure 6.8 Aromatic side chains in HTLV-1 active site can form π-π stacking interactions, 
primarily in edge-to-face configuration, with the P1 phenylalanine and P2′ aniline of DRV 
analogs. Frequency of the π-π stacking interactions (dashed lines) during MD simulations 




 HTLV-1 is a growing global threat with no DAAs or vaccines to prevent the spread 
of the disease. We sought to inhibit HTLV-1 protease using DRV, the most potent FDA-
approved HIV-1 protease inhibitor. Our results show that DRV is a promising scaffold for 
inhibitor design and antiviral development against HTLV-1 protease. With modifications 
to two moieties of DRV, the lead compound (PU6) achieved substantially (~27-fold) 
improved potency in vitro and inhibited Gag processing by HTLV-1 protease. The 
structural insights gained here will guide the design of highly potent HTLV-1 protease 
inhibitors. 
6.5 Methods  
6.5.1 Construction of the HTLV-1 Protease Expression Plasmid 
The 116 amino acid HTLV-1 variant (Uniprot Accession ID: Q82134) was ordered 
from Genscript on a pET11a plasmid with codon optimization for protein expression in 
Escherichia coli. A L40I mutation was included to prevent autoproteolysis.241  
6.5.2 Protein Expression and Purification 
The expression, isolation, and purification of HTLV-1 protease used for the kinetic 
assays and crystallization was carried out as previously described for HIV-1 protease.40, 
99 Briefly, the gene encoding the HTLV-1 protease was subcloned into the heat-inducible 
pXC35 expression vector (ATCC) and transformed into E. coli TAP-106 cells. Cells grown 
in 6 L of Terrific Broth were lysed with a cell disruptor and the protein was purified from 
inclusion bodies.245 The inclusion body centrifugation pellet was dissolved in 50% acetic 
acid followed by another round of centrifugation to remove impurities. Size exclusion 
chromatography was used to separate high molecular weight proteins from the desired 
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protease. This was carried out on a 2.1 L Sephadex G-75 superfine column (Millipore 
Sigma) equilibrated with 50% acetic acid. The cleanest fractions of HTLV-1 protease were 
refolded into a 10-fold dilution of 0.05 M sodium acetate at pH 5.5, 5% ethylene glycol, 
10% glycerol, and 5 mM DTT. Folded protein was concentrated down to 1–2 mg/mL and 
stored at -80°C. Protein aliquots were thawed, concentrated to ~10 mg/mL, and a final 
purification was performed with a Pharmacia Superdex 75 FPLC column equilibrated with 
0.05 M sodium acetate at pH 5.5, 5% ethylene glycol, 10% glycerol, and 5 mM DTT. 
Protease fractions purified from the size exclusion column were concentrated to 1–2 
mg/mL using an Amicon Ultra-15 10-kDa device (Millipore). Freshly purified protease was 
used for crystallization and the rest was stored at -80°C. This stored protease was used 
for KM and Ki assays.  
6.5.3 Enzyme Binding Assays to Determine KM 
To determine the enzyme activity, in a 96-well plate, purified protease was provided 
a 10-amino acid substrate containing the natural cleavage site (MA/CA or CA/NC) with 
an EDANS/DABCYL FRET pair dissolved in 8% DMSO was 2/3 serially diluted from 0 to 
40 μM for MA/CA and 0 to 100 μM to CA/NC. HTLV-1 protease was diluted to 12 μM and, 
using a PerkinElmer Envision plate reader, and 5 µL were added to the 96-well plate to 
obtain a final concentration of 1 μM. Fluorescence was observed with an excitation at 340 
nm and emission at 492 nm and monitored for 200 counts. A FRET inner filter effect 
correction was applied as previously described.103 Data corrected for the inner filter effect 
was analyzed with Prism8, as described in Chapter 3.  
 
 257 
6.5.4 Enzyme Inhibition Assays to Determine Ki  
To determine the enzyme inhibition constant (Ki), in a 96-well plate, each inhibitor 
was 2/3 serially diluted from 400 μM to 6.9 μM for IDV, 30 μM to 0.5 μM for DRV and UM6 
or 2 μM to 0.03 μM for PU6. All assays included a 0 μM control, and incubated with 1 μM 
protein for 1 hour. A 10-amino acid substrate containing a solubility enhanced HTLV-1 
MA/CA protease cleavage site with an EDANS/DABCYL FRET pair (BAChem) was 
dissolved in 4% DMSO at 120 µM. Using the Envision plate reader, 5 µL of the 120 µM 
substrate was added to the 96-well plate to a final concentration of 10 µM. The 
fluorescence was observed with an excitation at 340 nm and emission at 492 nm and 
monitored for 200 counts. Data was analyzed with Prism8, as described in Chapter 2. 
UM6 was used as a control in all assays.  
6.5.5 Protein Crystallization 
Many crystallization conditions produced HTLV-1 protease cocrystals with a 
hexagonal plate morphology, but the condition most reliably producing larger crystals in 
three dimensions was discovered using the JCSG+ sparse screen, well C6, containing 
40% (v/v) PEG 300, 0.1M Phosphate/Citrate pH 4.2. All cocrystals were grown at room 
temperature by hanging drop vapor diffusion method in a 24-well VDX hanging-drop trays 
(Hampton Research) with a protease concentration of 4.0 mg/mL with 5-fold molar excess 
of inhibitor and mixed with the precipitant solution at a 1:1 ratio. The precipitant solution 
consisted of 39–41% (v/v) PEG 300 with 0.1 M Phosphate/Citrate buffer at pH 4.2 and 
the crystallization drops were set with 1 µL of precipitant solution and 1 µL protein-inhibitor 
solution and micro-seeded with a cat whisker and dried over a well solution of 3.0-4.0 M 
NaCl. Diffraction quality crystals were obtained within 2 weeks. Data were collected at 
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100 K and due to the high percentage of low molecular weight PEG there was no need 
for supplemental cryoprotectant. The cocrystal of PU6 bound to HIV-1 protease was 
generated as previously described.37, 213, 243, 246  
6.5.6 Data Collection and Structure Solution 
The three HTLV-1 protease cocrystals were shot at the Chicago APS Synchrotron 
Beamline 23-ID-D using beamline control software JBluIce.247 The diffraction images 
were indexed, integrated, and scaled using the GM/CA autoprocessing pipeline which 
utilizes XDS,248 POINTLESS,249 and AIMLESS.250 X-rays diffracted through a cocrystal 
of PU6 bound to HIV-1 protease were collected by our in-house Rigaku Saturn944 system 
and intensities were indexed, integrated, and scaled using HKL3000.105  
Structures were solved by molecular replacement in the program PHASER106 
using an HTLV-1 protease monomer (PDB: 3WSJ) or a WT HIV-1 protease monomer 
(PDB: 6DGX). Model building and refinement was performed using Coot107 and Phenix.108 
Ligands were designed in Maestro and the output sdf file was used in the Phenix program 
eLBOW109 to generate the cif file containing atomic positions and constraints necessary 
for ligand refinement. Iterative rounds of crystallographic refinement were carried out until 
convergence was achieved. To limit bias throughout the refinement process, five percent 
of the data were reserved for the free R-value calculation.110 MolProbity was applied to 
evaluate the final structures before deposition in the PDB.111 Structure analysis, 
superposition and figure generation was done using PyMOL.251 X-ray data collection and 




6.5.7 Structural Analysis 
To calculate the intermolecular vdW interaction energies the crystal structures were 
prepared using the Schrödinger Protein Preparation Wizard.216 Hydrogen atoms were 
added, protonation states were determined, and the structures were minimized. The 
protease active site was monoprotonated at Asp25. Subsequently, force field parameters 
were assigned using the OPLS3 force field.217 Interaction energies between the inhibitor 
and protease were estimated using a simplified Lennard-Jones potential, as previously 
described in detail.218 Briefly, the vdW energy was calculated for pairwise interactions 
depending on the types of atoms interacting and the distance between them.  
6.5.8 Molecular Dynamics Simulations 
High resolution HTLV-1 cocrystal structures with DRV, UM6, and PU6 (PDB: 6W6Q, 
6W6R, 6W6S) were used as starting coordinates for molecular dynamics simulations. All 
starting structures were prepared using the Protein Preparation Wizard from 
Schrodinger.216 Crystallographic water molecules were retained, missing atoms were 
added using Prime,221 and PROPKA143-144 was used to determine the protonation state 
of side chains at pH 7.0. The resulting structure was minimized under restraint to a 
convergence criterion of 0.3 Å using Impref.145 
All molecular dynamics simulations were carried out using Desmond, within 
Schrodinger, 216 with the OPLS3e force field for the inhibitor and protein. The systems 
were prepared as previously discussed.85 Briefly, the cocrystal structures were placed 
within a cubic TIP3P water box measuring 15Å on each side. Chloride ions were first used 
to neutralize the system and sodium and chloride atoms were added to reach a 
physiological 0.15 M salt concentration. Prior to simulation, each solvated system was 
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relaxed using a series of restrained minimization stages as previously described.85 These 
stages consisted of successive minimizations with restraints on i) the heavy protein atoms, 
ii-iii) the protein backbone atoms and finally iv) no restraints. The restraining force 
constants were 1000, 1000 and 5 kcal mol-1 Å−2 for stages i), ii) and iii), respectively and 
the minimization was done using steepest descent followed with the limited-memory 
BFGS method to a tolerance of 0.5 kcal mol−1 Å−1. During unrestrained minimization, this 
tolerance was further reduced to 0.05 kcal mol−1 Å−1. Molecular dynamics for each system 
was carried out in triplicate, with each of the three 100 ns simulations starting with different 
randomized velocities. The root-mean-square deviation (RMSD) from the starting 
structures indicates that the simulations reached equilibrium after 10 ns. 
6.5.9 Analysis from MD Simulations 
vdW packing about the inhibitor was calculated as previously described.40, 147 Briefly, 
force field parameters are not optimized for sulfurs violating the octet rule (e.g. the sulfur 
of the P2’ moiety of DRV, UM6, and PU6). As such, the packing around this sulfur atom 
was calculated by averaging the vdW packing of the four adjacent atoms. 
π-π stacking interactions were analyzed utilizing the simulation interaction diagram 
within Maestro from the Schrodinger Suite.216 A π-π stacking interaction in the edge-to-
face configuration was identified when the distance between the ring centroids was less 
than 5.5 Å and the angle between the rings was between 60° and 120°. A π-π stacking 
interaction in the edge-to-face configuration was identified when the distance between 
the ring centroids was less than 5.5 Å and the angle between the rings was between 60° 
and 120°. A π-π stacking interaction in the face-to-face configuration was identified when 
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the distance between the ring centroids was less than 4.4 Å and the angle between the 
rings was less than 30°. 
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 CHAPTER 7: 
Optimal Refinement of Pseudomerohedrally Twinned P61 HIV-1 Protease–




7.1 Abstract  
Twinning is a crystal growth anomaly in which protein monomers exist in different 
orientations but are related in a specific way, causing diffraction reflections to overlap. 
Twinning imposes additional symmetry on the data, often leading to assignment of a 
higher symmetry space group. Specifically, in pseudomerohedral twinning, reflections 
imperfectly overlap and require a twin law to separate unique structural data from 
overlapping reflections. Neglecting twinning in the crystallographic analysis of quasi-
rotationally symmetric homo-oligomeric protein structures can mask the degree of 
structural non-identity between monomers. In particular, any deviations from perfect 
symmetry will be lost if higher than appropriate symmetry is applied during 
crystallographic analysis. Such cases warrant choosing between the highest symmetry 
space group possible, or determining if the monomers have distinguishable structural 
asymmetries and thus require a lower symmetry space group and a twin law. Using 
hexagonal cocrystals of HIV-1 protease, a C2 symmetric homo-dimer whose symmetry is 
broken by the bound ligand, we show that both assigning a lower symmetry space group 
and applying a twin law during refinement is critical to achieving the most accurate 
structural model. By re-analyzing three recently published HIV-1 protease structures, we 
demonstrate improvements in nearly every crystallographic metric. Most importantly, we 
find that the inhibitor can be modeled in a single orientation, allowing for more precise 





7.2 Introduction  
Macromolecular structures determined through X-ray crystallography allow for high-
resolution measurements and structural analyses. The accuracy of structures is 
especially important for protein–inhibitor complexes, as relatively small errors can greatly 
mislead drug design and structure-activity relationship studies. A common problem in 
crystallography is that disordered regions of proteins cannot reliably be modeled due to 
the averaging out of electron density. Less appreciated, data averaging can also occur 
when determining structures that are twinned due to pseudosymmetry.  
Twinning is a crystal growth anomaly in which the specimen is composed of 
separate domains whose orientations differ but are related in a specific way (Yeates, 
1997). The domains may be rotated, reflected, or inverted with respect to each other 
causing diffraction pattern reflections to overlap. Because amino acids are chiral, proteins 
only exhibit rotation symmetry (Parsons, 2003) which may cause twinning. The type of 
twinning is categorized by the number of dimensions the crystal lattices overlap. 
Merohedral twinning describes cases in which the lattices of two or more distinct domains 
coincide exactly in three dimensions, whereas nonmerohedral twinning is when the 
overlap occurs in fewer than three dimensions. Lattices imperfectly overlapping in three 
dimensions is referred to as pseudomerohedral (Yeates, 1997). Depending on the space 
group, twin laws are necessary to correct for crystallographic twinning and refine the 
structure to a high level of confidence (Zwart et al., 2008). Due to chirality, proteins may 
crystallize in 65 of the 230 possible crystallographic space groups, and twinning occurs 
only in lower symmetry space groups of the trigonal, hexagonal, tetrahedral, or cubic 
systems (Nespolo and Aroyo, 2016). Twinning imposes additional symmetry on the 
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diffraction pattern and may bias the data to be processed in a space group higher than 
appropriate (Zwart et al., 2008). In cases of pseudomerohedral twinning, where lattices 
do not perfectly overlap, processing data in the highest possible space group will average 
out asymmetric data, without allowing a twin law to later recover asymmetric information 
(Hamdane et al., 2009, Donovan et al., 2016, Campeotto et al., 2018). Of the ~145,000 
structures in the Protein Data Bank (PDB) (Berman et al., 2000, Berman et al., 2003) 
about 55,000 are homo-oligomers, 96% of which are rotationally symmetric (Tuvi-Arad 
and Alon, 2019). Pseudomerohedral twinning in such structures may lead to the 
assumption of perfect symmetry for distinct monomers of homo-oligomers. 
HIV-1 protease is a 99 amino acid C2 symmetric homodimer (Wlodawer et al., 1989). 
In the apo form, the two monomers are highly symmetric, but binding an inhibitor or 
substrate induces asymmetry in the protease, especially in the flaps [Figure 7.1A-B] 
(Rose et al., 1998, Prabu-Jeyabalan et al., 2000). HIV-1 protease is among the proteins 
with the most published structures in the PDB. When this manuscript was submitted, a 
BLAST search of WT HIV-1 Protease (UniProtID: Q8ULI9) returned 729 structures with 
at least 50% sequence identity and inhibitor or substrate bound at the active site. Of these 
729 cocrystal structures, most were solved in the primitive orthorhombic space groups 
P21212 or P212121, accounting for 260 and 229 structures, respectively [Figure 7.2A-B]. 
The P212121 space group is particularly fortuitous as it represents the biologically 
functional unit, containing two monomers in the asymmetric unit and the inhibitor bound 
in a single orientation. The P21212 space group also contains two monomers in the 
asymmetric unit, but about a third of the time the inhibitor is modeled in two orientations 
with split occupancies due to observed C2 symmetric electron density in the active site. 
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In these primitive orthorhombic space groups, unless two crystal axes are the same 




   
Figure 7.1 A) Side view: HIV-1 protease structure shown in cartoon representation with 
transparent surface. Inhibitor (DRV) shown as green sticks. B) Top view: HIV-1 protease 
structure in cartoon representation with DRV shown as green spheres. C) Inhibitors 
bound to HIV-1 protease whose cocrystal structures were investigated and re-refined in 





Figure 7.2 A) Number of HIV-1 protease-like cocrystals structures deposited into the PDB 
by space group. B) Violin plot showing the distribution of cocrystal structures published 




For HIV-1 protease cocrystals, the next most common space group is P61 with 99 
published structures [Figure 7.2]. Hexagonal cocrystals solved in P61 space group have 
two monomers in the asymmetric unit, and 50 of 99 structures have asymmetric inhibitors 
modeled in two orientations at roughly 50% occupancy. When HIV-1 protease crystallizes 
in this hexagonal form, the monomers remain highly symmetric resulting in 
pseudomerohedral twinning. This near-perfect symmetry causes the hexagonal data to 
appear as the higher symmetry space group P6122 (Erickson et al., 1990, Dreyer et al., 
1992). If the data were processed in P6122, all overlapping reflections derived from the 
two monomers would be combined and averaged to model the single monomer per 
asymmetric unit. Although choosing to process the pseudomerohedrally twinned data in 
P61 space group correctly models a dimer, by not applying a twin law when refining the 
structure, the asymmetries remain averaged out, as if modeling two identical P6122 
monomers. As previously described, a twin law is necessary to account for asymmetries 
in the reflections of overlapping diffraction patterns. Only once was a twin law operator 
used to refine a high-resolution structure of an apo HIV protease dimer in the P61 space 
group (PDB: 3IXO). In this case, the twin law was shown to decrease the R-factors and 
significantly improve the electron density of the asymmetric flaps (Robbins et al., 2010). 
Despite this precedent, twin laws have not been applied during refinement of hexagonal 
HIV-1 cocrystal structures.  
To evaluate and quantify the benefit of applying a twin law when refining a 
pseudomerohedrally twinned homodimer, we refined three HIV-1 protease cocrystal 
structures with increasingly asymmetric inhibitors [Figure 7.1C]. To determine any 
improvement with the twin law, our recently published HIV-1 protease structure with 
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darunavir (DRV) bound, both with and without the twin law applied, was refined. Next the 
twin law was applied to two recently published HIV-1 protease cocrystal structures from 
the PDB with bound inhibitors that were more asymmetric than DRV. We found that 
applying a twin law operator during refinement improves the structure and allows the 
inhibitor to be modeled in a single orientation. This case study may inform hundreds of 
other structures involving pseudomerohedrally twinned homo-oligomers with or without 
inhibitors bound.  
7.3 Materials and Methods 
7.3.1 Protein Preparation and Crystallization 
Details involving HIV-1 protease gene construction, protein expression and 
purification, and cocrystallization steps were previously published (Henes et al., 2019, 
Aoki et al., 2017, Schimer et al., 2015). 
7.3.2 Data Collection and Processing  
For our data set (PDB: 6OPV), cocrystal diffraction intensities were indexed, 
integrated, and scaled using HKL3000 (Otwinowski and Minor, 1997). For the previously 
published data sets (PDB: 5TYS (Aoki et al., 2017) and 4U7Q (Schimer et al., 2015)), the 
MTZ files were downloaded from the PDB. Data quality was checked with phenix.xtriage 
(Adams et al., 2010), which also provided the twin fraction and the suggested twin law. 
All three data sets were flagged as merohedrally twinned, with twin fractions estimated to 
be above 0.48 by the cumulative distance of H or above 0.45 by Britton analysis (Britton, 
1972, Yeates, 1988). The twin law (h,-h-k,-l) was detected for these hexagonal data sets.  
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7.3.3 Molecular Replacement  
Structures were solved using molecular replacement with PHASER (McCoy et al., 
2007). A WT HIV-1 protease monomer from a DRV bound cocrystal structure solved in 
P61 was used for molecular replacement (PDB: 6OPS) (Henes et al., 2019). 
7.3.4 Refinement  
After molecular replacement, model building and refinement was performed using 
Coot (Emsley and Cowtan, 2004) and Phenix (Adams et al., 2010). During refinement, 
optimized stereochemical weights and torsion-angle non-crystallographic symmetry 
operators were utilized. The twin law (h,-h-k,-l) was applied where specified. Ligands were 
modeled in Maestro and the sdf files were used in the Phenix program eLBOW (Moriarty 
et al., 2009) to generate the cif file containing atomic positions and constraints necessary 
for ligand refinement. Iterative rounds of crystallographic refinement were carried out until 
convergence was achieved. To limit bias throughout the refinement process, five percent 
of the data were reserved for the free R-value calculation (Brunger, 1992). MolProbity 
(Davis et al., 2007) was utilized to evaluate the quality of the final structures.  
7.3.5 Visualization of Structures  
Alignment by superposition and figure generation was done using PyMOL (DeLano, 
2002). Throughout this analysis, chain A is depicted as cyan sticks and chain B as light 
magenta sticks. To depict the electron density and difference map for each structure, 
Phenix was used to output maps as ccp4 files using map coefficients. Specifically, files 
used were: the MTZ file with R-free flags, final PDB file, and final MTZ file. Throughout 
this analysis, 2Fo-Fc direct maps are depicted as grey mesh contoured at 1.0 σ while the 
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Fo-Fc difference maps have positive density depicted as green mesh contoured at 3.0 σ 
and negative density as red mesh contoured at -3.0 σ.  
7.4 Results and Discussion 
7.4.1 Evaluating Twin Law and Inhibitor Orientation 
To determine the benefit of the application of a twin law, the first dataset evaluated 
was that of a high-resolution (1.91 Å) HIV-1 protease cocrystal structure with DRV bound, 
which we recently determined (PDB: 6OPV) (Henes et al., 2019). As the data was 
processed in the P61 space group, molecular replacement placed two monomers in the 
asymmetric unit. The dimer was refined to convergence with and without the twin law 
applied for the duration of the refinement process. In addition, to determine if the inhibitor 
orientation imposed any structural bias, the structure was refined with bis-THF moiety of 
DRV interacting with either the A chain, the B chain, or in both conformations at 50% 
occupancy [Figure 7.3]. This resulted in six separate models from the same dataset. 
All six structures were refined to convergence and finished with similar R-factor 
statistics. Comparing similar cocrystal structures, application of the twin law reduced Rwork 
by about 0.5% and Rfree by about 1.5%. The twin law visibly improved the electron density 
maps surrounding the inhibitor and flap tip residues, apparent by the reduction of density 





Figure 7.3 Electron density maps surrounding the flap tip residues, Ile50 and Gly51(top), 
and the inhibitor, DRV (bottom), shown as sticks. A, B, and A/B indicate the orientation of 
the modeled inhibitor. Rwork/Rfree values are indicated below each of the 6 structures 





Figure 7.4 Internal distance differences between Cɑ atoms of chain A and chain B of all 
re-solved structures of DRV bound HIV-1 protease (PDB: 6OPV) with and without the 




When the inhibitor was modeled in two orientations, the refinement began with 
exactly 50/50 split occupancy between inhibitor orientation A and B. During refinement, 
when the occupancies were allowed to change without any restriction, but no twin law 
was applied, the occupancies never diverged beyond a 55/45 split. Interestingly, when 
the twin law was applied, the inhibitor occupancies converged to an 80/20 split. 
Comparing successive rounds of refinement, under these parameters, the electron 
density map around the inhibitor became increasingly asymmetric. This demonstrates the 
twin law’s ability to, without bias, select the preferred single orientation of the inhibitor. In 
Figures 7.3-7.4, the structure with two inhibitors and the twin law applied had the inhibitor 
occupancies locked at 50/50 for the final round of refinement. This returned C2 symmetry 
to the electron density around the inhibitor and allowed for direct comparison to the 
structure with two inhibitor orientations without the twin law applied.  
While all structures refined to similar statistics, the application of the twin law 
enabled capturing asymmetric details of the structure of the complex, as highlighted by 
internal distance differences between the two chains. Without the twin law, the structures 
were highly symmetric, especially in the core [Figure 7.4]. Modeling the inhibitor in two 
orientations induces more symmetry between monomers than observed in the single 
orientation models, as any actual differences are averaged out. With the twin law, the 
monomers had more internal variations throughout the protease. This was especially true 
around the active site where the flaps and 80’s loop adopt different conformations 
between the two monomers, which has been characterized in other space groups when 
binding asymmetric inhibitors.  
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This first set of tests showed that the application of a twin law allows a near-perfectly 
twinned cocrystal structure to be solved as a homodimer with the inhibitor and flaps 
modeled in a single orientation without losing any confidence in the model. The twin law, 
in fact, teases out known asymmetries between the monomers, resulting in a more 
accurate model.  
7.4.2 Re-Solving Structure with a More Asymmetric Inhibitor  
DRV is a fairly symmetric inhibitor when rotated about the C2 axis, as its P1 and P2 
moieties roughly occupy the same three-dimensional space as its P1′ and P2′ moieties 
[Figure 7.1C]. To further test this protocol, we chose to investigate an HIV-1 protease 
cocrystal structure with a more asymmetric DRV analog, GRL-142, bound to the active 
site (PDB: 5TYS) (Aoki et al., 2017). This recently published structure was solved in the 
P61 space group with a dimer in the asymmetric unit and the highly potent inhibitor (GRL-
142published) modeled in two conformations with occupancies of 0.53 and 0.47 [Figure 
7.5A]. The 2.0 Å resolution structure was published with Rwork and Rfree at 19.5% and 
23.7%, respectively, and an overall model-map correlation coefficient of 0.877. We took 
the published P61 data from the PDB and solved the structure with molecular replacement, 
but refined the model with a twin law applied. In the re-solved structure, the inhibitor (GRL-
142twin) was modeled in a single orientation with the “crown-like” tetrahydropyranofuran 
group interacting with chain A. The R-factors decreased to 17.9 % and 20.5% with 
improved electron density around the inhibitor [Figure 7.5B]. The re-solved structure also 
exhibited improved protein B-factors, bond lengths, bond angles, and Ramachandran 





Figure 7.5 A) Electron density maps surrounding the published inhibitor, GRL-142published, 
shown as sticks colored light grey (orientation A) and dark grey (orientation B). B) Electron 
density maps surrounding the re-solved inhibitor, GRL-142twin, shown as sticks colored 
slate (orientation A). C) Alignment of the two GRL-142published inhibitor orientations and 




Table 7.1 X-ray data collection and crystallographic refinement statistics of the published 
and re-solved structures.  
 PUBLISHED TWIN LAW PUBLISHED TWIN LAW 
INHIBITOR GRL-142published GRL-142twin PDI-6published PDI-6twin 
PDB ID 5TYS - 4U7Q - 
RESOLUTION (Å) 2.01 2.01 1.70 1.70 
SPACE GROUP P61 P61 P61 P61 
CELL DIMENSIONS:     
A (Å) 63.13 63.13 62.65 62.65 
B (Å) 63.13 63.13 62.65 62.65 
C (Å) 82.23 82.23 80.12 80.12 
Α (°) 90 90 90 90 
Β (°) 90 90 90 90 
Γ (°) 120 120 120 120 
UNIQUE REFLECTIONS 12,475 12,475 23,062 23,062 
REDUNDANCY 10.2 (9.7) 10.2 (9.7) 5.1 (5.0) 5.1 (5.0) 
COMPLETENESS (%) 99.9 (100) 99.9 (100) 99.7 (99.8) 99.7 (99.8) 
RSYM (%)A 0.10 (0.46) 0.10 (0.46) 0.045 (0.711) 0.045 (0.711) 
AVERAGE I/Σ 26.6 (4.8) 26.6 (4.8) 20.8 (2.57) 20.8 (2.57) 
TWIN FRACTION:     
H-TEST 0.477 0.477 0.491 0.491 
BRITTON 0.453 0.453 0.452 0.452 
TWIN LAW  (h,-h-k,-l)  (h,-h-k,-l) 
B-FACTORS:     
WILSON B (Å2)   31.48  
MEAN B VALUE (Å2)  27.59 34.9 30.70 
PROTEIN (Å2) 28.36 27.53  30.73 
MAIN CHAINS (Å2) 25.84    
SIDE CHAINS (Å2) 31.11    
LIGAND (Å2) 20.05 23.57  32.34 
WATERS (Å2) 34.9    
RMSDB IN:     
BOND LENGTHS (Å) 0.008 0.003 0.016 0.006 
BOND ANGLES (°) 1.022 0.634 2.191 0.884 
RAMACHANDRAN 
PLOT:     
FAVORED (%) 97.94 98.45 95.5 98.97 
ALLOWED (%) 2.06 1.55 4.0 1.03 
RFACTOR (%)C 19.49 17.9 27.5 24.1 
RFREE (%)D 23.66 20.5 32.6 27.5 
aRsym = Σ | I − <I>|/ Σ I, where I = observed intensity, <I> = average intensity over symmetry 
equivalent; values in parentheses are for the highest resolution shell. 
bRMSD, root mean square deviation. 
cRfactor = Σ || Fo| − |Fc||/ Σ|Fo|. 
dRfree was calculated from 5% of reflections, chosen randomly, which were omitted from 
the refinement process. 
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When aligned, the GRL-142published and GRL-142twin structures highly overlap with 
subtle differences throughout. To quantify the differences between the inhibitors, pairwise 
root-mean-square deviation (RMSD) was calculated between common atoms. The 
RMSD of the two GRL-142published inhibitor orientations was 0.27 Å, while the RMSD 
between the GRL-142twin inhibitor and published orientations were 0.75 Å and 0.74 Å 
[Figure 7.5C]. The asymmetry between the monomers in each structure (GRL-142published 
and GRL-142twin) was also quantified. A simple alignment of the GRL-142published 
monomers returned an RMSD of 0.09 Å with nearly identical Cɑ differences between 
monomers except one outlier (residue Gly40) [Figure 7.6]. The GRL-142twin structure 
showed slightly larger Cɑ differences, mainly in the flaps and distal “40’s loop”, with an 
overall RMSD of 0.13 Å.  
This test case showed that structural models from high quality data can be improved 
with the application of a twin law. Not only did Rwork and Rfree decrease by 1.6% and 3.2%, 
respectively, but the inhibitor could be modeled in a single orientation, known asymmetric 
structural features were extracted, and the protease structure improved in nearly every 





Figure 7.6 Internal distance differences of Cɑ atoms of chain A compared to chain B of 
the published GRL-142 bound HIV-1 protease without the twin law (PDB: 5TYS) and of 
the re-solved structure with the twin law applied. Thicker tubes and warmer colors indicate 





7.4.3 Re-Solving Structure with a Highly Asymmetric Inhibitor  
Lastly, this protocol was applied to another HIV-1 protease cocrystal structure, with 
a larger and even more asymmetric photolyzable inhibitor (PDI-6) bound to the active site 
(PDB: 4U7Q) (Schimer et al., 2015). This structure was also solved in the P61 space 
group with a dimer in the asymmetric unit and the inhibitor (PDI-6published) modeled in two 
conformations at 50% occupancy [Figure 7.7A]. This structure had lower quality data, 
with Rwork and Rfree at 27.5% and 32.6%, respectively, which are uncharacteristically high 
for a 1.7 Å resolution structure. The overall model-map correlation coefficient was 0.805. 
We again took the published P61 data from the PDB and solved the structure with 
molecular replacement, but refined the model to convergence with a twin law applied. The 
inhibitor, PDI-6twin, was modeled in a single orientation, with the larger half of the inhibitor 
interacting with chain A and labeled P3-P1 [Figure 7.7B]. The R-factors decreased by 
several percent to 24.1 % and 27.5%, which significantly improved the electron density 
around the inhibitor. Again, the protease of PDI-6twin had improved B-factors, bond lengths, 
bond angles, and Ramachandran angles [Table 7.1], while the overall model-map 





Figure 7.7 A) Electron density maps surrounding the published inhibitor, PDI-6published, 
shown as sticks colored light grey (orientation A) and dark grey (orientation B). B) Electron 
density maps surrounding the re-solved inhibitor, PDI-6twin, shown as sticks colored pink 
(orientation A). C) Alignment of the two PDI-6published inhibitor orientations and alignment 




When aligned, the PDI-6published and PDI-6twin inhibitor structures had some 
differences throughout, particularly at the P1 and P2′ moieties [Figure 7.7C]. Pairwise 
atomic RMSD of the two PDI-6published inhibitor orientations was 0.93 Å, while the RMSD 
between the PDI-6twin inhibitor and published orientations were much larger, at 1.48 Å 
and 1.57 Å. As for the protease, the PDI-6published structure only exhibited differences in 
internal distances involving the flaps, with an overall RMSD of 0.03 Å between the two 
monomers [Figure 7.8]. The PDI-6twin structure revealed that the twin law allows 
asymmetric structural features to be resolved throughout the protease, as should be 
expected due to the extremely asymmetric nature of the inhibitor. The RMSD between 
the monomers in the PDI-6twin structure was an order of magnitude larger, at 0.33 Å.  
This test case demonstrated that structures refined from lower quality data can also 
improve with the application of a twin law. The PDI-6twin structure had improved electron 
density around the inhibitor and some moieties exhibited notably different binding 
conformations. Examining this cocrystal structure highlights that SAR studies based on 





Figure 7.8 Internal distance differences of Cɑ atoms of chain A compared to chain B of 
published PDI-6 bound HIV-1 protease without the twin law (PDB: 4U7Q) and of the re-






The application of a twin law improves cocrystal structures of psuedomerohedrally 
twinned homo-oligomers with inhibitors bound. We demonstrated this for HIV-1 protease 
where we resolved and refined crystal structures determined in P61, but this rule should 
be generally applicable to any potentially asymmetric homo-oligomeric complexes. 
Refining the crystal structure in the appropriate space group with a twin law results in 
structures with inhibitors modeled in a single orientation and extracts asymmetric 
structural differences between the monomers. In addition, the final model has clearer 2Fo-
Fc electron densities, fewer Fo-Fc difference densities, and better statistics overall. This 
protocol is immediately applicable to about a dozen hexagonal HIV-1 protease structures 
that are released each year, and may benefit hundreds of other symmetrical homo-
oligomeric structures in the PDB. Overall, when applicable, processing data in a lower 
symmetry space group while applying the relevant twin law will result in better models, 










8.1 Structural and Dynamic Analyses are Essential to Elucidate Complex 
Mechanisms of Resistance   
The prevalence of small molecule inhibitors used as antimicrobial drugs, pesticides, 
and herbicides has made drug resistance a common phenomenon in many systems. 
Different organisms have evolved diverse mechanisms of resistance against various drug 
pressures. Whether in a single- or multi-celled organism, the mechanisms of resistance 
can be classified as “target-site” or “non-target-site”.252-253 Target-site resistance includes 
changes to the target (usually an enzyme) that reduce inhibitor binding affinity or potency. 
This includes single-site mutations in the target or horizontal gene transfer, as well as 
improved drug tolerance caused by increasing gene copy numbers and enzyme 
overexpression.252-253 Non-target-site resistance includes altering drug uptake and efflux, 
improved drug sequestration, and chemical alterations to the drug to increase 
metabolism.252-253 Our lab and my work focuses on target-site drug resistance, specifically 
target-site mutations that reduce inhibitor binding affinity.  
The epidemic of target-site drug resistance suggests that our current drug design 
paradigms, focused solely on disrupting the activity of WT targets, are insufficient for long-
term efficacy. Greater success against target-site resistance requires a deeper 
understanding the underlying molecular mechanisms: the structural and dynamic 
alterations in the enzyme–inhibitor system. Understanding drug resistance in HIV-1 
protease, one of the most mutable and genetically diverse enzymes, can shed light on 
other rapidly evolving disease targets.  
Resistance occurs when a mutation causes a reduction in the affinity for an inhibitor 
with minimal effect on substrate processing. The primary mutations of resistance usually 
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occur near the active site. More robust inhibitors incorporate strategies to withstand these 
primary resistance mutations. In Chapter 2, I looked at a few common proximal mutations 
in HIV-1 protease and how they altered the binding of a small panel of DRV analogues 
with modifications at the P1′ moiety. Using static structures and employing PCA we were 
able to extract why the I50V mutation greatly reduced affinity for the DRV analogs while 
the I84V mutation did not.  
Unlike proximal mutations, distal mutations reduce inhibitor affinity by propagating 
changes to the active site. Analyzing the dynamics of the protease-inhibitor complex is 
critical for elucidating the mechanism distal mutations use to propagate resistance 
throughout the protease. Chapter 3 involved quantifying the reduction in potency due to 
the accumulation of mutations and how distal mutations affected inhibitor binding. This 
analysis evaluated the potency of one inhibitor (DRV) across many variants. This 
research showed that distal mutations do not significantly change the size and shape of 
the active site, but dramatically alter the dynamics. Analyzing which protease-inhibitor 
interactions were conserved over time indicates where inhibitor modifications could 
potentially improve potency against resistant variants.  
8.2 Elucidating Conserved Static and Dynamic Protein-Inhibitor Interactions is 
Key to Inhibitor Optimization 
The large number of HIV-1 protease resistant variants, generated in lab or in 
patients, provide many proteases with active sites of different sizes, shapes, and 
dynamics. These diverse targets allow us to test which inhibitor modifications improve 
potency against mildly and highly resistant proteases. In Chapter 4, we modified the P2′ 
moiety of DRV to emulate the optimal interactions of the P2 bis-THF moiety by 
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accommodating additional hydrogen bonding interactions with NH groups of the protease 
backbone. That research showed modest improvements against WT and primary 
resistant mutants but showed greater improvements against highly mutated variants 
compared to the unmodified DRV.  
SBDD involves improving existing scaffolds and exploring new scaffolds. We have 
learned that designing inhibitors on a static structure does not always translate to success 
in vitro and evaluating the dynamic ensemble better predicts if the protease-inhibitor 
interactions are maintained over time. In Chapter 5, we made a novel inhibitor scaffold by 
combining components of three FDA-approved inhibitors. This research showed that the 
static structures revealed enhanced protease-inhibitor hydrogen bonding interactions, but 
the dynamics showed the hydrogen bonds were non-optimal, with key interactions lost or 
at low frequency throughout the simulations.  
8.3 Recipe for Robustness Against Resistance   
My research on drug resistance in HIV-1 protease and inhibitor design provides a 
template for designing robust inhibitors against other genetically diverse systems. 
Inhibitor design is a long, iterative process which requires a multidisciplinary collaboration 
between biochemists, enzymologists, medicinal chemists, cellular biologists, structural 
biologists, and computational biologists. Although many of the techniques we utilized are 
common, it’s how our expertise is combined that creates a product greater than the sum 
of its parts.  
The first step of inhibitor design is to identify a therapeutic target, specifically an 
enzyme that a small molecule can bind to and inhibit its function to cure or alleviate the 
disease. Choosing a good target enzyme is not a trivial step. The target must be a 
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necessary enzyme, preferably with high evolutionary conservation, to minimize resistant 
heterogeneity, and low homology to host enzymes, to minimize off-target effects. It is also 
favorable if an enzyme has many substrates to interact with, so that it will have a well-
defined substrate envelope and more evolutionary constraints.  
After choosing an enzyme, it is important to optimize expression and purification of 
properly folded, active protein and to develop an activity assay that can also function as 
a precise inhibition assay. If there are no lead compounds for the target of interest, the 
inhibition assay should be miniaturized for lead discovery via high-throughput screens. If 
compounds are found to inhibit the enzyme, you may need to confirm they are competitive 
inhibitors, assuming that is the design strategy.   
Structural analysis of high-resolution enzyme-inhibitor complexes is critical to the 
success of robust inhibitor design. Not only does structure-based drug design (SBDD) 
allow planning of inhibitor modifications in three-dimensional space, structures also 
demonstrate exactly which residues the inhibitor interacts with when bound to the enzyme.  
It is possible to create highly potent inhibitors through structure activity relationship (SAR) 
studies alone, but that methodology lacks unambiguous binding information. Even if an 
unbound (apo) structure of the enzyme is available, numerous studies have shown that 
inhibitor docking software is unreliable at predicting binding conformations. Also, if the 
structure of the target enzyme is not known, it can be modeled from a homologous 
structure in silico, but that comes with assumptions and uncertainty.   
Knowing enzyme-inhibitor interactions on a per residue level is necessary to design 
inhibitors that minimize interactions with variable residues and maximize interactions with 
invariant residues. Residue variability can be inferred by comparing homologous 
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enzymes which can be mapped onto a structure. If possible, it is best to force resistance 
by evolutionary selection through sub-optimal drug pressure and to determine 
heterogeneity through genetic sequencing or protein mass spectrometry. This process is 
not always performed, but should be a standard experiment if minimizing drug resistance 
is the ultimate goal. Also, forcing resistance is one of the only ways to identify which 
mutations, especially distal, contribute to reductions in inhibitor binding.  
Lastly, it is extremely important to take the additional step beyond structural analysis 
into dynamic analysis by utilizing molecular dynamics (MD) simulations. My research has 
shown that while SBDD is able to generate highly potent inhibitors, it is unable to 
anticipate dynamic mechanisms of resistance. MD simulations on the protein-inhibitor 
complexes, across several resistant variants and different inhibitors, elucidate which 
protein-inhibitor interactions are sustained dynamically over time. Optimizing these 
conserved interactions increases the probability of maintaining potency against all 
evolutionarily accessible variants and should therefore improve rates of resistance.  
8.4 Future Directions: HTLV-1 Protease 
Unlike HIV, which has an abundance of data, HTLV inhibition is in its infancy. Luckily, 
we can use the HIV model to quickly design a potent protease inhibitor which may improve 
patient overall survival rates. In Chapter 6, I show that the FDA-approved HIV-1 protease 
inhibitor DRV can inhibit HTLV-1 protease at 800 nM potency. Evaluating a small panel 
of inhibitors, we discovered that modifications at two moieties improved potency 27-fold, 
to 30 nM. If one were to continue this research, they could continue to test additional 
modifications to the DRV scaffold. A more thorough SAR study would likely improve 
potency several-fold more. They could also synthesize novel scaffolds that better mimic 
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HTLV-1 protease’s natural substrates. This should create more accurate transition state 
analogues which may improve potency and would likely reduce susceptibility to 
resistance.  
While there is no resistance data for HTLV-1 protease, we should expect resistance 
to occur and should design inhibitors accordingly. To orient SBDD with 3D constraints in 
mind, it would be useful to determine the static substrate envelope for HTLV-1 protease. 
It would also be useful to thoroughly process sequencing data from patients with 
HIV/HTLV co-infections who are also taking HIV-1 protease inhibitors/antiretrovirals. This 
could tell us if drugs like DRV are causing primary resistance mutations. It would also be 
informative to generate drug resistance mutations via passaging and sequencing. Our 
collaborators have an assay for generating virus-like particles (VPLs) which allows for a 
more in vivo quantification of if our inhibitors are crossing the cellular membrane and 
inhibiting HTLV-1 protease. However, there are currently no assays for propagating 
infectious virus, therefore there can be no evolutionary selection through drug pressure. 
For now, the active site identity between HIV and HTLV protease can give us clues to 
what residues should be variant and avoided or invariant and exploited.  
8.5 Other Rapidly Evolving Disease Targets that Could Benefit From this 
Methodology 
Although HIV-1 protease is the optimal model system to study resistance, with many 
variants, inhibitors, structures, and simulations, our methods can likely be applicable to 
most other rapidly evolving systems. For any given drug target where you would like to 
improve potency and reduce resistance, you really just need some known inhibitors with 
inhibition data and a structure of the target in complex with one of the inhibitors. Of course, 
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it would be best to have a lot of inhibitors with a good range of potencies and many high-
resolution structures. With those parameters in mind, our lab has identified some 
candidates of disease targets that could benefit from our methodologies. Instead of viral 
targets, we have chosen to explore antibiotic and oncology targets, where inhibition data 
with corresponding cocrystal structures are common.  
One class of targets are dihydrofolate reductases (DHFRs). A variant of this enzyme 
is present in all organisms as DHFR is essential in the synthesis of purine, thymidine, 
certain amino acids and thus cell growth. Specific targeting of DHFR has permitted 
development of chemotherapy agents in oncology such as methotrexate (MTX) and the 
clinical antibiotic, trimethoprim (TMP). Unfortunately, TMP resistant strains of bacteria 
have emerged in clinic, due to both mutation and horizontal gene transfer. The extensive 
variation that exists within DHFR variants provide a rich dataset to unravel molecular 





Figure 8.1 Resistant variants of DHFR to TMP with mutations mapped on the structure. 
Decrease in potency relative to WT (fold-change) is listed and colored according to 




Kinases are another class of enzymes with clinical resistance, targeted in cancer 
treatment. Drug resistance is a major problem in oncology, with mutations in kinases 
obliterating effectiveness of chemotherapy. The FDA has approved 48 small molecule 
kinase inhibitors to date,255 and 25 of those drugs are tyrosine kinase inhibitors (TKI), a 
mainstay therapy in many cancers. Approximately 25% of patients need to alter their TKI 
usage due to molecular resistance. The TKI targets we would like to explore include BCR-
ABL and epidermal growth factor receptor (EGFR). Both proteins have many resistance 
mutations, both proximal and distal [Figure 8.2].256-261 Although the inhibitors are potent 
(low-nanomolar IC50), resistance still occurs. It’s possible that evaluating these resistant 




                  
Figure 8.2 Left) BCR-ABL mutations and resistance to FDA-approved inhibitors. Mapped 
onto BRC-ABL structure (PDB: 2HYY) with proximal and distal mutations shown as red 
and blue sticks.256 Right) EGFR kinase domain with resistance mutation sites shown as 





8.6 The Future of SBDD 
Structures are integral to drug design (SBDD) and for reliable MD simulations, which 
are critical for the methodologies our lab promotes. Every structural determination method 
has its pros, cons, and limitations. X-ray crystallography is well established with over 
140,000 structures in the PDB, but some proteins do not crystallize. Solution state NMR 
has around 13,000 structures, but they are often very small proteins or short strands of 
DNA/RNA, which rarely have a ligand bound. Cryo Electron Microscopy (CryoEM) is an 
emerging technology with about 4,500 published structures. CryoEM was limited to very 
large proteins at low resolution, but has undergone a “resolution revolution” over the past 
few years and is constantly improving.  
The latest structural technique is called electron crystallography, which blends 
electron microscopy and protein crystallography. Because this technique uses protein 
crystals that are a billionth the size needed for X-ray crystallography, it is also known as 
microcrystal electron diffraction (MicroED). Although this structural determination method 
still requires crystallization of target protein, when done correctly, MicroED can generate 
high resolution (< 3.0 Å) structures in a very short amount of time. Since 2013, there are 
only about 100 structures on the PDB solved by MicroED, but like CryoEM, the more 
structures that are derived from this technique, the more it will be utilized.  
8.7 Concluding Remarks 
Drug resistance remains a significant threat and the currently employed drug design 
techniques are not equipped to solve this problem. Although resistance will occur any 
time evolution exists under the selective pressure of an imperfect inhibitor in a 
heterogeneous population, this research outlines the types of analyses necessary to 
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design more robust inhibitors. More specifically, this thesis outlines methodologies to 
diagnose various mechanisms of drug resistance and how to identify and optimize critical 
enzyme-inhibitor interactions. While this thesis focused on the ideal HIV-1 protease model 
system, our protocols are compatible with nearly any drug target. For example, we 
demonstrated how quickly we could improve potency against HTLV-1 protease, with 
many ideas for future optimization. Hopefully this thesis work directly contributes to the 
development of a HTLV-1 drug which will improve overall survival for those suffering from 
leukemia/lymphoma. More broadly, I hope these strategies guide future drug design 
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